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IL  Insulin loaded   
IL-6   Interleukin-6 
LA  Linoleic acid 
LMWH   Low molecular weight heparin  
LPS   Lipopolysacchride  
M-cells  Microfold cells  
MPS     Mononuclear phagocyte system  
MTT   3-4,5 dimethyl thialzol2,5 diphenyl tetrazolium bromide  
MW  Molecular weight 
NAcHis-GC  N-acetyl histidine-conjugated glycol chitosan  
NEAA   Non- essential amino acids 
NIL   Non-insulin loaded  
NLC   Nanostructured lipid carriers  
Pa2.5  Palmitoyl grafted Polyallylamine 
Pa2.5R  Rhodamine labelled Palmitoyl grafted Polyallylamine  
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PAA   Polyacrylic acid  
PAEMA  Poly[N-(2-aminoethyl)methacrylamide trifluoro acetate  
PAH  Polyallylamine 
PAMAM  Poly amidoamine 
PBS   Phosphate buffer tablets  
PBS   Phosphate buffered saline  
PCL-g-PDMAEMA Polycaprolactone-graft-poly(N,N-dimethylaminoethyl methacrylate)  
PDI   Polydispersity index 
PECs   Amphiphilic polyelectrolyte complexes (Binary complexes)  
PEG   Polyethylene glycol  
PEI   Polyethylenimine  
P-gp   P- glycoprotein 
PLGA   Poly(lactic-co-glycolic acid 
PLL   Poly(L-lysine)  
PMAP   Poly(methylaminophosphazene) hydrochloride  
PMLA   Poly (β-malic) acid  
PCL-g-PDMAEMA /DNA/PGA-g-PEG  Poly(e-caprolactone)-graft-poly(N, N dimethylaminoethyl 
methacrylate-DNA- polyglutamic acid-graft-polyethylene glycol  
PPS   Propanesulfonate  
PVA   Poly(vinyl alcohol)  
QPa2.5  Quaternized polyallylamine 
QPa2.5R  Rhodamine labelled Quaternized polyallylamine 
RBITC   Rhodamine Β isothiocyanate  
RCEC   Rabbit conjunctival epithelial cells  
RhB   Rhodamine B 
RhB-CHNP  Rhodamine B (RhB) labeled chitosan hydrochloride grafted nanoparticles  
RhB-CMCNP  Rhodamine B (RhB) labeled carboxymethyl chitosan grafted nanoparticles  
ROS   Reactive oxygen specie  
RP-HPLC  Reverse phase high performance liquid chromatography  
RPM  Revolutions per minute 
sCT   Salmon calcitonin  
SNOCC   N-sulfonato-N,O-carboxymethylchitosan  
sPECs   Standard polyelectrolyte complexes (Binary complexes),  
SPHC   Superporous hydrogel composite  
SQV   Saquinavir 
TEC   Triethyl chitosan 
TEER   Transepithelial electrical resistance  
TEM   Transmission Electron Microscopy  
TJs   Tight junctions  
TMB   3, 3´-5, 5´-tetramethylbenzidine  
TMC   Trimethyl chitosan  
TNFα   Tumor necrotic factor alpha 
TPP  Tripolyphosphate  
ZnSO4   Zinc sulfate  
ZO-1   Zonula occludens 
ZP   Zeta potential  
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ABSTRACT 
Introduction 
Oral delivery of proteins faces numerous challenges due to their enzymatic 
susceptibility and instability in the gastrointestinal tract. In recent years, the 
polyelectrolyte complexes have been explored for their ability to complex protein and 
protect them against chemical and enzymatic degradation. However, most of the 
conventional binary polyelectrolyte complexes (PECs) are formed by polycations 
which are associated with toxicity and non-specific bio-interactions. The aim of this 
thesis was to prepare a series of ternary polyelectrolyte complexes (APECs) by 
introduction of a polyanion in the binary complexes to alleviate the aforementioned 
limitations.   
Method  
Eight non-insulin loaded ternary complexes (NIL APECs) were spontaneously formed 
upon mixing a polycation [polyallylamine (PAH), palmitoyl grafted-PAH (Pa2.5), 
dimethylamino-1-naphthalenesulfonyl grafted-PAH (Da10) or quaternised palmitoyl-
PAH (QPa2.5)] with a polyanion [dextran sulphate (DS) or polyacrylic acid (PAA)] at 
2:1 ratio, in the presence of ZnSO4 (4µM). A model protein i.e., insulin was added to a 
polycation, prior to addition of a polyanion and ZnSO4 to form eight insulin loaded (IL) 
APECs. PECs were used as a control to compare APECs. The complexes were 
characterised by dynamic light scattering (DLS) and transmission electron microscope 
(TEM). In vitro stability of the complexes was investigated at pH (1.2-7.4), temperature 
(25˚C, 37˚C and 45˚C) and ionic strength (NaCl-68mM, 103mM and 145mM). Insulin 
complexation efficiency was assessed by using bovine insulin ELISA assay kit. The in 
vitro cytotoxicity was investigated on CaCo2 and J774 cells by MTT (3-4,5 dimethyl 
thialzol2,5 diphenyl tetrazolium bromide) assay. All complexes were evaluated for their 
haemocompatibility by using haemolysis assay, oxidative stress by reactive oxygen 
species (ROS) assay and immunotoxicity by in vitro and in vivo cytokine generation 
assay. The potential of the uptake of complexes across CaCo2 cells was determined by 
flow cytometry and fluorescent microscopy. The underlying mechanism of transport of 
complexes was determined by TEER measurement, assessment of FITC-Dextran and 
insulin transport across CaCo2 cells.  
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Results 
NIL QPa2.5 APECs (except IL QPa2.5-DS) exhibited larger hydrodynamic sizes (228-
468nm) than all other APECs, due to the presence of bulky quaternary ammonium 
moieties. QPa2.5 APECs exhibited lower insulin association efficiency (≤40%) than 
other APECs (≥55%) due to a competition between the polyanion and insulin for 
QPa2.5 leading to reduced association of insulin in the complexes. DS based APECs 
generally offered higher insulin association efficiency (≥75%) than PAA based APECs 
(≤55%) due to higher molecular weight (6-10kDa) of DS. In comparison to other 
complexes, Pa2.5 PECs and APECs were more stable at varying temperature, ionic 
strength and pH due to the presence of long palmitoyl alkyl chain (C16) which reduced 
the chain flexibility and provided stronger hydrophobic association. The cytotoxicity 
of polycations on CaCo2 and J774 cells is rated as PAH>Da10=Pa2.5>QPa2.5. The 
introduction of PAA in Pa2.5 and Da10 brought most significant improvement in IC50 
i.e., 14 fold and 16 fold respectively on CaCo2 cells; 9.3 fold and 3.73 fold respectively 
on J774 cells. In comparison to other complexes, Da10 (8mgml-1) induced higher 
haemolytic activity (~37%) due to a higher hydrophobic load of 10 percent mole 
grafting of dansyl pendants. The entire range of APECs displayed ≤12% ROS 
generation by the CaCo2 cells. The degree of in vitro TNFα production 
(QPa2.5≥Da10≥Pa2.5=PAH) and in vitro IL-6 generation 
(QPa2.5≥Pa2.5=PAH≥Da10) by J774 cells established an inverse relationship of 
cytotoxicity with the cytokine generation. Similar to MTT data, the introduction of 
PAA in APECs brought more significant reduction in in vitro cytokine secretion than 
DS based APECs. Pa2.5-PAA brought the most significant reduction in both in vitro 
and in vivo cytokine generation. All the formulations were able to significantly reduce 
original TEER, however did not demonstrate appreciable paracellular permeation of a 
hydrophilic macromolecular tracer of paracellular transport i.e., FITC Dextran. The 
uptake study revealed internalisation of APECs predominantly by a transcellular route. 
Transcellular uptake of IL QPa2.5 (≤73%), IL QPa2.5-DS (67%) was higher than their 
NIL counterparts, whereas the uptake of NIL Pa2.5 (≤89%), NIL Pa2.5-PAA (42%) 
was higher than their IL counterparts.  
Conclusion 
In essence, amphiphilic APECs have shown polyanion dependent ability to reduce 
polycation associated toxicity and they are able to facilitate transcellular uptake of 
insulin across CaCo2 cells. 
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1 INTRODUCTION 
Oral delivery of proteins has been attempted for many years to offer a convenient 
and non-invasive route, however, several challenges still remain before successful oral 
delivery of proteins can be achieved [1, 2]. Figure 1.1 displays a schematic diagram of 
the barriers to the absorption of proteins in the gastrointestinal tract (GIT). The oral 
delivery of proteins is strictly limited due to their chemical and physical instability in 
the GIT [3, 4]. The proteins require a minimum degree of lipophilicity to partition into 
the cell membrane [5] but the hydrophilic nature, high molecular weight and tertiary 
conformation of proteins prevent their passive diffusion across the lipophilic  cell 
membrane [6-8]. On the other hand, the cell-cell tight junctions (TJs) limit their 
paracellular absorption as only molecules smaller than 200 Da can permeate across the 
paracellular junctions [5].  
The whole length of the small intestine comprises of the dense and well-organized 
microvilli at the apical surfaces of the enterocytes [7]. The surface of epithelial cells is 
covered by a thin layer of mucus, made of glycocalyx and glycoproteins, produced by 
the goblet cells [9]. It acts as a diffusional barrier for large macromolecules and 
selectively allows the permeation of biomolecules like nutrients, water and small 
molecules [10]. Electrostatic repulsion between protein drugs and the mucus layer 
(negatively charged) has been found to prevent  the  contact of protein drug and the 
absorptive epithelial cells [7]. Thus, an orally administered protein drug must be able 
to infiltrate through the mucus layer before reaching the surface of intestinal epithelium. 
The mucus layer also serves as an enzymatic barrier [9, 11].  The pre-systemic 
degradation of protein by proteolytic enzymes in the GIT lead to a low bioavailability 
[12-14]. Therefore, if proteins are to be successfully delivered by the oral route, they 
must be able to resist chemical and enzymatic degradation in the GIT, and traverse the 
intestinal epithelium without undergoing extensive metabolism [15].  
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Figure 1.1 Barriers to oral protein delivery 
 
 
 
19 
 
An important obstacle to the absorption of proteins is the extreme pH range in the 
GIT which can denature the proteins and render them biologically inactive [1]. The gut 
luminal pH varies from highly acidic in the stomach (pH 1.2-3.0) to weakly acidic to 
basic in the intestine (small intestine pH 6.5- large intestine 8.0) [8]. The acidic 
environment in the stomach causes acid catalysed degradation of proteins [4, 16, 17]. 
Under the influence of pH and the enzymes, the proteins are broken down into their 
constituent amino acids which do not have actual biological activity like the original 
proteins [18, 19].  
Pepsin is the primary proteolytic enzyme produced in the stomach and has been found 
to be responsible for approximately 10% to 20% of total protein degradation [20, 21]. 
Proteolytic enzymes such as proteases and peptidases also play an important role in 
denaturing the proteins [4, 16, 17]. The intestinal proteases are located in three major 
sites defined as intraluminal, membrane bound or cytosolic proteases [7, 20]. The 
membrane-bound and cytosolic proteases are particularly active against di- and tri-
peptides and form an important barrier to the absorption of biologically active peptides 
across the intestinal mucosa [7, 20].  
Despite all these challenges to oral protein delivery, a large number of proteins are 
under clinical investigation and over 30 proteins have been approved by the FDA [19]. 
Polypeptide drugs such as desmopressin, cyclosporin A [22] Gefitinib [23] Imatinib 
[24] have all been developed as oral dosage forms. Further efforts are still being made 
to progress orally administered proteins. A number of different approaches are being 
used to avoid the barriers to oral protein delivery but each approach has its own 
advantages and limitations. 
 
20 
 
1.1 APPROACHES USED TO ENHANCE ORAL PROTEIN DELIVERY 
Much attention has been paid to overcome the barriers to oral protein delivery and to 
maintain the biological activity of proteins in the body [25]. A large number of 
approaches have been used to promote oral protein delivery, such as the use of enzyme 
inhibitors, penetration enhancers, mucoadhesive polymers and polymeric nano-drug 
delivery systems [2, 8]. Despite a great deal of progress being made today, oral protein 
delivery still presents a significant challenge. 
1.1.1 Enzyme inhibitors 
Enzyme inhibitors inhibit the proteolytic activity of protein digesting enzymes such 
as trypsin and chymotrypsin. The co-administration of enzyme inhibitors (protease 
inhibitors) and protein formulations has been shown to prevent or delay the rate of 
degradation of protein and thus increase the rate of protein absorption [26]. Proteolytic 
enzymes require divalent cations such as Ca2+ or Zn2+ within their active site (as a 
cofactor) for their functional enzymatic activity [27]. The chelation of these cations by 
using polyanionic enzyme inhibitors, e.g., carbomers and poly(acrylates) have been 
shown to circumvent the enzymatic barrier [28, 29]. Carbomers have been shown to 
facilitate the paracellular transport of the proteins by chelating ions; this has however 
been shown to cause irreversible damage to the GIT epithelium [28].  
Yomamoto et al. studied the effect of a number of enzyme inhibitors on protein 
absorption and found that sodium glycocholate, camostat mesilate, and bacitracin were 
efficient excipients in reducing insulin degradation in the large intestine, but, not in the 
small intestine [30]. This was because a considerably higher concentration of enzyme 
inhibitors was required to maintain their effectiveness in the enzyme rich small intestine 
which could possibly lead to disturbed digestion of nutritive proteins [14, 31]. It was 
later found that the co-administration of enzyme inhibitors and mucoadhesives tend to 
improve the absorption of drugs without requiring high concentrations of enzyme 
inhibitors [31]. Recently, Su et al. used diethylene triamine penta-acetic acid (DTPA), 
as a protease inhibitor and conjugated it with a mucoadhesive drug-delivery system to 
form DTPA- poly(γ-glutamic acid)-chitosan nanoparticles. The idea was to concentrate 
the enzyme inhibitory activity within a localised zone of the intestinal mucosa by using 
the mucoadhesive properties of chitosan. This system demonstrated a substantial 
protective effect against the intestinal proteases resulting in enhanced insulin absorption 
and significant reduction in the blood glucose levels [31]. A similar approach was used 
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to prepare polymer–inhibitor conjugates carboxymethylcellulose-bowmann-birk and  
carboxymethylcellulose- ellastinal inhibitor which although demonstrated strong 
enzyme inhibiting activity towards chymotrypsin and carboxypeptidases, presented 
systemic intoxications, disturbed digestion of nutritive proteins and hypertrophy as well 
as hyperplasia of the pancreas [1, 26, 27]. Due to the toxicological concerns associated 
with enzyme inhibitors, efforts are being directed to improve the absorption of protein 
drugs by using a number of other different approaches. 
1.1.2 Penetration enhancers 
Penetration enhancers (PEs) are known to promote the intestinal absorption of poorly 
permeable therapeutic proteins either by permeabilizing the mucus layer, enhancing 
transport across the epithelial cell membrane or by opening the TJs [2, 32]. A variety 
of PEs have been used to enhance the macromolecular permeability across the intestinal 
epithelium including surfactants, bile salts and fatty acids, chelating agents, salicylates 
and phosphonate derivatives [2, 33, 34]. However, most of these compounds, if not all, 
have failed due to the inherent toxicities related to their mechanisms of action. Fatty 
acids, monoglycerides, bile salt and surfactants have all been shown to increase the 
permeability of epithelial cells by the partial solubilisation of cell membrane [2, 35]. In 
this way, they damage the cell membranes leading to local inflammation or may even 
increase the non-specific absorption of luminal contents and pathogens by solubilising 
the phospholipids and membrane proteins [35, 36]. These effects have been a major 
setback in the progress of PE’s. However, recently, Chun et al. have shown that the 
addition of bile salts to pravastatin sodium could enhance drug absorption by 
mechanism other than solubilising behaviour, i.e., through the paracellular route and P- 
glycoprotein (P-gp) inhibition [34]. Likewise, Gupta and co-workers reported dimethyl 
palmitoyl ammonio propanesulfonate to be a non-toxic penetration enhancer and a 
potent alternative for providing enhanced oral uptake of peptides [2]. Such reports 
suggest that the attempts to enhance oral protein delivery using permeation enhancers 
are back in favour. In fact, sodium caprate (C10), a potent PE, has reached the clinical 
trial (phase II) [37, 38]. It was considered to exert its enhancing effect mainly via the 
paracellular route and by inhibiting the P-gp efflux pumps [39]. Its surfactant-like 
properties at high doses (100mM) have been shown to increase the bioavailability of 
associated protein drugs [38, 39]. However, histological examination revealed that the 
increase in permeability was related in part to superficial epithelial damage [38]. These 
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findings once again increase the demand for safer alternatives of PE such as cell-
penetrating peptides (CPPs). 
Over the last few decades, CPPs have become an important class of permeation 
enhancers because of their remarkable ability to traverse the cell’s plasma membrane 
in a non-toxic and highly efficient manner [40]. The first CPP was discovered while 
investigating the ability of the human immunodeficiency virus (HIV) transactivation 
protein (TAT) to penetrate the cells and so named as HIV type 1 (Tat) [41]. Later on a 
range of  different CPPs were discovered such as penetratin transcription factor derived 
from Antennapedia (pAntp) [42], transportan [43] and polyarginine [44]. A preliminary 
in vivo study using Tat revealed that Beta-galactosidase, a macromolecule, which was 
previously considered impermeable to cells, was taken up by cells in a cell-type 
independent manner, when covalently cross-linked to Tat [45]. Soon after this study, it 
was recognised that CPP have the potential to act as a carrier to achieve successful 
intracellular delivery of poorly permeable therapeutic macromolecules. It was found 
that a small amino acid sequence of CPP, approximately 10–30 residues long, mostly 
positively charged, cargo the peptide and proteins inside the cell. It is now known that 
Tat are taken up by the cells via an endocytotic pathway by interaction between the 
positively charged arginine of CPP and the negatively charged proteoglycan on the cell 
membrane surface [40]. They have also been reported to be internalised by lipid raft-
dependent endocytosis involving either macropinocytosis [46], caveolae dependent 
endocytosis [47] or clathrin dependent endocytosis [48]. They can translocate through 
the membranes of numerous cells because of their low cell specificity and deliver their 
cargo into the cytoplasm by directly perturbing the lipid bilayer structure of the cell 
membrane or by endocytosis [40]. The cytotoxicity analysis demonstrated that 
antennapedia, TAT, transportan and polyarginine display no significant toxicity even 
at 100 mM concentrations [40]. However, further efforts are required in this field to 
explore their potential for clinical use. 
1.1.3 Mucoadhesive polymers 
Mucoadhesive polymers have evolved as a promising alternative for improving the 
transport of peptides and proteins. They function by adhering to the mucosal wall by 
non-specific electrostatic interactions and transiently enhance the mucosal permeability 
by opening TJs or by permeabilising the mucus lining [49]. The prolonged contact of 
the delivery system with the mucosa facilitates their transport across the mucous layer 
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[49, 50]. The mucoadhesive polymers like chitosan, alginate, polyacrylate and 
cyclodextrins are thought to reach the epithelial cell surface by interpenetrating the 
mucous layer followed by association with the negatively charged units on the cell 
membrane via electrostatic interaction.  
Colloidal carriers made of chitosan have been widely investigated as carriers for 
protein delivery [13, 49]. They have favourable biological properties such as 
biocompatibility and biodegradability [51-53]. Chitosan based systems have 
demonstrated the facilitation of paracellular transport of large hydrophilic 
macromolecules by opening the TJs of mucosal membranes [4, 54-56]. This behaviour 
of chitosan has been attributed to its bio-adhesive property. The positively charged 
amino groups of chitosan interact with the negatively charged sites on the cell surfaces, 
thereby transiently open the TJs to facilitate paracellular transport [49]. 
Recently, Tahtat et al. found that association of chitosan with alginate increased the 
adherence percentage of alginate/chitosan beads to the mucosal surface of the rat 
intestine to 90%, compared to 35% for pure alginate beads [50]. This behaviour was 
associated with the interaction of the d-glucosamine residue of chitosan with the sialic 
acid residues of mucin by electrostatic interaction; thus facilitating more efficient 
absorption [50]. 
Despite several advantages, chitosan presents problems such as limited aqueous 
solubility [57]. A number of chitosan derivatives have been synthesised to improve its 
properties including trimethylchitosan chloride (TMC) [4, 58], N-(2-hydroxyl) propyl-
3-trimethyl ammonium chitosan chloride (HTCC) [51, 59] and thiolated chitosans [60, 
61]. TMC has demonstrated higher aqueous solubility than chitosan and carries a 
permanent positive charge regardless of the pH [57, 58]. Both TMC and HTCC allow 
mucoadhesion and penetration enhancement across intestinal epithelium [58, 59]. A 
number of different thiolated polymers (thiomers) such as thiolated chitosan and 
polyacrylates, have also been used as mucoadhesive polymers for enhancing oral 
delivery of hydrophilic macromolecular drugs because of their ability to form covalent 
bonds with the cysteine-rich subdomains of mucus glycoproteins via thiol/disulfide 
exchange reactions [60, 62, 63]. They act as enzyme inhibitors, permeation enhancers 
and efflux pump inhibitors as well as being capable of protecting the incorporated 
peptide and protein drugs against enzymatic degradation in the intestine [64, 65]. 
24 
 
However, their stability in solutions is a major concern which may reduce their efficacy 
[61, 62]. In addition, the drawback associated in using non-specific mucoadhesive 
systems (first generation) is that adhesion may occur at sites other than those intended. 
Therefore, current efforts focus on designing specific and targeted mucoadhesion 
systems within the GIT as well as other polymer based systems which can provide a 
site specific platform for oral delivery of proteins. 
1.1.4 Polymeric nano-drug delivery systems 
In recent years, incorporation of proteins into polymeric nano-drug delivery systems 
has proved to be a very promising approach for their oral delivery [66-68]. Polymeric 
nanocarriers are submicron-sized (10-1000 nm in diameter) colloidal particles [69, 70]. 
They are of particular interest, because of their ability to deliver the challenging 
therapeutic agents, such as proteins [69, 71, 72] and DNA [73, 74]. The most widely 
used and FDA approved polymers include poly(lactic acid) (PLA), poly(glycolic acid) 
(PGA) and poly(lactide-co-glycolide) (PLGA) and their co-polymers because of their 
biocompatibility [69]. 
A variety of polymeric nano-sized drug carrier systems have been developed e.g., 
nanospheres [75], nanocapsules [76, 77], polymeric micelles [78] and polymeric 
polyelectrolyte complexes [54, 79]. The choice of a suitable polymeric system is crucial 
and it depends on the properties of the polymers such as polymer architecture, surface 
charge, protein association efficiency and uptake profile [69, 80].  
Different types of nanostructures can be obtained from similar polymers, depending 
on the method of preparation  [81].  Chitosan, and its derivatives and polyethylene 
glycol (PEG) have also been used to fabricate various forms of nanostructures [49, 55, 
79, 82]. Some of the commonly used polymeric nano-sized systems are described 
below. 
1.1.4.1 Polymeric nanospheres and nanocapsules 
The term nanoparticle collectively refers to the nanospheres and nanocapsules 
(Figure 1.2) [20]. Nanocapsules are vesicular systems in which the solubilized or solid 
drug is confined to an aqueous or oily core surrounded by a unique polymer membrane 
[81, 83, 84]. The oily core allows entrapment of a lipid-soluble drug, whereas, an 
aqueous core enables encapsulation of water-soluble drugs [85-87]. Nanospheres are 
solid matrix type structures in which the drug is homogeneously dispersed in the bulk 
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matrix or confined to the particle surface [20, 81, 87-89]. In general, nanocapsules are 
spherical in shape but nanospheres may have other shapes [85]. 
 
 
 
 
 
 
Figure 1.2 Schematic representation of (a) Nanocapsule (b) Nanosphere 
Nanoparticles have been prepared by a number of different techniques, 
predominantly via emulsion based techniques such as emulsion solvent evaporation, 
and emulsion solvent diffusion techniques [69]. These  techniques commonly involve 
the use of organic solvents, toxic chlorinated compounds, heat and vigorous agitation 
that may potentially be harmful to the associated proteins and peptides [53, 69]. Many 
of these methods can easily disrupt the delicate protein structure rendering the protein 
inactive. In addition, many of the nanoparticle preparation methods require a surfactant 
to stabilize the dispersed phase in an emulsion based technique. Some of the 
nanoparticles have shown limitations in terms of their biodegradability, toxicity and 
biocompatibility. In addition, the majority of nanoparticles have experienced rapid 
clearance from the systemic circulation, and have ended up almost exclusively in the 
mononuclear phagocyte system (MPS). In order to avoid these problems, techniques 
have been designed to manipulate the surface of nanoparticles to achieve the desired 
properties [90, 91]. PEG is a hydrophilic flexible, non-ionic and biodegradable polymer 
[59]. Surface modification of polymers with PEG allow an increase in the circulation 
time and also provides thermodynamic stability to the particles [92]. It also tends to 
avoid or reduce the interactions of nanoparticles with the blood proteins [93]. These 
properties have been utilised by several researchers. Zhu and colleagues prepared PEG 
grafted chitosan-N-trimethylaminoethylmethacrylate chloride (CS-TM–PEG) 
copolymers not only to improve the solubility of chitosan in a physiological 
environment but also to enhance biocompatibility and reduce their interaction with 
blood cells and proteins [92] PEGylated nanosystems have also demonstrated the 
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ability to adhere to the mucosa. Recently, PEG modified starch acetate nanoparticles 
were prepared by Minimol et al. for controlled delivery of insulin. These nanoparticles 
were non-cytotoxic and demonstrated greater bioadhesiveness than chitosan [90]. 
Nanoparticles have demonstrated high protein loading efficiency, protection of 
protein degradation in GIT and ability to facilitate protein uptake [94]. Pan et al. 
prepared insulin-loaded chitosan nanoparticles which demonstrated high protein 
loading and biocompatibility [49]. Recently, Shu et al. prepared glutathion responsive 
polyelectrolyte nanocapsules composed of cysteamine conjugated chitosan (CS-SH) 
and dextran sulfate (DS), which protected protein drugs from destruction by gastric acid 
and allowed release of the protein inside the cells [95]. The drug was released 
intracellularly under the effect of intracellular glutathion secretion [95]. Polymeric 
nanoparticles, e.g. amine-modified graft polyesters, chitosan nanoparticles [96] or 
thiolated trimethylchitosan nanoparticles [97] have all been shown to increase the 
bioavailability of insulin. All these reports indicate the potential of nanoparticles to 
achieve oral protein delivery, however, the methods of fabrication of nanoparticles are 
very complex and use expensive reagent [20]. This is the reason that suitable large-
scale production is essentially restricted [98]. This leads to the consideration of 
designing polymeric systems with simple techniques which do not require toxic 
chemicals, heat or vigorous agitation.  
1.1.4.2 Polymeric micelles  
Polymeric micelles gained a lot of interest in recent years due to their simple and 
versatile fabrication process. They are  formed spontaneously by the self-assembly of 
amphiphiles in an aqueous medium, generally as a result of hydrophobic or ion pair 
interactions between polymer segments [99]. The hydrophobic groups on the polymeric 
chains are directed towards the internal zone of the particle while the hydrophilic groups 
such as poly(ethylene glycol) and poly(ethylene oxide) are directed towards the solvent 
(Figure 1.3) [100, 101]. This behaviour reduces the contact of the hydrocarbon chain 
with water and acts as a driving force for micelle formation (or micellization) [100, 
102]. The hydrophobic inner core is capable of protecting the drug from the aqueous 
environment and against premature enzymatic degradation, whereas the hydrophilic 
portion provides stability by forming a tight shell around the micellar core by forming 
hydrogen bonds with the surroundings water molecules [103-105]. 
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Figure 1.3 Schematic representation of a micelle 
 In comparison to nanoparticles which display a static and stable structure, polymeric 
micelles form dynamic structures which are formed by diverse molecular architecture 
such as block copolymer and graft copolymer [15]. Aliabadi and coworkers prepared 
methoxy poly(ethylene oxide)-b-poly(ɛ-caprolactone) (PEO-b-PCL) micelles as 
alternative vehicles for the solubilization and delivery of CsA [106]. Although, these 
micelles demonstrated higher CsA to vehicle loading, and superior controlled drug 
delivery properties, they required organic solvents, low temperatures and sophisticated 
methods for their fabrication.  
The advanced drug delivery approaches allow spontaneous self-assembly of micelles 
and simple fabrication process which are viewed as major advantages compared to solid 
nanoparticle [15]. Other key advantages of polymeric micelles is their thermodynamic 
stability in physiological solution, low cytotoxicity and high entrapment efficiency [98, 
107]. However, this makes them more suitable for intravenous administration and is the 
reason why most micelle based formulations are administered intravenously [98, 107]. 
Nevertheless, numerous research groups have now focused on oral administration of 
micelles [107, 108]. In this context, Li and coworkers fabricated polyanionic copolymer 
mPEG grafted-alginic acid (mPEG-g-AA)-based polyion complex (PIC) micelles 
which demonstrated enhanced oral absorption of salmon calcitonin (sCT) [107]. These 
micelles were found to be internalised by Caco-2 cells predominantly via endocytosis 
[107].  
The hydrophobic character of the core of a micelle enables efficient entrapment of 
hydrophobic drugs, however, it is difficult to entrap hydrophilic drugs such as protein 
[81], and thus the use of polymeric micelles for protein delivery has been limited [15, 
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109]. However, Lee et al. recently successfully developed protein loaded polyionic 
complex (PIC) micelles which contained a block copolymer with poly(ethylene glycol) 
(PEG) as a neutral block and a poly(amino acid) as an ionic block. These micellar 
systems demonstrated high stability, reduced immune response, and prolonged 
circulation time [108]. More recently, glucose-responsive complex micelles i.e., 
phenylboronic acid-contained block copolymer PEG-b-P(AA-co-APBA) and a 
glycopolymer P(AA-co-AGA) [110] and monomethoxy poly(ethylene glycol)-b-
poly(L-glutamic acid-co-N-3-L-glutamylamidophenylboronic acid) [111] have been 
prepared for protein delivery and have demonstrated higher glucose-responsiveness and 
glucose triggered insulin release. The self-assembling character of amphiphiles have 
also been utilised for the fabrication of polyelectrolyte complexes by ion pair 
interactions. It is considered that this system will associate with a protein drug to form 
complexes for oral delivery. 
 
1.1.4.3 Polyelectrolyte complexes 
Polyelectrolyte complexes are an important class of nanocarriers which have shown 
tremendous potential for protein delivery in the past few decades [68, 112]. 
Polyelectrolytes are polymers containing ionisable groups [113]. In a suitable polar 
solvent (generally water), the ionisable groups acquire charge by releasing low 
molecular weight ionic moieties called counter-ions [79, 114]. The charged polymeric 
chains tend to remain expanded in the solution due to electrostatic repulsion between 
the like charges on the polymeric chains. This effect prevents the polymeric chains from 
coming closer and forming agglomerates [115, 116]. However, any condition causing 
neutralisation of the surface charges (e.g., salt) leads to coiling of the polymer chains 
around itself leading to aggregation [117]. Many important biological macromolecules 
are polyelectrolyte in nature e.g., DNA and RNA. A large number of naturally occurring 
and synthetic polyelectrolytes have been used in biopharmaceutics for drug and protein 
delivery purposes. Some of the commonly used polyelectrolytes include chitosan, 
polyacrylates, poly (lactide-co-glycolide) (PLGA), polyethylenimine (PEI), poly (L-
lysine) (PLL), chondroitin sulfate and alginate. 
The ability of polyelectrolytes to form complexes with oppositely charged polymers 
or protein provides prospects for the oral delivery of protein. The charged polymeric 
chains interact with the oppositely charged polymers or proteins to form polymer-
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polymer, polymer-protein and polymer-protein-polymer complexes, predominantly via 
electrostatic interactions. The polyelectrolyte complexes formed between amphiphilic 
polymers and proteins may provide an additional contribution of hydrophobic 
association resulting in higher stability and protein association efficiency. 
1.1.4.3.1 Types of polyelectrolyte complexes 
There are three main types polyelectrolyte complexes employed in the protein 
delivery systems, namely the standard polyelectrolyte complexes (sPECs - binary 
complexes), amphiphilic polyelectrolyte complexes (PECs - binary complexes), and 
polycation-polyanion-protein polyelectrolyte complexes (ternary complexes) which 
can be formed in the absence (aPECs) or presence (APECs) of a cross-linker (Figure 
1.4). sPECs are formed by the association of oppositely charged polymer and protein 
whereas, PECs are formed by the association of an amphiphilic polymer and a protein. 
A number PECs have been developed for the oral protein delivery [118, 119]. Recently, 
Thompson et al. demonstrated the potential of using novel comb shaped PECs for the 
oral  delivery of protein [120]. These PECs demonstrated the ability to prevent 
enzymatic degradation, exhibited paracellular absorption, and high complexation 
efficiency. The amphiphilic quaternary ammonium palmitoyl polyallylamine (QPa) 
demonstrated the ability to produce nanocomplexes with cationic peptides (i.e., sCT) 
[118], as well as anionic peptides (i.e., insulin) [121], due to contribution of both 
electrostatic and hydrophobic associations in their formation. This shows the ability of 
PECs to deliver both the cationic and anionic proteins using this system [118, 121].  
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Figure 1.4 Types of polyelectrolyte complexes (a) Standard complexes – sPECs  
(b) Amphiphilic complexes - PECs (c) Polycationic-Polyanionic protein complexes - aPECs  
(d) Polycationic-polyanionic protein complexes stabilised by cross-linker - APECs 
 
APECs are formed by the complexation of a polycation with a polyanion and a 
protein. They can be formed in the presence or absence of cross-linkers such as zinc 
sulphate (ZnSO4) [122], tripolyphosphate (TPP) [123, 124] which facilitate their 
formation. The cross-linkers are low molecular weight ions which are considered to 
bridge the polymeric chains [125]. Divalent and multivalent ions reinforce the 
polymeric chains and thus induce the formation of ionically cross-linked systems [125]. 
They can facilitate the formation of stable and homogenous colloidal dispersions. 
Previously, Jintapattanakit et al. demonstrated the use of TPP counter ion to cross link 
trimethyl chitosan (TMC) as a carrier for insulin [4]. This system produced stable, 
uniform and nanosized trimethyl chitosan (TMC) and polyethylene glycol graft-TMC 
copolymer complexes. They demonstrated that increasing cross-linker concentration 
resulted in increased particle sizes, association efficiency, process yield and decreased 
zeta potential (ZP) and polydispersity index (PDI) of PECs [124]. These complexes 
prevented insulin degradation at 50˚C and displayed an inhibitory effect towards trypsin 
[4]. 
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APECs allow formation of fine-tuned complexes whereby desirable size and charge 
can be obtained by changing the ratio of polycation: polyanion: cross-linker. Recently, 
Zheng and colleagues prepared chitosan-polyaspartic acid PECs of efficient drug 
delivery properties by using gluteraldehyde (GLA) as a cross linker. Their study 
showed that the mean size of PECs could be adjusted by changing GLA concentration 
[113].  
APECs have been shown to significantly lower the toxicity associated with 
polycations in the binary systems. Tiyaboonchai and colleagues prepared 
polyethylenimine-dextran sulphate- DNA PECs, stabilised by ZnSO4 through ionic 
interaction. Interestingly, these PECs possessed efficient transfection efficiency of 
DNA and a 10 fold reduction in toxicity in the presence of dextran sulphate (DS) [73].  
Moreover, polyelectrolyte complexes have demonstrated significant absorption 
across in vitro and in vivo models and increased bioavailability of proteins. Sarmento 
and colleagues prepared alginate-chitosan (Alg-CS) by using calcium chloride as a 
cross-linker. An in vivo study in streptozotocin induced diabetic rats showed that oral 
application of these Alg-CS insulin PECs was able to reduce basal serum glucose level 
up to 40% for over 18h [126]. All these findings show that polyelectrolyte complexes, 
as a nano-drug carrier system, hold tremendous promise for the oral delivery of the 
therapeutic proteins. However, there are numerous factors which influence the stability 
of these colloidal systems, therefore, it is very important to understand the underpinning 
concepts of the formation and stability of PECs to produce stable colloidal dispersions. 
1.1.4.3.2 Factors influencing the stability of colloidal dispersions  
There are a variety of factors which govern the formation and stability of PECs [4, 
79]. The charge density of the complexes has been identified as one major factor which 
accounts for the stability of the complexes [79]. The magnitude of the charge density 
of the polymers determines the degree of electrostatic interaction between the 
oppositely charged polymers and proteins which in turn is responsible for maintaining 
the complex stability [115]. The high positive charge allows the attachment of 
complexes to the anionic cell membrane and increases the residence time in the GIT 
and subsequently enhances the bioavailability. However, the excess cationic charge has 
been shown to cause high toxicity and in vivo instability, due to non-specific 
interactions and protein adsorption [127, 128]. Efforts have been made to reduce the 
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cytotoxicity and improve the stability of the delivery system either by surface 
modification of the polymer with safer hydrophobic moieties such as palmitoyl graft 
[129], hydrophilic moieties such as PEG and quaternary ammonium moieties [129, 
130] or by introduction of a polyanion [131] in the complex to reduce the charge 
density. It has been found that attaching a hydrophilic non-ionic block or side chain 
e.g., poly(ethylene oxide) (PEO) to the polyelectrolyte can improve stability of the 
system [132]. Wang et al. reported that the hydrophobic (linoleic acid-LA) and 
hydrophilic (poly (β-malic) acid-PMLA) modification of chitosan contributed to 
suppress non-specific adsorption. In addition, hydrophobic LA grafting also promoted 
resistance against enzymatic degradation and cellular uptake through the clathrin-
mediated pathway while hydrophilic PMLA substitution inhibited these effects [130].  
The ratio of polymer and protein and the nature of the ionic group have a significant 
impact on both the degree of interaction and the physical properties of polyelectrolyte 
complexes [71, 79]. The non-stoichiometric ratios of polymers form soluble complexes 
[133-135], whereas, polymers with 1:1 stoichiometry form insoluble and electroneutral 
complexes which tend to destabilize and flocculate [134]. The insoluble stoichiometric 
PECs are ideal materials for several large-scale industrial applications e.g. as membrane 
materials, coatings, binders, and flocculants, but, remain poorly investigated for drug 
delivery applications due to their electro-neutral behaviour [135]. Recently, ternary 
insoluble stoichiometric interpolyelectrolyte complexes of insulin with biodegradable 
synthetic polymers, poly(methylaminophosphazene) hydrochloride (PMAP) and 
dextran sulfate (DS) (Insulin-PMAP-DS) were prepared by Burova and co-workers 
under conditions imitating the human gastric environment (pH 2, 0.15 M NaCl). The 
findings showed complete immobilization of insulin in the complexes. These ternary 
complexes dissolved and dissociated under conditions imitating the human intestinal 
environment (pH 8.3, 0.15 M NaCl) liberating free insulin and soluble binary Insulin-
PMAP complexes. The results showed an almost 100% protection of insulin against 
proteolytic degradation [136]. These findings establish the potential of ternary insoluble 
stoichiometric complexes in oral protein delivery.  
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Nonstoichiometric complexes are ideal for pharmaceutical applications. They have 
been prepared by numerous groups including chitosan-dextran sulfate CS-DS 
complexes [137], PEG graft trimethyl chitosan copolymer- insulin complexes [67], CS-
DS-amphotericin B complexes [55], PEI-DS-insulin [122], polysodium 
styrenesulfonate - nonionic poly(ethylene oxide) ether methacrylate complexes [135].  
Several research groups have demonstrated that the mixing order and mixing ratio 
also play an important role in the formation and stability of polyelectrolyte complexes 
[138]. Muller et al. prepared polyelectrolyte complexes between poly(ethyleneimine) 
(PEI) and poly(acrylic acid) (PAA) and showed that the size and internal structure of 
PEI/PAA particles could be regulated by parameters such as mixing order and  mixing 
ratio [139]. All these properties reflect the numerous advantages of polyelectrolyte 
complexes as a protein delivery.  
1.1.4.3.3 Advantages of polyelectrolyte complexes 
Polyelectrolyte complexes are of particular interest due to their attractive advantages 
and numerous applications in the biomedical field. They are an inexpensive, 
biocompatible and versatile substitute to the current polymeric delivery strategies 
[115].  Firstly, the process of fabrication of polyelectrolyte complexes is very simple 
and mild [79]. Moreover, polyelectrolyte complexes are formed spontaneously in 
solvents such as water and do not require high heat, toxic chlorinated compounds or 
organic solvents for their preparation, thereby reducing the possible toxicity and other 
undesirable effects of the reagents [115, 140]. Polyelectrolyte complexes are formed 
via electrostatic interactions which not only allow easy complexation but also avoid the 
use of chemical modification of the polymer and protein by covalent interactions [140]. 
Some of the polyelectrolyte complexes, if not all, act to protect proteins from 
proteolysis in the GIT, resulting in a prolonged retention of the protein activity [72, 84, 
141, 142]. The novel comb-shaped amphiphilic polyelectrolytes (QPa) prepared for the 
oral delivery of insulin [121, 129] and sCT [118] have been reported for their ability to 
protect insulin and sCT from the in vitro gastrointestinal enzymatic degradation by 
pepsin, trypsin, elastase, or chymotrypsin. Despite the many advantages of 
polyelectrolyte complexes, their interaction with cells such as nanotoxicity and 
mechanism of uptake has not been widely explored.  
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1.2 NANOTOXICOLOGY AND IN VITRO TESTING 
Nanotoxicology is a modern branch of toxicology which has revolutionised the 
evaluation of nanocarrier toxicity in the recent years [143]. It essentially identifies the 
adverse nano-bio interactions. It provides better understanding on, how different 
nanomaterial properties affect their biological response. Nanostructures may be 
efficient as drug delivery systems; however, there is an increasing concern about their 
potential toxicity which may arise following their in vivo administration. So far, most 
of the nanotoxicological studies have been conducted on inorganic nanoparticle such 
as iron oxide, ZnO, CuO, MgO and TiO2 [144, 145] and carbon nanostructures [146-
148]. However, currently, there has been limited research done on the evaluation of 
nanotoxicity of polymeric nanostructures which may delay their progress to clinics 
(Duncan & Gaspar, 2011). This knowledge is crucial to understand the biocompatibility 
of polymeric nanostructures and their interaction with the cells. Therefore, a 
comprehensive nanotoxicological characterisation of nanocarriers is required for every 
study [15]. 
1.2.1 Challenges to the polymer based nano-structures 
Generally, the success of polymeric nano-structures strongly relates to their 
pharmacological and toxicological properties [149]. However, the properties which 
favour drug delivery may result in undesirable toxic effects. The cationic charge of the 
polycationic systems is one good example of a property which although favours drug 
delivery, is associated with toxicity. The positive charge on the nanocarriers has been 
found to be essential for their initial contact with the negatively charged cell membrane 
and consequently for the cellular uptake [150]. A large number of polycationic 
polymers such as PEI, PLL and polyallylamine (PAH) have been implicated in the 
charge dependent toxicity [143, 151, 152]. These polycations possess primary amino 
groups on their backbone which have been found to be the primary origin of their 
toxicity [153]. However, it has been shown that modification of primary amines by 
groups such as PEG or imidazoyl grafting is able to decrease the charge density on the 
polymer backbone and hence decreases the toxicity associated with the polycation 
[152]. Similarly, glycolation of PAH [154] and PEI [155] have been shown to decrease 
the positive charge and hence the polycation associated cytotoxicity.  
High molecular weight polymers have been implicated in inducing a greater degree 
of toxicity than low molecular weight polymers [156]. Fischer and co-worker have 
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shown that low molecular weight PEI displays significantly less cytotoxicity than high 
molecular weight counterparts [156, 157]. Mao et al. has also shown that the 
cytotoxicity of TMC increased with the increasing MW such that 5kDa TMC chitosan 
was completely non-toxic compared to 400kDa which exhibited an IC50 of 15µgmL
-1 
[67]. 
Polymer based nano-structures are formed from a diverse polymer architecture, for 
example amphiphilic polymers form polymeric micelles while dendrimers are globular 
three dimensional structures. Therefore, the adverse effects of nanostructures may arise 
from a combination of factors such as nano-structure chemistry, size, shape and 
electromagnetic properties [158]. The high surface area to volume ratio of 
nanostructures can lead to increased chemical reactivity and biological activity [150]. 
The increased chemical reactivity results in production of reactive oxygen species 
(ROS), including free radicals which is one of the primary mechanisms of nano-carrier 
toxicity and the cause of most of the pro-inflammatory effects. In vitro and in vivo 
studies using nanostructures of different composition and particle sizes have shown cell 
and tissue damage due to ROS production as a major contributory factor in the 
inflammation and toxicity. ROS production has been found in a diverse range of 
nanostructures including carbon fullerenes, carbon nanotubes and nanoparticle metal 
oxides [159]. However, this behaviour is not well explored for polymeric 
nanostructures. 
The intrinsic surface properties of nano-structures e.g., hydrophobicity and 
hydrophilicity also play an important role in causing toxicity. The exposure of 
nanocarriers to the blood may cause them to be adsorbed onto the surface of 
erythrocytes which may lead to the failure of cellular regulatory mechanisms or even 
haemolysis of cells. On the other hand, nanocarriers can also activate inflammatory and 
immunological responses and may affect both local and distant tissues and organ 
function.  
As a result of polymer heterogeneity, nanostructures might interact with the cells in 
a large number of ways. In order to advance the polymer based nanostructures to 
clinical use, it is important to select a range of appropriate in vitro tests to understand 
the molecular events leading to toxic events.   
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1.2.2 Challenges to in vitro toxicity testing for polymer based 
nanostructures 
Cell based in vitro models can play an important role in analysing the toxic effects 
of nanomedicines. The challenges to the in vitro toxicity testing of polymer based nano-
structures extend from selecting appropriate cell lines to using more relevant, robust 
and validated in vitro methodologies which cover aspects such as route of 
administration, time and dose related toxicities. The literature is rich with an impressive 
array of in vitro assays (Table 1.1). The most commonly used assays include cell 
viability assays, particularly 3-4,5 dimethyl thialzol2,5 diphenyl tetrazolium bromide 
(MTT), 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) (MTS), (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) (XTT) [160, 161], lactate 
dehydrogenase assay (LDH), adenosine triphosphate (ATP), trypan blue [144, 160] and 
neutral red uptake assay (Hillegass et al., 2010). Other less commonly employed assays 
include haemocompatibility, immunogenicity and cellular uptake studies (Table 1.1 
and 1.2) [162]. There are techniques to measure other endpoints such as inflammatory 
potential, genotoxicity and carcinogenicity but these are least employed because of their 
complexity and difficulty in interpretation [162]. These and several other techniques 
are in general consideration by the regulatory authorities and may add to the 
mechanistic understanding of the underlying toxicity of nano-structures [51].  
Before performing in vitro testing, a number of questions should be considered, for 
example, 1) do the polymeric nanostructures alter cellular metabolism and specialized 
cell functions?; 2) how are they taken up by the cells and do they reside in the cells?; 
3) do they mediate effects like inflammation, immunostimulation and 
immunosuppression? [163]; 4) do they have tendency to damage DNA and other 
cellular organelles? ; 5) How are they metabolised and eliminated from the body?; 6) 
how sensitive and specific are the toxicological data? [164, 165]. Due to the biological 
complexity, toxicity may be generated as a result of a number of mechanisms. 
Therefore, there is a need to employ a range of different in vitro tests to cover all related 
endpoints. It is essential to prioritise and standardise in vitro testing depending on which 
endpoint correlates well with the route of administration and physical and chemical 
properties of the formulation. The notion is to achieve a standard battery of assays to 
evaluate the safety of polymeric nanostructures for a better clinical correlation.  
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Table 1.1  Summary of In Vitro assay systems used in the assessment of nanotoxicity 
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38 
 
1.2.2.1 Types of in vitro toxicity testing 
1.2.2.1.1 Basal cytotoxicity 
Basal cytotoxicity assays are usually performed as initial assessments to determine 
general toxicity (Table 1.1) [160, 166]. The end point employed is usually IC50 
(inhibitory concentration 50%), i.e., the concentration required to kill 50% of the cell 
population [167]. Once the IC50 or no observable effect level (NOEL) and sub lethal 
concentrations have been established, more relevant mechanistic endpoints can be 
determined by specialised toxicity assays (Table 1.1). However, this should proceed 
only if suitable in vitro results are achieved. In order to validate the findings, 
experiments should be performed on more than one cell line and at several different 
time points [160].  
1.2.2.1.2 Specialised toxicity 
The specialised toxicity assays determine cell-selective mechanistic toxicity capacity 
and specialized end-points like alteration in cellular metabolism, specific cellular 
functions and signalling pathways (Table 1.1) [160, 166]. The polymeric nanostructures 
can elicit an immune response which triggers the release of various cytokines or 
chemokines and may initiate a cascade of biochemical reactions. They may induce 
oxidative potential by the release of ROS which can further lead to altered metabolic 
and regulatory processes of cells, DNA damage, altered signalling pathway or gene 
expression [168]. Therefore, specialised in vitro assays can add to the understanding of 
the underpinning mechanism at the molecular and cellular level. They can expand our 
understanding related to the safety, biological activity and interaction of polymeric 
nanostructures in the body. The type of assay and endpoint to be employed can be 
improvised depending on the route of administration, type of cell line and special 
cellular functions [160]. 
1.3 UPTAKE AND TRANSPORT  
The elucidation of uptake and intracellular trafficking of the polymer based nano-
structures is commonly performed to determine their efficacy as targeted delivery 
systems. However, the uptake and trafficking may cause nanocarrier-cell interaction 
which can potentially lead to unwanted effects. The concentration, size and surface 
charge of the polymer based nano-structures can affect cellular uptake as well as 
potentially lead to undesirable uptake [165]. Uptake studies are mainly conducted on 
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cell culture models such as CaCo2, MDCK, LLC-PK1, 2/4/A1, TC-7, HT-29, IEC-18  
[169, 170].  Quantification and visualisation of nanostructures at a cellular and 
subcellular level enable the understanding of transport and localisation of nanocarriers 
within the cell and cellular organelles. A number of valuable tools are used to determine 
the mechanism and rate of uptake of nanostructures e.g. confocal laser scanning 
microscope and transmission electron microscope (TEM) (Table 1.2) [166, 171]. 
Particle quantification can also be carried out via fluorescently labelled nanostructures 
using a flow cytometry [141, 166].  
 
 Table 1.2 Summary of techniques used to assess the in vitro uptake and transport of 
formulations across cells 
 
The transport of substances across the intestinal epithelia occurs via different routes 
namely paracellular, passive transcellular, carrier/receptor mediated transcytosis and 
via M cells in Payer’s Patches, as briefly described below [96, 172, 173]. Figure 1.5 
displays the various modes of uptake of biomolecules by the cells. 
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1.3.1 Paracellular Transport: 
Paracellular transport is the passive movement of solute between the adjacent cells 
across the intestinal epithelial barrier. Intestinal epithelial cells lie very close to each 
other such that they form TJs between the cells [174]. The TJs are dynamic structures 
formed by a collection of macromolecular proteins confined to the apical region of 
epithelial cells termed as zonula occludens [175]. It has been found that the TJs are built 
from almost 40 different proteins, including claudin, occludin and zonula occludens-1 
(ZO-1) [27, 174].  
 
 
Figure 1.5 Mechanism of uptake of biomolecules by intestinal enterocytes 
 
Claudins are considered as the primary tight junction-forming proteins which have 
pore-like properties [176]. They act as intercellular adhesion molecules and form a 
paracellular seal [174]. The claudin based pores of 4 Aº radius are most often quantified 
by transepithelial electrical resistance (TEER). The resistance varies along the scale 
from tight to leaky epithelia [174, 176]. Immunohistological studies confirm that 
claudins form a distinct intact ring/pore around the periphery of individual cells [177]. 
Studies have shown alteration in the staining pattern of the ring following incubation 
with various polycations. Martien and co-workers have shown reduction in claudin 
staining around the apical part of the cell following treatment with thiolated chitosan 
nanoparticle suspension for 4 h. The discontinuous staining in some areas along with 
the presence of intracellular staining implied disruption of cell–cell contacts and 
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removal of claudin into vesicles inside the cell [177]. However, after removal of the 
nanoparticle suspension, the intact staining around the cell periphery was observed 
again indicating re-establishment of the cell integrity [177]. Similar finding have been 
reported by Yeh et al. who reported the redistribution of the TJ protein claudin 4 
(CLDN4). The normal continuous ring appearance of claudins between adjacent cells 
was disrupted and fluorescence signal of CLDN4 became weaker after treatment with 
chitosan [178].  
ZO-1 are cytosolic proteins which interact with each other, and serve as a platform 
to link the TJs to the cytoskeleton. ZO-1 interacts with multiple other TJ regulatory 
proteins to organize them to control TJs function. It is thought to be a linkage molecule 
between occludins and actin cytoskeleton [179, 180]. It has been shown to control the 
paracellular permeability by connecting to the perijunctional actin and myosin [180]. 
The subcellular localisation of ZO-1 has been investigated by numerous research 
groups [181-185]. A number of researches have indicated the role of translocation of 
ZO-1 in altering the paracellular permeability. Smith et al. reported that chitosan 
mediates TJs disruption by translocation of TJ proteins from the membrane to the 
cytoskeleton [182]. They observed that chitosan causes a dose-dependent reduction in 
TEER of up to 83% of CaCo2 monolayers and a corresponding increase in horseradish 
peroxidase permeability across the monolayer which was found to be 18 times greater 
than the control. The ZO-1 protein appears as a continuous ring between the adjacent 
cells before incubation with nanocarriers [186]. Immunofluorescent localisation of ZO-
1 elucidated the loss of membrane-associated ZO-1 from discrete areas. Analysis of 
cellular fractions showed a dose-dependent loss of ZO-1 and occludin from the 
cytosolic and membrane fractions into the cytoskeletal fraction [182].  
A similar study done by Ranaldi et al. compared the effects of chitosan and other 
polycations (polyethylenimine, poly-L-lysines) on the TJ [183]. Their results showed 
that all polycations investigated were able to induce a reversible increase in the TJ 
permeability. This effect was associated with morphological changes in the F-actin 
cytoskeleton, and the localization of tight junctional proteins [183]. Vllasaliu and co-
workers studied the effect of chitosan nanoparticles on the distribution of ZO-1. They 
found that the chitosan nanoparticles produce a sharp and reversible decrease in TEER 
and increased the permeability of two FITC-dextrans (FDs), FD4 (MW 4 kDa) and 
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FD10 (MW 10 kDa). In addition, chitosan nanoparticles produced changes in ZO-1 
distribution indicating a TJs effect, however, no improvement in permeability of 
chitosan nanoparticles was observed [184]. Lin et al. reported similar findings 
according to which the incubation of cells with the CS-coated poly-γ -glutamic acid 
nanoparticles caused a discontinous staining pattern of ZO-1 proteins with a 
corresponding reduction in the TEER values indicating the opening of TJs [179].  
There have been studies which have reported contradictory findings. One good 
example is of the study done by Rosenthal and co-worker which elucidated that chitosan 
affects both, the paracellular and the transcellular resistance. However, no effects on 
expression and subcellular distribution of TJ proteins or the actin cytoskeleton were 
observed. They indicated that the reversible absorption-enhancing chitosan effect is 
actually due to the changes in intracellular pH caused by the activation of a chloride-
bicarbonate exchanger [181]. There have been reports which indicate the relation of 
other factors in the permeation enhancement properties of polymers. Li and co-workers 
related the permeation enhancement property of carbopol polymers to the chelation of 
extracellular or tight-junctional Ca2+ by charged polymer’s carboxylate groups. 
Depletion of extracellular Ca2+ results in opening of epithelial TJs, thereby facilitating 
paracellular transport [187]. 
 A plethora of reports on similar polymers state differences in their mechanism of 
uptake. These differences might mean that the uptake of these polymers is occurring by 
a combination of different pathways. It is also possible that these polymers were able 
to open the TJs with or without causing a substantial transport of nanocarriers. This 
means that even if polymers are able to open up the TJs, it is difficult to explain the 
paracellular uptake of particles >50 nm by a widening of the intercellular spaces. These 
effect have been reported by Ma and co-workers where the paracellular pathway was 
not adequately widened to allow the passage of a substantial amount of insulin 
molecules across the cell monolayer [188]. These findings have led researchers to 
consider the uptake of nanocarriers by a transcellular pathway. The transcellular 
pathway has been widely reported to transport macromolecules and particles across 
absorptive epithelial cells which is briefly described below.  
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1.3.2 Transcellular Transport 
Transcellular transport refers to the transport of substance across the cell membrane. 
It occurs by energy in dependent or independent mechanisms such as  receptor/ carrier 
mediated endocytosis or adsorptive endocytosis respectively (Figure 1.5) [172]. 
Adsorptive endocytosis involves internalisation of nanocarriers without requiring 
receptors or carriers for their uptake [22]. It is preceded by nonspecific interactions of 
a ligand with the cell membrane. As no ligand-specific receptors have been identified 
for most of the polycations, therefore, the polycations are considered to interact with 
the cell membranes by nonspecific electrostatic interactions. Chitosan has been shown 
to enter the cells by various endocytic processes, however, predominantly by adsorptive 
endocytosis [189]. N-acetyl histidine conjugated glycol chitosan has been shown to be 
internalised by adsorptive endocytosis [190]. These nanocarriers have been reported to 
localise in the endosomes and undergo time dependent exocytosis. Adsorptive 
endocytosis depends primarily on the size and surface properties of adsorbed material, 
therefore, offers potential for delivering the macromolecules and colloidal carriers into 
the cells [141]. Positively charged particles with a size ≤100nm are readily internalised 
via adsorptive endocytosis, however, particles 100-500nm have also been reported to 
be taken up by adsorptive endocytosis but with a lesser tendency [191]. 
The receptor and carrier mediated endocytosis are energy-dependent, saturable 
endocytic pathways initiated by ligand binding to specific cell membrane receptors or 
transporters at the apical cell membrane [141, 192]. The macromolecular proteins such 
as insulin are internalised by receptor mediated endocytosis [22]. However, since all 
nanocarriers do not have specific receptors for internalisation, research has been 
focused on incorporating specific ligands to the polycations to allow cell-specific 
uptake by receptor-mediated mechanisms [193]. The polycations have been linked with 
ligands, such as folate [194-196] transferrin [197, 198], galactose [199] and vitamin 
[200] for receptor specific recognition and effective endocytosis.  
The two commonly investigated endocytic pathways include classical clathrin 
mediated endocytosis and caveolae-mediated endocytosis [201, 202]. These endocytic 
mechanisms are distinguished by the composition of their coat, size of the detached 
vesicles, and fate of the internalised material [201]. 
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1.3.2.1  Clathrin mediated endocytosis: 
Clathrin-dependent endocytosis is a well characterised receptor-mediated 
endocytosis (Figure 1.6) [203, 204]. It occurs at clathrin coated sites which contain 
receptors specific to the ligands to be internalised [204]. Clathrin are cytosolic proteins 
associated with the formation of endocytic vesicles [203]. The plasma membrane 
comprises of specific domains called clathrin-coated pits [203]. These coated pits are 
able to concentrate large extracellular molecules that are internalised by receptor-
mediated endocytosis, e.g., folate, vitamins, transferrin, galactose and antibodies. 
 Once the ligand is bound to the membrane receptors, a signal is sent to generate 
membrane coating at the receptor sites. This is followed by the invagination of plasma 
membrane to capture the receptor-ligand complex. Later on, the invagination buds and 
pinches off from the plasma membrane and gives rise to clathrin-coated vesicles. Once 
internalised the vesicles loose the clathrin coats, which is a prerequisite for mediation 
of their fusion with the early endosomes [203]. The endosomes fuse with the acidic 
lysosomes which result in sequestration followed by degradation of the cargo 
therapeutics by lysosomal enzymes [201]. The system is saturable because the ligand 
is internalized with the receptor, however the uptake returns to normal when the 
receptors recycle to the surface.  
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Figure 1.6 Schematic diagram of clathrin mediated endocytosis 
Clathrin inhibitors such as chlorpromazine inhibit the receptor recycling by 
disrupting the assembly-disassembly of clathrin and hence are used to elucidate the 
clathrin-mediated endocytosis [188, 205]. A plethora of nanocarriers systems have been 
shown to be internalised by clathrin-mediated endocytic process. Tahara and co-
workers reported that chitosan (CS)-modified PLGA nano-structures (CS-PLGA) are 
preferentially taken up by human lung adenocarcinoma cells (A549 cells) by an energy 
dependent mechanism [206]. The uptake of particles was reduced at lower temperatures 
and in hypertonic growth medium confirming uptake by a clathrin-mediated endocytic 
process [206]. Another similar study reported the cellular uptake of chitosan 
nanoparticles as a saturable process which was found to be concentration and 
temperature dependent [188]. The uptake was unaffected by co-administered filipin 
(inhibitor of caveolae pathway and clathrin-independent endocytic pathway). However, 
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chlorpromazine reduced the number of coated pit-associated receptors at the cell 
surface indicating the internalisation via clathrin-mediated endocytosis [188]. Huang 
and colleagues also used chitosan nanoparticles but showed a contradictory result where 
uptake was neither inhibited by chlorpromazine nor filipin [207]. However, since the 
cellular uptake of chitosan nanoparticles was temperature dependent, these findings led 
them to conclude internalisation of chitosan nanoparticles predominantly mediated by 
the adsorptive endocytosis initiated by nonspecific interactions between nanoparticles 
and cell membranes and in part by the clathrin-mediated process.  
It is important to note here that nanocarriers with similar composition have been 
shown to exhibit different mechanisms of endocytosis [190]. The variation in the uptake 
mechanism can be explained by the differences in their physicochemical properties. 
Harush-Frenkel reported that positively charged nanoparticles internalised rapidly via 
the clathrin-mediated pathway whereas negatively charged nanoparticles showed 
reduced rate of endocytosis and did not utilize clathrin-mediated endocytosis pathway 
[208]. Particle size also determines the route of uptake and the mode of endocytosis. It 
has been reported that clarthrin-mediated endocytosis allows endocytosis of particles ≤ 
100nm in diameter [191]. However, this size limit does not agree well with the sizes of 
the drug delivery nano-structures which are commonly larger in size than 100 nm.  
 
1.3.2.2  Caveolae mediated endocytosis: 
Caveolae mediated endocytosis is a form of non-classical endocytic pathways which 
is based on the balance between caveolin-1 and the raft lipids (Figure 1.7). Caveolins 
are integral membrane proteins of 21kDa, which are responsible for formation of flask-
shaped plasma membrane invaginations, 60–80 nm in diameter called caveolae [203, 
204, 209]. Caveolae are formed by the assembly of highly hydrophobic membrane 
domains called lipid raft domains [202, 210]. They have a unique morphology mainly 
composed of cholesterol and sphingolipids [202]. 
The formation of caveolae is dependent on the expression of caveolin-1 in non-
muscle cells and caveolin-3 in muscle cells [210]. Cells that do not express caveolins 
have no caveolae [209]. Once caveolae are internalised they form caveolar vesicles. 
Researches have shown multicaveolar assemblies of caveolae which appear as bunches 
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of grapes [204]. The caveolar structures and vesicles travel to the intracellular 
distribution centres called caveosome [203]. The caveosomes are distinct from 
endosomes in terms of content and pH [202]. The internalized ligands or membrane 
constituents reside in caveosomes, and are sorted either to the Golgi complex, or to the 
endoplasmic reticulum [211]. 
 
 
Figure 1.7 Schematic diagram of caveolae mediated endocytosis 
A number of nanocarriers have been reported to be taken up by caveolae mediated 
endocytosis. Chung and co-worker reported that oligonucleotide-coated histidine-
conjugated polyallylamine complexes (PAA-HIS/DNA) could specifically recognize 
adenosine receptors on the cell surface and were taken up by adenosine receptor 
mediated process. Uptake experiments with various endocytic inhibitors indicated that, 
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after receptor/ligand binding, oligonucleotide-coated PAA-HIS/DNA/complexes were 
mainly internalized via caveolae-mediated pathway [212]. Similar results have been 
shown by Van der Aa and colleagues. They showed that poly(2-(dimethylamino)ethyl 
methacrylate (pDMAEMA) and polyethylenimine (PEI) complexed DNA co-localise 
with fluorescently-labelled transferrin and cholera toxin after internalisation by COS-7 
cells, which indicates uptake via the clathrin and caveolae-dependent pathways [213]. 
Blocking the uptake with route specific inhibitors only resulted in a marginal decrease 
in polyplex uptake indicating that the uptake routes of polyplexes are interchangeable. 
However, despite a minor effect of inhibitors on polyplex internalisation, blocking the 
caveolae-mediated uptake route resulted in an almost complete loss of polyplex-
mediated gene expression. On the other hand, gene expression was not negatively 
affected by blocking the clathrin-dependent route of uptake indicating more important 
role of caveolae mediated uptake in polyplex uptake [213]. These findings indicate that 
uptake of particles may occur by one or more than one pathway, however, it may vary 
with the particle properties and type of cell. Although, the data on the uptake of 
nanocarriers by caveolae-mediated endocytosis proposes a size limit of 50-80nm 
diameter, however there are contradictory reports [191]. Rejman et al. has shown 
internalisation of nanoparticles having a diameter below 200 nm by clathrin-mediated 
endocytosis [214]. However, it was shown that as the size of the particles increased up 
to 500 nm, caveolae mediated internalisation pathway became the predominant 
pathway for the uptake of particles [214]. 
1.3.2.3            Gut-associated lymphoid tissue (GALT) system: 
GALT is not only an essential component of immune system in the digestive tract 
but is also associated with the process of particle uptake via oral route [215] (Figure 
1.8). GALT comprises of well-organized lymphoid tissues, such as mesenteric lymph 
nodes and Peyer’s Patches and diffusely scattered lymphocytes in the intestinal lamina 
propria [216]. Peyer’s Patches are macroscopic aggregates of lymphoid nodules, few 
centimetres in length present exclusively in the lowest portion of the small intestine, 
the ileum [217]. The Peyer’s Patches play an important part in the immune surveillance 
system (antigen sampling) of luminal contents and directly stimulate immune response 
within the mucosa [217]. 
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The lymphoid tissues of the digestive system are lined by specialized layer of 
intestinal enterocytes known as follicle associated epithelium (FAE) [217]. The FAE 
lining forms a dome shaped region over the follicle which serve as depot for the immune 
cells, such as T and B lymphocytes and dendritic cells [218]. It is distinguished from 
the intestinal epithelium covering the villi by low digestive enzymes levels, less 
pronounced brush border, infiltration of immune cells such as B cells, T cells, 
macrophages and dendritic cells and most importantly specialized epithelial cells called 
microfold cells (M-cells) [217, 219]. The notable feature of M cells which make them 
different from other epithelial cells are absence of  surface microvilli and the normal 
thick mucus layer [219]. M cells have been shown to transport antigens from the lumen 
to the sub-epithelial dome [219].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic diagram of gut associated lymphoid tissue 
The uptake of polymeric nanocarriers from M cells allows a direct way into the 
lymphatic system. Their high transcytotic activity makes them an interesting choice for 
drug delivery. This route favourably avoids first pass metabolism. Since M-cells do not 
express P-glycoprotein efflux pumps, therefore, decrease the likelihood of cellular 
efflux of nanocarriers [217]. In addition, uptake via M cells prevents the need to 
50 
 
traverse the thick glycocalyx coating present on the epithelial cells [217, 220]. 
Additionally, since M-cells are known to have a limited number of lysosomes [220], 
the intracellular degradation of nanocarriers can be prevented. All these favourable 
findings have led researchers to consider uptake of nanocarriers via M cells.  
Researchers have used M cell specific ligands at the nanoparticle surface to target M 
cells. Garinot and co-workers prepared antigen-loaded PEGylated Poly(ε-
caprolactoneco-ethylene glycol -based nanoparticles (PCL–PEG), which were grafted 
with M cell specific ligand i.e., RGD peptide. Formulation was targeted to β1 integrins 
expressed at the apical surface of M cells. The RGD ligand at the surface of the 
nanoparticles increased the transport of the nanoparticles across the M cell in in vitro 
co-cultures [221]. In a similar study, integrin targeting was studied by investigating the 
transport of arginine-glycine-aspartate (RGD)-coated nanoparticles across the ileal 
specimens. Integrin targeting with RGD has been shown  to dramatically improve the 
nanoparticle transport across the FAE [222]. However, it is being considered that, since 
the number of M-cells in FAE is very low, the potential of uptake of nanocarriers by M 
cells may be limited [220]. Secondly, the nanocarriers encounter large quantities of 
local macrophages upon translocation via M cells which may phagocytise the particle. 
However, whether the particle will be taken up or not or will be phagocytised essentially 
depends on the particle properties such as size, charge and M cell specific ligands on 
the surface of particles.  
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1.4 CONCLUSION 
Polyelectrolyte complexes offer the prospect and promise for the oral delivery of 
proteins. However, conventional carrier systems such as binary polyelectrolyte 
complexes are associated with toxicity related issues which severely limit their clinical 
use. The fabrications of systems which are able to alleviate the toxicity of the 
conventional systems are in high demand to fulfil the promise of oral delivery of 
protein. The APECs are fabricated in this project to circumvent the limitations of 
previously formed binary polyelectrolyte carrier systems.  The analysis of basic toxicity 
as well as specialised toxicity of carrier systems is essential to determine the magnitude 
and mechanism of toxicity. This will help to establish the effect of polymer based 
nanocarriers on the cellular functions as well as regulatory and metabolic processes. It 
is equally important to determine the cellular uptake and trafficking of polymeric 
nanostructures in biological systems to understand and predict their fate in vivo. 
Employing a number of assays in different cell lines will contribute towards a better 
correlation between in vitro and in vivo studies.  
1.5 AIM 
The aim of this study was to fabricate non-insulin loaded (NIL) and insulin loaded 
(IL) ternary polyelectrolyte complexes (APECs) between (i) amphiphilic PAH with 
different hydrophobic groups i.e., 5-(Dimethylamino) naphthalene-1-sulfonyl chloride 
(Da10) and palmitoyl moiety (Pa2.5); and quaternised Pa2.5 and (ii) polyanions (PAA 
& DS), and compare their physicochemical properties, stability, biocompatibility, 
uptake and transport with binary complexes (PECs). 
1.5.1 Objectives 
 Synthesis of modified polyallylamine by grafting hydrophobic (Pa2.5 & 
Da10) and hydrophilic (QPa2.5) pendant groups on PAH backbone 
 Fabrication of NIL and IL PECs and APECs 
 Determination of insulin association efficiency of PECs and APECs 
 Determination of stability of IL PECs and APECs at various ionic 
strengths (68mM, 102mM, and 145mM of NaCl), temperature (37˚C & 45˚C) 
and pH (1.2 and 6.6) 
52 
 
 Determination of cytotoxicity of PECs and APECs on CaCo2 cells 
assessed using the MTT assay 
 Determination of haemocompatibility of PECs and APECs assessed 
using the haemolysis assay 
 Determination of effect of PECs and APECs in inducing oxidative stress 
assessed by the reactive oxygen specie (ROS) generation assay 
 Determination of the effect of PECs and APECs in in vitro and in vivo 
immunotoxicity by investigation of cytokine (IL-2, IL-6 and TNFα) generation  
 Determination of the drop in the percentage TEER on exposure to free 
insulin, PECs and APECs. 
 Determination of the paracellular flux of FITC-Dextran across CaCo2 
cell monolayers. 
 Quantitative analysis of the permeation of insulin across CaCo2 cell 
monolayer.  
 Evaluation of the uptake of various PECs and APECs by CaCo2 cells 
using flow cytometry and fluorescent microscopy. 
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2 POLYMER SYNTHESIS AND CHARACTERISATION  
2.1 AMPHIPHILIC POLYMER 
Amphiphilic polymers have demonstrated significant potential in protein delivery 
[118]. They consist of hydrophobic and hydrophilic segments which can self-organise 
in aqueous media to form well defined nano-structures like micelles and vesicles [223, 
224]. A hydrophobic segment forms the inner core and contributes to hydrophobic 
interactions while a hydrophilic segment maintains the polymer solubility and stability 
in aqueous environment by forming hydrogen bonds with the surrounding water 
molecules [119, 225]. Amphiphilic polymers commonly exist as block copolymers, 
which are fabricated via copolymerisation of hydrophilic and hydrophobic monomers 
(Figure 2.1) [119, 224]. However, nowadays comb shaped amphiphilic polymers are 
gaining a lot of interest.  
Comb shaped polymers are formed by grafting hydrophobic and/or hydrophilic 
pendant groups on a homopolymer or copolymer backbone which gives rise to a comb-
like architecture (Figure 2.1) [224, 226]. The hydrophilic pendant groups such as poly 
(ethylene glycol) (PEG) [227] or quaternary ammonium moieties are added to improve 
water solubility of the polymer [226]. These comb-shaped amphiphilic polymers have 
proven very versatile due to their ability to form different supra-molecular structures in 
the aqueous environment such as solid nanoparticles, polymeric micelles, vesicles and 
polyelectrolytes [119, 228]. Recently, Thompson et al. demonstrated the potential of 
using novel comb shaped polymers to form polyelectrolyte complexes for oral protein 
delivery [119]. 
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Figure 2.1 Schematic diagram of (a) homopolymer (b) block copolymer (C) comb 
shaped polymer 
In this study, comb shaped amphiphilic polymers were synthesised by grafting 
hydrophobic or hydrophilic groups onto a water-soluble homopolymer polyallylamine 
backbone (PAH). PAH is a synthetic cationic polymer prepared by polymerization of 
allylamine.  It has a long alkyl chain with a high density of primary amino groups (-
NH2
+) (Figure 2.5). PAH was selected because of the ease of performing modification 
at the primary amine site which allows grafting of hydrophilic and hydrophobic 
moieties by simple nucleophilic substitution and addition reactions [229]. Its cationic 
nature enables this polymer to interact electrostatically with negatively charged proteins 
and polymers [152]. The positive charge also allows interaction with negatively 
charged proteoglycans of the cell membrane, leading to enhanced uptake [154]. The 
cross-linked PAH is currently used clinically as an oral phosphate binder [230]. Unlike 
other polycationic polymers (e.g., polyethylenimine, poly-l-lysine), PAH is less toxic, 
a property which makes it suitable for pharmaceutical applications [120]. However, the 
presence of primary amines in PAH still confers some degree of cytotoxicity [152, 231]. 
It has been shown that the modification of primary amines on PAH can lead to a 
reduction of cytotoxicity [120, 152, 154]. Boussif et al. has shown that the glycolation 
of PAH with hydrophilic methyl glycolate is able to reduce the cytotoxicity of 
unmodified PAH. Similarly, Pathak et al. demonstrated that PAH modified with 
imidazolyl is less toxic than unmodified PAH. All these reports showed that PAH has 
a lower cytotoxicity index in its modified form, due to a reduction of primary amines 
on the polymer backbone [152]. Therefore, in this study, PAH was grafted with the 
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hydrophobic pendant group (5-(Dimethylamino) naphthalene-1-sulfonyl chloride - 
dansyl) and palmitoyl moiety - Pa2.5); and a hydrophilic moiety (quaternary 
ammonium moiety - QPa2.5).  
Thompson and colleagues studied the effect of the degree and type of hydrophobic 
and hydrophilic substitution on the properties modified PAH based nanocomplexes 
[119]. They reported that the hydrophilic and hydrophobic modifications of PAH lead 
to substantial differences in the physicochemical properties of the complexes. The 
substitution of primary amines on the PAH lead to a significant reduction in the positive 
charge density. They also reported that the hydrophobic grafting reduces the flexibility 
of the PAH backbone. Alternatively, the hydrophilic polymers tend to increase the inter 
chain repulsion due to a permanent positive charge on its surface [120]. In this project, 
the degree of substitution was devised in a manner to retain sufficient number of 
primary amino groups on the PAH backbone, to complex with oppositely charged 
polymer and protein for subsequent studies.   
To confirm the success of modification on the polymer, a number of techniques are 
needed to characterise the polymers. Elemental analysis, nuclear magnetic resonance 
spectroscopy (NMR) and gel permeation chromatography (GPC) are very useful and 
commonly used techniques applied for the analysis of polymer properties, like 
elemental composition [232, 233].  
2.2 CHARACTERISATION OF POLYMERS 
2.2.1 Elemental Analysis 
Elemental analysis is performed to characterize the organic compound for its 
elemental composition [233]. It can identify the elements in an organic compound by 
qualitative (type of elements present) or quantitative analysis (relative number of 
atoms) [234, 235].  
The most common type of elemental analysis is carbon, hydrogen and nitrogen 
known as CHN analysis [236]. In addition, analysis for atoms such as halogens i.e., 
sulphur, chlorine, and fluorine can also be performed. CHN analysis is performed by a 
CHN elemental analyser by combustion analysis. A schematic representation of an 
elemental analyser is shown in Figure 2.2.  
 
57 
 
 
Figure 2.2 Schematic diagram of an elemental analyser 
 
A small amount of unknown sample is burnt in the presence of oxygen at high 
temperature (˃1000ᵒC) [233, 235]. The combustion mixture passes over a layer of 
catalyst (e.g., chromium trioxide and tungsten trioxide) which enables the complete 
combustion of the sample. As a result, all of the carbon in the compound is converted 
to carbon dioxide and all of the hydrogen in the compound is converted to water vapours 
[235]. The resulting gas mixture (CO2, H2O, nitrogen oxides and remaining oxygen) 
then flows through a silica tube packed with copper granules called copper turnings, 
which form a reduction column (500 °C) [237]. In this column, the gases such as 
nitric/nitrous oxides are reduced to unreactive elemental nitrogen (N2) [235, 237, 238]. 
The leaving gas stream (CO2, H2O and  N2 ) is swept by the high purity helium, used 
as the carrier gas into the detector for quantitative analysis [238, 239].  
The micro-analytical detection system allows quantitative analysis of the final 
product. The most commonly used analysis for determination of gas content is gas 
chromatography, a method that can separate each gas. In most of the instruments, the 
separated gases are carried to a thermal conductivity detector which detects the 
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elements and determines their relative amounts [235]. The thermal conductivity 
detector  generates an electrical output signal proportional to the concentrations of each 
of the individual elements [240]. The percentage of each element can be calculated from 
the integrated weight values [237]. 
2.2.2 Nuclear magnetic resonance spectroscopy (NMR) 
Nuclear magnetic resonance spectroscopy is a well-established technique, commonly 
referred as NMR [241]. It is a versatile analytical technique that utilizes the magnetic 
properties of atomic nuclei for compositional and structural characterisation of 
molecules [242-244]. It is extensively used for the determination of structure of 
polymers. [244]. Figure 2.3 displays a schematic illustration of NMR spectroscopy.  
As virtually all organic molecules carry protons, therefore, the Proton Nuclear 
Magnetic Resonance (1H NMR) provides information about the hydrogen present in a 
mole. The nuclei of atoms generally have a defined characteristic spin [244]. The 
spinning protons generate a magnetic field around themselves, which allow them to 
move in a random fashion called a magnetic moment (μ) [242]. However, when the 
protons (1H ) are placed in an external magnetic field, they absorb electromagnetic 
radiation at a specific frequency and resonate [245]. The frequency of resonance of a 
proton is called its chemical shift [246]. In an NMR spectrum, the x- axis expresses the 
chemical shift (in ppm) against the intensity of absorption on y-axis [245].  
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Figure 2.3 Schematic illustration of NMR spectroscopy 
The difference in the absorption of the electromagnetic radiation by different protons 
is due to the distinct electron densities and dissimilar chemical environments around 
them [244]. Therefore, each chemically discrete proton or group of protons generate a 
distinct resonance in the NMR spectra. The area measured under the NMR resonance 
represents the relative number (not the absolute number) of the chemically distinct 
protons in that chemical shift. The electrons around the proton act as a barrier and shield 
the proton from the applied magnetic field, and so prevent them from generating a high 
chemical shift. This phenomenon is termed the nuclear shielding [242]. The shielded 
proton, therefore, present only a small chemical shift [244]. Conversely, the removal of 
electrons by the electron withdrawing groups reduces the electron density around the 
proton and de-shields the protons. This effect allows the protons to generate a higher 
chemical shift [242]. 
Different functional groups have different characteristic chemical shifts. Figure 2.4 
displays a schematic diagram of some typical chemical shift in 1H NMR spectra. The 
shielded protons undergo lower chemical shifts and appear on the right hand side of the 
axis, which is called the up field. On the other hand, the de-shielded protons undergo 
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higher chemical shifts and appear on the left hand side called the down field side 
(increase in ppm). Trends in the proton NMR chemical shift are influenced by factors 
such as distance from the unsaturated groups (e.g., aromatic). The unsaturated groups 
are de-shielded and hence appear towards the down field side (left; increase in ppm) 
[247]. More precisely, a large chemical shift in a 1H-NMR spectrum corresponds to a 
proton that either has relatively little electron density around it, or is lying adjacent to 
the electron withdrawing groups. Similarly, a small chemical shift represents a proton 
that has greater electron density around it, indicating no adjacent electron withdrawing 
groups [248].  
 
 
Figure 2.4 Schematic representation of some typical chemical shifts in 1H NMR 
2.2.3 GPC 
GPC, also known as Size Exclusion Chromatography is a rapid and reliable technique 
for polymer characterisation [233]. It is a chromatographic technique that separates 
molecules on the basis of the molecular size. The analytes are pumped through the 
specialized columns containing a microporous packing material. The smaller analytes 
penetrate the pores more easily, therefore, are retained for longer time in these pores 
[241]. Alternatively, the larger analytes are retained for a less time in the pores and are 
eluted quickly. In this way, a range of molecular weights can be separated and 
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determined [241]. The comb shaped polymers can further be characterised by GPC to 
determine their molecular weight and size [233, 249]. 
2.3 AIM 
The hydrophobic and hydrophilic modification of PAH backbone. 
2.3.1 Objectives: 
 Substitution of hydrophobic (palmitoyl (Pa2.5) and dansyl (Da10)) and hydrophilic 
(QPa2.5) moieties on PAH backbone. 
  Characterisation of polymers by elemental analysis and 1H NMR spectroscopy to 
confirm grafting of hydrophobic and hydrophilic moieties on to the PAH backbone. 
2.4 MATERIALS AND METHODS 
2.4.1 Materials 
Materials Supplier 
Amberlite 96 resin Fluka, UK 
Dansyl chloride Sigma Aldrich, UK 
Deionised water milliq apparatus Millipore, UK 
Deuterated Water Sigma Aldrich, UK 
Dialysing membrane (7 and 12-14kDa cut-off limit) Medicell international Ltd, UK 
Diethyl ether Fisher Scientific, UK 
Dioxane Fisher Scientific, UK 
Ethanol Fisher Scientific, UK 
HCl Sigma Aldrich, UK 
Methanol Fisher Scientific, UK 
Methyl Iodide Sigma Aldrich, UK 
PAH-HCl Sigma Aldrich, UK 
Palmitic acid N hydroxy succinimide ester Sigma Aldrich, UK 
Polyallyllamine hydrochloride (MW= 15KDa) Sigma Aldrich, UK 
Sodium Carbonate Sigma Aldrich, UK 
Sodium Hydrogen Carbonate Sigma Aldrich, UK 
Sodium hydroxide Fisher Scientific, UK 
Sodium Iodide Sigma Aldrich, UK 
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2.4.2 Method 
2.4.2.1 Conversion of polyallylamine hydrochloride (PAH-HCl) to PAH free 
base 
PAH-HCl (10g) was dissolved in 100mL of deionised water.  1M NaOH was added 
into the PAH-HCl solution under gentle magnetic stirring, until pH 13 was achieved. 
The resulting solution was stirred for one hour. The solution was then dialysed with a 
visking tube of Mw cut-off = 7 kDa, against 5L of water with at least 12 water changes 
in 24 h [120]. The dialysate was freeze dried for 48h using inoLab WTW series pH 720 
Mechatech System Freeze Drier. PAH was recovered as a white rubbery solid. Figure 
2.5 represents the chemical structure of PAH. 
CH2 CH
CH2
NH2
*
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Figure 2.5 Chemical Structure of PAH 
2.4.2.2 Synthesis of modified polymers 
The synthesis of all polymers was performed using the method reported by  
Thompson et al. and briefly described as below [120].  
2.4.2.2.1 Synthesis of palmitoyl 2.5-polyallylamine (Pa2.5) 
Briefly, a solution of palmitic acid-N-hydroxysuccinimide ester (0.304 g in 100mL 
ethanol) was added drop-wise to the PAH solution (PAH free base 2 g in 100mL 
deionised water). Sodium hydrogen carbonate (2.35 g) was gradually added to the 
solution over 1 h. The reaction was stirred for 72 h at 500 rpm. The solvent was then 
evaporated in the rotary evaporator and the residue was dissolved in 50mL of deionised 
water. The solution was subsequently dialysed against 5L of water with 12 water 
changes (molecular weight cut-off=12-14 kDa). The dialysate was then freeze dried 
and collected as a white cotton-like solid [120]. Figure 2.6 presents the chemical 
reaction of synthesis of Pa2.5. 
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Figure 2.6 Chemical reaction of the synthesis of Pa2.5 
2.4.2.2.2 Synthesis of Quaternary ammonium amphiphilic polymer (QPa2.5) 
Pa2.5 (0.6 g) was dissolved in 100mL of methanol. Sodium hydroxide (0.557 g) and 
sodium iodide (0.25 g) were added into the Pa2.5 solution and stirred until completely 
dissolved. Methyl iodide (3.5 mL) was added into the mixture and the reaction was 
carried out at 36°C, over 3 h under nitrogen atmosphere. The supernatant was poured 
off and diethyl ether (400mL) was added to the white precipitate. The solution was then 
left to settle overnight at 25°C. The diethyl ether was then decanted and the precipitate 
was dried overnight. The dried precipitate was dissolved in 100mL of 1:1 (v/v) mixture 
of ethanol and distilled water and dialysed as described above section 2.4.2.2.1. The 
dialysate was then passed through an amberlite 93 exchange resin column (30mL), 
which had been previously washed with HCL (2 M, 100mL) and titrated to neutral pH 
with distilled water. The resulting clear elute was then freeze dried as above and 
collected as a white cotton-like solid [120]. Figure 2.7 presents the chemical reaction 
of quaternisation of Pa2.5 to QPa2.5. 
 
Pa2.5 
    PAH 
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Figure 2.7 Chemical reaction of synthesis of QPa2.5 
2.4.2.2.3 Synthesis of Dansyl 10-polyallylamine (Da10) 
The PAH free base was dissolved in 150mL dioxane: water (1:1v/v). Sodium 
carbonate (0.185g) was added and the solution was stirred until it was completely 
dissolved. Dansyl chloride (0.472g) was dissolved in dioxane (20mL), and was added 
drop wise to the polymer solution over 2h at 0˚C. The reaction was stirred for 4h at 0˚C, 
followed by 8 h stirring at room temperature. The solvent was evaporated and the 
residue washed 3 times with diethyl ether. The precipitate was then dissolved in doubly 
distilled water and dialyzed as mentioned above in section 2.4.2.2.1 and freeze dried 
for 48h [120]. The Da10 was recovered as a yellow fluffy solid. Figure 2.8 presents the 
synthesis of Da10.    
CH3I 
    Pa2.5     QPa2.5 
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Figure 2.8 Chemical reaction of synthesis of Da10 
2.4.2.3 Characterisation of polymers 
2.4.2.3.1 Elemental analysis 
Synthesised and unmodified polymers were characterized for their carbon, hydrogen 
and nitrogen contents by elemental analysis. 4 mg samples were analysed using a Flash 
EA® 1112 Elemental Analyser. The determination of percentage by weight of C, H and 
N was based on the quantitative “dynamic flash combustion” method as provided by 
Medac Ltd. The analysis was performed by combusting the sample at 1000˚C in oxygen 
in the presence of a catalyst under controlled conditions. The gases (CO2, H2O and N2) 
were separated by gas chromatography. 
2.4.2.3.2  Nuclear magnetic resonance spectroscopy (1H NMR) 
The polymers were characterized by 1H-NMR. A total of 3-5mgmL-1 of the polymer 
was dissolved in deuterated water (D2O), sonicated for 5min at maximum amplitude 
and allowed to cool down. The samples were filtered through cotton and loaded into 
the NMR tube (0.8 mL). The spectrums were obtained using JEOL 600 MHz 
Ultrashield spectrometer. Each spectrum is an average of 64 scans acquired at room 
temperature. 
    PAH 
    Da10 
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2.5 RESULTS 
2.5.1 Polymer Yield 
Table 2.1 demonstrates the initial molar feeds and percentage yield of the various 
polymers. 
Polymer yield was calculated by the following formula: 
% Yield =
Weight of product
Weight of reactants
 X 100 
 
The polymer percentage yield of hydrophobically modified polymers was found to 
be ˃80%. Unlike hydrophobically modified polymers, the quaternised polymer 
demonstrated a lower yield of ˂66%.  
Table 2.1  Properties of polymers (mean±SE) 
Polymer Type of 
grafting 
Initial 
molar feed 
ratio 
% Yield(mean±SE) 
(n=≥3) 
Physical 
appearance 
PAH - - 95%  Transparent 
sticky rubber like 
Pa2.5 Palmitoyl 1:0.025 86%  White cotton like 
Q Pa2.5 Quaternised 
palmitoyl 
1:0.025 65%  White cotton like 
Da10 Dansyl 1:0.10 82% Yellow cotton 
like 
2.5.2 Elemental analysis 
2.5.2.1 PAH 
Table 2.2 presents the findings from the elemental analysis of PAH. Using equation 
1, the molar ratios were calculated from the percentage weight obtained from the 
elemental analysis. Subsequently, the molar ratio relative to nitrogen was calculated by 
using equation 2. 
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For PAH, the element molar ratio relative to nitrogen was found to be 3.05:7.87:1 
(Table 2.2 ), which is in good agreement with 3 C’s, 7 H’s and 1 N theoretical atoms 
ratio of the empirical formula of the PAH monomer (Figure 2.5 ).  
Table 2.2 Calculation of the empirical formula of PAH 
  Elements 
C H N 
Element weight % obtained from elemental analysis 57.07 12.27 21.77 
Element molar ratio (x) 4.76 12.27 1.56 
Element molar ratio relative to N (x′) 3.05 7.87 1.0 
2.5.2.2 Modified polymers 
Table 2.3 demonstrates the elemental analysis results of the modified polymers. The 
molar ratio and molar ratio relative to nitrogen were calculated from the aforementioned 
equations 1 & 2 and subsequent calculations were performed by using the following 
equations 3 and 4.   
 
 
 
 
 
𝑀𝑜𝑙𝑒𝑠 𝑜𝑓 𝑒𝑙𝑒𝑚𝑒𝑛𝑡 𝑖𝑛 𝑡ℎ𝑒 𝑔𝑟𝑎𝑓𝑡𝑒𝑑 𝑔𝑟𝑜𝑢𝑝 𝑜𝑓 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑃𝐴𝐻 =
𝐸𝑙𝑒𝑚𝑒𝑛𝑡′𝑠 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑁 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 –  𝐸𝑙𝑒𝑚𝑒𝑛𝑡′𝑠 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑁 𝑜𝑓 𝑡ℎ𝑒 𝑃𝐴𝐻 (𝑥′)                                                                                                                       
           Equation 3 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑚𝑜𝑙𝑒 𝑚𝑜𝑑𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛
=
𝑀𝑜𝑙𝑒𝑠 𝑜𝑓 𝑐𝑎𝑟𝑏𝑜𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑔𝑟𝑎𝑓𝑡𝑒𝑑 𝑔𝑟𝑜𝑢𝑝 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑃𝐴𝐻 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑟𝑏𝑜𝑛 𝑎𝑡𝑜𝑚𝑠 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 𝑖𝑛 𝑡ℎ𝑒 𝑔𝑟𝑎𝑓𝑡𝑒𝑑 𝑚𝑜𝑖𝑒𝑡𝑦
 𝑥 100% 
                 
           Equation 4 
𝐸𝑙𝑒𝑚𝑒𝑛𝑡′𝑠 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 (𝑥) =
𝐸𝑙𝑒𝑚𝑒𝑛𝑡′𝑠 𝑤𝑒𝑖𝑔ℎ𝑡 % 𝑜𝑏𝑡𝑎𝑖𝑛𝑒𝑑 𝑓𝑟𝑜𝑚 𝑒𝑙𝑒𝑚𝑛𝑡𝑎𝑙 𝑎𝑛𝑎𝑙𝑦𝑠𝑖𝑠
𝐸𝑙𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡
      
          Equation 1 
         
𝐸𝑙𝑒𝑚𝑒𝑛𝑡′𝑠 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑁 (𝑥′) =
𝐸𝑙𝑒𝑚𝑒𝑛𝑡′𝑠 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 (𝑥)
𝐸𝑙𝑒𝑚𝑒𝑛𝑡′𝑠 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 𝑁
                  
Equation 2 
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Mole modification of the Pa2.5 and Da10 groups on the modified polymers was 
determined relative to PAH. The number of extra moles in modified polymers were 
determined by calculating the difference in the moles of PAH (3.05 moles) from Pa2.5 
and Da10 given as (3.75-3.05 = 0.70 extra moles of carbon) and (4.06 - 3.05 = 1.01 
extra moles of carbons) respectively (refer to Table 2.3). These results demonstrate that, 
for every 1 mole of nitrogen in Pa2.5, there were 3.75 moles of carbon and 12.34 moles 
of hydrogen. For each mole of nitrogen in QPa2.5, there were 6.54 moles of carbon and 
17.64 moles of hydrogen.  In addition, for every 1 mole of nitrogen in Da10 there were 
4.06 moles of carbon and 9.18 moles of hydrogen.   
On the other hand, the extra moles of carbon atom from quaternary amine moieties 
was determined relative to Pa2.5 i.e., 6.54- 3.75= 2.79 extra moles of carbon. The mole 
modification of various polymers was calculated from equation 4, as 4.3%, 46.6% and 
8.4% for Pa2.5, QPa2.5 and Da10 respectively.  
 
Table 2.3 Calculation of the % mole modification and empirical formula of modified PAH 
i.e., Pa2.5, QPa2.5 and Da10 
Polymers Pa2.5 QPa2.5 Da10 
Elements C H N C H N C H N 
Element weight % 
obtained from 
elemental analysis 
52.2 10.80 16.26  26 7.41 5.99 47.51 8.91 13.6 
Element molar 
ratio (x) (Equation 
1) 
4.35 10.80 1.16 2.16 7.47 0.42 3.95 8.91 0.97 
Element molar 
ratio relative to N 
(x′) (Equation 2) 
3.75 12.34 1.0 5.15 17.64 1.0 4.06 9.18 1.0 
Moles of the 
respective  element 
in the grafted 
moiety (Equation 
3) 
0.70 4.47 0 1.40 5.3 0 1.01 1.31 0 
% modification 
(Equation 4) 
4.3% 46% 8.4% 
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2.5.3 Nuclear Magnetic Resonance  
Each peak in the spectrum was identified and assigned a value based on the number 
of protons resonating at that chemical shift (δ). Peak areas were acquired by the 
integration of the 1H NMR spectra of protons. The mole modification of the polymers 
was calculated from the 1H NMR spectra by using the equation 5. A summary of the 
corresponding chemical shifts for each attached hydrophobic/hydrophilic group and 
percentage mole modification is tabulated in Table 2.4.  
 
    Percentage mole modification  
    =    Integration value of the peak i / number of protons i                        X 100 
        Integration value of CH2 PAH peak at δ2.5) / number of protons of CH2 PAH  
             Equation 5 
 
2.5.3.1 1H NMR spectra of PAH 
The proton chemical shifts of 1H NMR spectra of PAH in D2O were achieved as CH2 
(A) = δ1.05, 1.1 and 1.2, CH (B) = δ1.43, = CH2 (C) = δ2.5, 2.8 (Figure 2.9). The integration 
ratio of these peaks was found to be 97:52:100, respectively. This ratio correlates well 
with the theoretical 2:1:2 proton ratios in the PAH structure (Figure 2.5).  
        CH2: CH: CH2 
100
52.2
: 
52.2
52.2
:
97.15
52.2
 
1.91: 1: 1.86 
The two protons connected to the nitrogen atom are indiscernible in the NMR spectra, 
due to the fast exchange with deuterated solvent.  
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Figure 2.9 1H NMR spectra of PAH in D2O conducted by 600 MHz spectrometer at 25 ᵒC. 
2.5.3.2 1H NMR spectra of Pa2.5 
The 1H NMR spectra of Pa2.5 in D2O provides information regarding the 
palmitoylation of PAH on the primary amines. The proton chemical shifts of 1H NMR 
spectra of Pa2.5 in D2O were achieved as CH3 (A) = δ0.73, CH2 (B) = δ1.05, 1.12, 1.14, 1.16, 
CH (C) = δ1.5 and CH2 (D) = δ2.6, 2.7 of PAH (Figure 2.10; Table 2.4). In comparison to 
the PAH spectra, an additional small peak appeared much up field at δ0.73, just before 
the CH2 proton peak of PAH (Figure 2.10, A). This peak corresponds to the terminal 
CH3 and CH2 proton in the palmitoyl pendant group. The δ0.73 appears poorly resolved 
due to the overlapping between the peaks i.e., CH3 peaks from Pa2.5 and the CH2 peak 
from PAH. The grafting percentage was therefore calculated by comparing the CH3 
peaks from Pa2.5 with the CH2 peak from PAH at δ2.5, as the signal appeared clear with 
no overlapping between the peaks in this region.  The grafting percentage of Pa2.5 at 
peak at δ0.73 in the 1H NMR spectra was calculated as follows:    
 Grafting percentage 
= Integration value of the δ0.73 / number of protons in palmitic CH3 peak   x 100 
Integration value of δ2.5 / number of protons in PAH CH2 
 
(8.57 / 3) x 100 = 5.7 % 
      (100 /2) 
The percentage grafting of Pa2.5 was found to be 5.7%, which is close to the initial 
molar feed ratio.   
CH2 CH
CH2
NH2
*
x
*
 
A B 
C 
A B 
C 
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Table 2.4 Summary of the chemical shifts, number of protons attached to hydrophobic/ 
hydrophilic group generating resonance and the percentage mole modification 
Polymer  Peak (δ)  No of protons % Mole modification 
Pa2.5 0.73 3 5.7% 
QPa2.5 3.19-3.2 9 40.6% 
Da10 7.5- 8.28 6 7.7% 
 
 
Figure 2.10 1H NMR spectra of Pa2.5 in D2O conducted by 600 MHz spectrometer at 25 ᵒC. 
2.5.3.3 1H NMR spectra of Da10 
The 1H NMR spectra of Da10 in D2O showed an expanded spectrum consisting of 
multiple peaks from 7.5- 8.28 ppm (Figure 2.11; Table 2.4). In relation to PAH, two 
additional peaks i.e., at δ3.4-3.5 and at δ6.9-8.5 were obtained. These peaks correspond to 
the CH3 proton groups linked to the nitrogen atom of the dansyl moiety (peak A in 
Figure 2.11) and protons of the naphthalene ring (peaks B-F in Figure 2.11) 
respectively. The grafting percentage from peaks (B-F in Figure 2.11) at δ7.5-8.3 was 
calculated as given below. 
  Grafting percentage  
= Integration value of the δ8.3 / 6 protons from CH3 group attached to N of dansyl moiety   x 100 
Integration value of δ2.5 / number of protons in PAH CH2 
 
 = (23.27 / 6)    x 100 = 7.7% 
     (100/ 2) 
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The results indicate that 7.7% of the dansyl moiety was grafted on the PAH 
backbone, which appears to be in good agreement with the 8.4% obtained from the 
elemental analysis. 
 
 
Figure 2.11 1H NMR spectra of Da10 in D2O conducted by 600 MHz spectrometer at 25 ᵒC. 
 
2.5.3.4 1H NMR spectra of QPa2.5 
Figure 2.12 shows the 1H NMR spectra of QPa2.5 in D2O. The 
1H NMR spectra of 
QPa2.5 showed additional peaks in comparison to the PAH spectra. The additional peak 
was found at δ3.19-3.2 in the 1H NMR spectra after quaternisation of Pa2.5 (Figure 2.12, 
A). This peak corresponds to the quaternary ammonium moiety. This confirms the 
presence of quaternary ammonium moieties in the polymers. The grafting percentage 
from peaks δ3.19-3.2 in the 1H NMR spectra after quaternisation of Pa2.5 was calculated 
as given below 
Grafting percentage  
= Integration value of the δ3.2 / 9 protons in CH3 attached to quaternary ammonium moiety x 100 
Integration value of δ2.5/ number of protons in PAH CH2 
 
(182 / 9)    x 100 = 40.6% 
  (100/2) 
 
The grafting percentage (40.6%) calculated from peaks at δ3.19-3.2 corresponds well 
with the level of quaternisation obtained from the elemental analysis (46.6%). 
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Figure 2.12 1H NMR spectra of QPa2.5 in D2O conducted by 600 MHz spectrometer at 25ᵒC. 
 
2.6 DISCUSSION 
PAH has previously been used in the gene-delivery systems due to the presence of 
primary amine functional groups, which allowed it’s complexation with the negatively 
charged DNA [153]. The primary amine functional groups are also suitable sites for 
chemical modifications. Numerous reports have shown the ability of the modified PAH, 
like imidazolyl modified PAH [152], polyethylene glycol grafted PAH [250] and 
glycolated PAH [154] to reduce the cytotoxicity index compared to the unmodified 
PAH.  
In this project, a hydrophilic (QPa2.5) and two hydrophobic combed-shaped 
amphiphilic polymers (Pa2.5 and Da10) were synthesised successfully by grafting 
hydrophilic and hydrophobic grafts on to the PAH backbone. All the modified polymers 
displayed good percentage yield; Pa2.5= 86%, QPa2.5= 65% and Da10= 82%. Presence 
of hydrophilic and hydrophobic grafting on the PAH backbone was confirmed and 
quantified by using elemental analysis and NMR spectroscopy. Elemental analysis data 
determined the elemental composition whereas the corresponding 1H NMR spectra 
allowed determination of the approximate number of protons per structural unit.  
 
 
A 
A 
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The element molar ratios of the PAH obtained from the elemental analysis 
(3.05:7.87:1) corresponded well with the theoretical atoms ratio of the PAH monomer 
(3 C’s, 7 H’s and 1 N). The percentage grafting of the Da10 (8.4%) and Pa2.5 (4.3%) 
obtained from the elemental analysis were close to the initial molar feeds. The degree 
of quaternisation of Pa2.5 was found to be 46.6%. Thus the findings from the elemental 
analysis confirmed that hydrophobic (Pa2.5 and Da10) and hydrophilic (QPa2.5) 
moieties were successfully grafted on to the PAH backbone.  
The proton assignments for the PAH on the 1H NMR spectra were found to be,                      
δ1.01, 1.1 and 1.2 indicating CH2 protons (A), δ1.35 - CH protons (B) and δ2.4 indicating CH2 
protons adjacent to NH2 group (C). The chemical shift of proton in (-NH2) is dependent 
upon the temperature, solvent, concentration and the neighbouring group. The signals 
from the proton attached to NH2 group appeared obscured which may be ascribed to 
the fast exchange with deuterium. The integration ratio 1.91:1:1.86 of peaks of the PAH 
monomer determined from 1H NMR relates well to the theoretical monomer structure 
of PAH (CH2: CH: CH2), i.e., 2 protons: 1 proton: 2 protons 
The 1H NMR spectrum of the hydrophobically substituted PAH i.e., Pa2.5 resonated 
a small singlet peak at δ0.73 for protons from the terminal CH3 proton and CH2 protons 
of palmitoyl pendant group. The percentage modification was found to be 5.7% from 
the 1H NMR and 4.3% from the elemental analysis.  
Aromatic protons are absorbed in a region between 6-8.5 ppm. Multiplet peaks were 
recognized in the absorption region from 7.5 to 8.2 ppm due to overlapping between 
protons of different carbons in the naphthalene rings, which were assigned to the 
protons of the dansyl group. This higher chemical shift (δ7.5-8.2) towards the downfield 
upon dansylation confirms the presence of aromatic signal from the naphthalene ring 
of the dansyl moiety. Due to the multiple peaks splitting, it was difficult to differentiate 
between peaks of various equivalent protons. However, the presence of these peaks 
indicate the grafting of dansyl moiety on to the PAH backbone. The percentage grafting 
of Da10 calculated from NMR (7.7%) was found to be in close agreement with the 
initial molar feed as well as the results achieved from elemental analysis (8.4%).  
Signals of the methyl groups from the quaternary ammonium group appeared in the 
lower field i.e., 3.5ppm. The percentage modification achieved from the elemental 
analysis was 46.6% while 40.4% from 1H NMR, which are again consistent with each 
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other. The small variation between findings achieved from elemental analysis and 1H 
NMR results may be attributed to the integration boundaries setting. The data from 1H 
NMR studies together with elemental analysis confirms the grafting of the hydrophobic 
and hydrophilic moieties on to the PAH backbone.  
2.7 CONCLUSION 
Hydrophobic and hydrophilic moieties were successfully grafted on to the PAH 
backbone. The degree of substitution was confirmed by elemental analysis and nuclear 
magnetic resonance and was found to be in agreement with each other.  
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Chapter 3 
FABRICATION OF TERNARY 
POLYELECTROLYTE 
COMPLEXES 
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3 INTRODUCTION 
3.1 POLYELECTROLYTE COMPLEXES  
Polyelectrolyte complexes have emerged as a very useful means for the delivery of 
protein drugs. They are formed spontaneously by a simple process which is devoid of 
potentially harmful organic solvents and heat [251-253].  
As mentioned in chapter one, the conventional binary polyelectrolyte complexes are 
generally fabricated by using positively charged polymers which are known to be 
associated with non-specific binding with other negatively charged entities in the body, 
such as serum proteins [3, 97]. These polycation based systems also associated with a 
higher toxicity index [157]. Shielding the positive charge on particles reduces the non-
specific binding, whereby the polymer is not recognized as a foreign entity in the body 
and consequently is not opsonised [254]. In addition, shielding of the charge has also 
been shown to reduce the toxicity associated with the binary systems [153]. 
 A number of strategies have been employed by researchers to reduce the positive 
surface charge and hence the likelihood of non-specific interactions and charge 
associated toxicity. These strategies involve the modification of surface either with 
moieties which can effectively shield the surface charge such as PEGylation with poly 
(ethylene glycol) [254] or layer by layer technique where alternating layers of 
polycation and polyanion are tailored to achieve the desired morphology, surface 
charge and surface composition [255]. Boussif et al. has shown that modification of 
PAH with hydrophilic methyl glycolates not only enhanced its ability to mediate gene 
transfer into cells but also decreased charge associated cytotoxicity [154].  
Ternary polyelectrolyte complexes have shown to reduce the positive surface charge 
and hence the associated toxicity and non-specific interactions with the biocomponents 
[127, 131, 256]. Nimesh et al. has shown that polyallylamine-dextran sulphate-DNA 
(PAH-DS-DNA) nanoplexes considerably reduced the cytotoxicity associated with 
positive charge of polyallylamine [153]. A number of ternary polyelectrolyte systems 
such as poly(e-caprolactone)-graft-poly(N, N-dimethylaminoethyl methacrylate-DNA- 
polyglutamic acid-graft-polyethylene glycol complexes [127], polycaprolactone-graft-
poly(N,N-dimethylaminoethyl methacrylate) [256] and polyanion/pDNA/PEI 
complexes [131] have been prepared recently to reduce the positive surface charge and 
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hence toxicity associated with the corresponding binary complexes. Peng et al. showed 
that adding different anions and controlling their concentrations reduced the 
nonspecific interactions and hence the toxicity of chitosan nanoparticles to the cell 
membranes [257]. Poly(acrylic acid) (PAA) and dextran sulphate (DS) are two 
commonly used polyanions which have been used to form ternary complexes by a 
number of research group [258-260]. 
3.1.1 Polyanions 
3.1.1.1 Poly (acrylic acid) (PAA) 
Poly (acrylic acid) (PAA) is a weak polyacid with high density of carboxylic acid 
units on its surface which are deprotonated to yield negatively charged moieties (COO-
) (Figure 3.1). The COO- units are known to interact with the amines (NH3
+) of proteins 
to form polyelectrolyte complexes [261].  
PAA was chosen for the study because of its in vivo and in vitro biocompatibility 
[262]. Wang et al. coated CeO2 nanoparticles with dextran or PAA due to their 
enhanced biocompatibility properties, low toxicity, and reduced clearance by the 
immune system [260]. Zhang et al. has shown the ability of PAA to crosslink with PAH 
and improve the stability of complexes via interaction between carboxyl of PAA and 
amine groups of PAH [263]. 
The carboxyl groups on surface of PAA form mucoadhesive bonds with the mucosal 
surface [264]. This allows it to adhere to the gastrointestinal mucosal lining and 
improve the complex uptake by intestinal enterocytes [265]. This property permits the 
PAA based delivery system to increase the bioavailability of associated drug.  
PAA has been used as a scaffold for immobilization of biologically active molecules 
e.g., molecules containing amine groups such as proteins [266]. It has also been used 
to stabilize magnetic nanoparticles by providing electrostatic and steric repulsion 
against particle aggregation [261].  
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Figure 3.1 Chemical Structure of Poly(acrylic) acid 
3.1.1.2 Dextran Sulphate (DS) 
The polyanion dextran sulphate (DS) is a member of the family of 
glycosaminoglycan. It is a hydrophilic polysaccharides synthesized from the 
fermentation of sucrose by the enzymes, bacteria (Leuconostoc mesenteroides) or yeast 
[73]. It comprises of a branched chain of anhydroglucose units which contain 
approximately 2–3 sulphate groups per glucosyl unit (Figure 3.2) [267]. The presence 
of the sulphate groups (SO4
-2) ensures strong electrostatic interactions with the amino 
groups of proteins and polycations [96, 137].  
DS is used in this study because of its biodegradability and biocompatibility [96, 
153]. It has widely been used as blood plasma substitute and as a delivery vehicle of 
drugs due to its good biocompatibility and aqueous solubility [268]. It is characterized 
by its high molecular weight (3000- > 1 000 000 Da) and low toxicity [260]. Its 
hydrophilic nature allows it to complex with the water soluble proteins [96]. DS 
benefits from its low pKa which permits a charged state over a broad pH range. DS has 
also been shown to act as a colloidal protectant via steric hindrance.  
DS has been found capable of reducing the cationic charge of PEI nanoparticles [55]. 
Studies have shown that PEI and DS self-assemble at room temperature to complex 
amphotericin B [252], insulin [122] and DNA [269]. It has also been reported that DNA 
and insulin structures are protected when DS is used in the formulation of PEI-DS 
nanoparticles [55, 122].  
DS has been used to prepare chitosan-DS by a number of research groups [55, 258, 
270-272]. It has been used to complex anti-angiogenic hexapeptide (ARH peptide) 
[270], bovine serum albumin (BSA) [258], curcumin [271] and insulin [72]. The 
advantages of CS-DS nanoparticles [258, 270] are enhanced stability and increased 
mechanical strength over binary systems and CS-TPP microparticles [72]. The lower 
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stability and mechanical strength of binary systems and CS-TPP microparticles limit 
their usage as drug delivery systems. Pan et al. reported that chitosan-tripolyphosphate 
(CS-TPP) nanoparticles dissolved and dissociated at low pH in several minutes [49] 
whereas chitosan-DS complexes were stable in low pH [270]. Recently DS has also 
been used to complex modified chitosan such as glycol-chitosan (GCS) [273] and N-
(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride (HTCC) (Shu, Zhang, 
Wu, Wang, & Li, 2011) to spontaneously form methotrexate-loaded glycol-chitosan-
DS (GCS–DS) and HTCC-DS respectively upon mixing DS aqueous solution (0.1% 
w/v) under magnetic stirring. 
 
 
 
 
 
Figure 3.2 Chemical Structure of Dextran Sulphate 
The present study aimed to incorporate a polyanion (PAA or DS) into the binary 
complexes (PECs, between polycation and protein) to form ternary complexes (APECs 
between a polycation, polyanion, protein) to alleviate the problems of toxicity and non-
specific interactions associated with the binary complexes. Each polyanion (DS, 6-
10KDa and PAA, 1.8KDa) was complexed with a polycation (PAH, palmitoyl grafted 
PAH (Pa2.5), dansyl grafted PAH (Da10) or quaternised palmitoyl PAH (QPa2.5) to 
form eight NIL ternary polyelectrolyte complexes (APECs). Insulin was used as a 
model protein to form eight IL ternary APECs. The PECs were used as a control. The 
effect of different hydrophobic groups (Pa2.5 and Da10) and quaternisation on the 
formation and stability of the APECs was established. The influence of polyanion on 
the physico-chemical properties, stability and insulin association efficiency of APECs 
was also investigated. The changes in formulation pH, temperature and ionic strength 
have significant effect on the stability of complexes [125]. Therefore, the stability of 
PECs and APECs was assessed and compared at varying pH (7.4, 6.6 and 1.2), ionic 
strength (NaCl 68mM, 102mM, and 145mM) and temperature (25ᵒC, 37ᵒC, 45ᵒC).  
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3.2 POLYELECTROLYTE INTERACTION AND COLLOIDAL STABILITY 
The ability of a colloidal dispersion to resist aggregation is defined as colloidal 
stability [274]. The stability of the colloidal systems is well- explained by Derjiaguin, 
Landau, Verwey and Overbeek (DLVO) theory (Figure 3.3) [275]. This theory provides 
a concept for assessing the balance between repulsive and attractive interactions 
between two particles in a dispersion which serves for their stability [276]. It is based 
on the principle that the forces between two particles are determined by the sum of two 
forces i.e., van der Waals attractive forces and electrical double layer repulsive forces 
[277]. As the particles in a solution approach each other due to Brownian motion, an 
energy barrier resulting from the electrical repulsive forces prevent the particles from 
diffusing close to each other [278]. However, in case the repulsive forces are weak or 
if the particles collide with sufficient energy to overcome the energy barrier, the short-
range Van der Waals attractive forces may pull the particles closer leading to 
aggregation or flocculation [278]. Therefore, a balance of the repulsive and attractive 
forces is required to maintain the stability of the particles which is essentially dependent 
on the magnitude of the surface charge.  
 
Figure 3.3  The interaction forces involved in a colloidal particulate system as stated by 
DLVO theory. The net energy is given by the sum of both attractive and repulsive forces 
when particles approach each other (Adapted from Malvern instrument ltd., 2004). 
 
Double layer repulsive force 
Net Energy 
Van der Waals attractive force 
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3.2.1 Factors influencing the formation and stability of polyelectrolyte 
complexes  
3.2.1.1 Effect of pH on stability of ternary complexes 
The formation of polyelectrolyte complexes requires the polymers/protein to be in an 
ionised state and bear opposite charges to mediate electrostatic interaction [79]. 
However, the degree of ionisation of charged groups of colloidal dispersions is affected 
by small changes in pH which subsequently affect the charge density of the 
polyelectrolyte solution [279, 280]. This is the reason that the formation of 
polyelectrolyte complexes occurs in a limited pH range, i.e., at pH values in the vicinity 
of pKa of the polymers/protein [125]. The acidic and basic groups of polymers exist in 
a protonated form at acidic pH and deprotonated form at alkaline pH. Therefore, the 
amino groups from the polyelectrolytes are ionised at an acidic pH (i.e., pH below their 
pKa) when they exist in their protonated form (NH3
+) while remain deprotonated and 
hence unionised at pH above their pKa. On the other hand, the acidic groups such as 
carboxylic acid and sulfonyl groups are completely deprotonated/ionized (COO-) at 
basic pH (i.e., pH above their pKa) and are protonated (COOH) at a pH below their 
pKa. Consequently, basic groups are ionised at acidic pH while acidic groups are 
ionised at alkaline pH [281]. This shows that the stability of the complexes depends 
upon the pH of the medium. It is essential that the polyelectrolyte complexes are stable 
at physiological pH of the stomach (pH 1.2−2.5) as well as the intestine (pH 6.6) to 
cargo the protein drug safely across the cellular barrier in the intestine. However, it is 
difficult to achieve a system which is stable at both stomach and intestinal conditions 
as both the cationic and anionic polyelectrolytes are required to be in their highly 
charged state to achieve optimum complexation and stability at aforementioned pH.  
There have been investigations on the influence of formulation pH on the stability of 
polyelectrolyte complexes. Reschel et al. has shown that the stability of complexes 
formed by polycations depend on their basicity i.e., number of primary amine groups 
and their degree of dissociation. It was shown that the coagulation of poly[N-(2-
aminoethyl)methacrylamide trifluoro acetate (PAEMA) complexes started at lower pH 
values than for poly(L-lysine) (PLL), which was assigned to its higher basicity [282]. 
By contrast, the lower basicity of PLL led to a higher degree of dissociation of amino 
groups of PLL compared to those of PAEMA. Burnova et al. investigated the effect of 
pH on ternary interpolyelectrolyte complexes of insulin-
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poly(methylaminophosphazene) hydrochloride-dextran sulphate complexes (PMAP-
DS). It was shown that under conditions imitating the human gastric environment (pH 
2, 0.15 M NaCl), insulin-PMAP-DS complexes showed a complete immobilisation of 
insulin in the complexes. However, under conditions imitating the human intestinal 
environment (pH 8.3, 0.15 M NaCl), the ternary complexes were shown to dissolve and 
dissociate leading to free insulin and soluble binary insulin-PMAP complexes [136].  
Investigations have been done to increase the stability and prevent the dissociation 
of complexes at a broader pH range. Quaternised groups have been introduced in 
polycations such as chitosan [259] and polyallylamine [120] to increase their stability 
at a wider pH range. It is thought that quaternisation can prevent the loss of protein 
drugs in the gastric cavity by generating electrostatic interaction at a wide pH range due 
to a permanently charged state [259]. At pH 6.0, TMC a quaternised derivative of 
chitosan and γ-PGA are ionised and therefore form spherical shaped polyelectrolyte 
complexes. γ-PGA has a pKa of 2.6 and therefore, at pH 1.2-2.0, most carboxylic 
groups on γ-PGA remain unionised. Hence, there was little electrostatic interaction 
between TMC25 and γ-PGA, leading to disintegration of the complexes. At pH values 
above 6.6, the free amino groups on TMC25 are deprotonated, thus again leading to the 
disintegration of nanoparticles [186]. These findings show that type of polyanion plays 
an important role in the stability of complexes.  
DS has a much lower pKa (1.2) which ensures a charged state at highly acidic pH 
resulting in greater stability. This effect has been demonstrated by Shu and group who 
prepared polyelectrolyte complexes via electrostatic interaction between HTCC and DS 
and investigated their stability at various pH. Since there were more N+(CH3)3 groups 
in HTCC and more ionised SO4
–2 groups in DS, at pH 1-2 (simulating the pH in stomach 
after meal), pH 2.5-3.7 (simulating the pH in the fasting stomach) and pH 6.0-6.6 
(simulating the pH in the duodenum) [186], therefore strong electrostatic interactions 
resulted and so the complexes remained intact over a broader pH range [259]. 
3.2.1.2 Effect of ionic strength on stability of ternary complexes 
Stability of colloidal dispersion may also be affected by increasing the ionic strength 
of the medium [113]. The addition of salt in the polyelectrolyte solution can screen the 
charge on the surface of particles leading either to reduction in the net charge or charge 
neutralisation [113]. Reduction in charge reduces the mutual electrostatic repulsion 
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between the particles and causes them to aggregate [279, 283]. Holappa et al. studied 
the effect of salt concentration (20 and 80mM NaCl solutions) on the complexes formed 
between a diblock copolymer (comprising of an anionic block and an electroneutral 
one, poly(ethylene oxide-block-sodium methacrylate), PEO block- PMANa) and a 
polycation, poly(methacryloyloxyethyl trimethylammonium chloride) [284]. It was 
shown that increasing the salt concentration increased the particle size which was 
attributed by authors to screening of the repulsive charges which resulted in the 
formation of bigger complexes [284]. However, numerous reports have indicated the 
role of salt in facilitation of complex formation [285]. Recently, Yousefpour and co-
workers have shown a salt dependent interaction of doxorubicin-DS particles [285]. 
Besides, it has been shown by Sun et al. that the addition of NaCl up to 300mM did not 
bring any change in the size of complexes suggesting their stability in the salt conditions 
[54]. 
3.2.1.3 Effect of temperature on stability of ternary complexes 
The temperature may or may not affect the polyelectrolyte complexes adversely. It 
may bring about a change in aqueous solubility of the polymers resulting in soluble, 
less soluble or insoluble systems [286]. It is thought that certain molecular interactions 
such as hydrogen bonding and hydrophobic effects are temperature dependent [287]. 
Therefore, an elevated temperature may favour/oppose polymer chain association 
leading to chain rearrangements which subsequently changes the particle conformation 
[288]. The hydrophilic segments of polymer chain may experience dehydration caused 
by the desolvation of water molecules upon increase in temperature. This may cause 
loss of interaction of polymer chain with water molecules leading to destabilisation of 
complexes [112]. Alternatively, the polymeric chains may acquire a more hydrophobic 
structure and hence stronger hydrophobic association leading to a shrinkage in size 
[288]. Kleinen et al. has shown that increase in temperature causes shrinkage in particle 
size which subsequently increases the colloidal stability [289]. Mao et al. also reported 
that elevated temperatures facilitated polyelectrolyte complex formation (Mao et al., 
2001, 2005a). 
3.2.1.4 Effect of formulation parameters on stability of ternary complexes 
The formation and stability of polyelectrolyte complexes may be controlled by 
manipulating the formulation parameters. The mixing ratio of polycations and 
polyanions is a crucial parameter that controls the stability of complexes. Chen et al. 
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has shown that the particle size, surface charge and protein complexation efficiency are 
all dependent on the polycation: polyanion (Chitosan: DS) ratio [270]. Reduction in 
particle surface charge reduces the electrostatic interaction between polymeric chains 
resulting in change in particle sizes. The non-stoichiometric polycation/DNA 
complexes prepared with an excess of polycation have been shown to possess a positive 
surface charge [282]. However, the introduction of polyanion in binary complexes 
reduces the positive charge and hence the charge ratio. Chen et al. has shown that the 
charge of arginine-rich hexapeptide loaded nanoparticles changed from positive to 
negative on addition of the DS indicating that complexation has occurred [270].  
Umerska et al. has shown that addition of hylauronic acid in chitosan at first either 
decreased the particle sizes slightly with decreasing hylauronic acid/chitosan ratio or 
did not change the size significantly [290]. However when the charge ratio reduced to 
an extent that polymers approached a charge equivalence point (n−/n+ = 1), the particle 
sizes rapidly increased and large aggregates were formed. This behaviour was attributed 
to a decrease in electrostatic repulsion between the particles as the net surface charge 
decreased [290]. Hu et al. has also shown that the ratio of chitosan to acrylic acid 
influenced the mean particle size [253]. The surfaces of chitosan–PAA nanoparticles 
was found to have positive charge of about 20–30mV at different ratio of chitosan to 
acrylic acid [253]. However, as the ratio of chitosan/acrylic acid increased, the ZP also 
increased and vice versa [253]. Tiyaboonchai and colleagues showed that as the charge 
ratio of PEI to DS increased from 0.5:1 to 3:1, the mean particle size decreased [122].  
The polymer charge ratio has shown a considerable influence on the viscosity of 
colloidal dispersion [290]. When one of the polymers is used in excess, there are still 
molecules of that polymer which do not participate in the formation of complexes or 
which only weakly interact with the complexes, these polymer molecules are 
responsible for increasing the viscosity of the colloidal system [290].  
Chen et al. has shown that the charge ratio of the two ionic polymers i.e., chitosan 
and DS affects the complexation efficiency of bovine serum albumin by altering the 
electrostatic binding with the protein [258]. The higher the charge ratio, the higher was 
the entrapment efficiency [258]. However, on the other hand, Peng et al has shown that 
adding different anions in chitosan and controlling their concentrations did not 
influence DNA encapsulation [257]. Saboktakin et al. investigated the effect of the 
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order of mixing of polymers and protein on the complexation efficiency of 5-
aminosalicylic acid (5-ASA). They showed that the order of mixing had no effect on 
the complexation efficiency of 5-ASA as well as the size of 5-ASA-loaded chitosan-
DS [291].  
The polymer architecture has been found to have significant effect on the 
physicochemical properties of complexes [120]. Thompson et al. has shown that the 
level of grafting and type of hydrophobic pendant groups has an impact on the 
behaviour of the assemblies in water [120]. Increasing the hydrophobic load was shown 
to reduce the particle size. The authors attributed this effect to the ability of higher 
hydrophobic payload to shield the hydrophobic portions from water more effectively 
due to stronger hydrophobic interactions. On the other hand, their counterparts required 
more amphiphilic polymers to come together to achieve the same level of protection 
which resulted in an increase in hydrodynamic size of complexes with less hydrophobic 
payload [120].  
The presence of hydrophobic moieties in copolymers also enhance the stability of 
complexes due to the added hydrophobic associations as compared to non-hydrophobic 
complexes. Filippov et al. has shown that the colloidal stability of polyplexes increases 
with increasing the hydrophobic cholesterol content in polycations [251]. The 
complexes prepared from polycations P17 with the lowest content of cholesterol 
showed the highest coagulation rate. The rate of coagulation was lower for the 
polyelectrolyte complexes prepared with polycations bearing higher amounts of 
cholesterol [251]. Reschel et al. has also shown a higher stability of (PAEMA)/DNA 
complexes, compared to PLL/DNA complexes which was attributed to a more 
hydrophobic nature of the polymer carbon chain [282]. 
The presence of bulky groups in the side chain of the polycation have been reported 
to have notable effects on the protein complexation efficiency and physicochemical 
properties of complexes [120, 292]. The permanent positive charge of bulky 
quaternised polymers have shown increased inter-chain repulsion and ability to 
counteract the hydrophobic interactions between grafts [120]. The bulky side chains on 
chitosan have shown significant steric hindrance effects that reduced the charge based 
interactions leading to low protein complexation efficiency [292].  
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A number of research groups have shown that the use of a cross-linker such as 
tripolyphosphate (TPP) or zinc sulfate (ZnSO4) is essential  for the formation and 
stability of the complexes [122, 293]. The cross-linker stabilises the particles through 
interactions with polymeric chains [73]. However, high concentration of TPP has been 
shown to be unfavourable, as it neutralised the positive charge of chitosan and led to 
aggregation of the complexes [294]. This is the reason that cross-linkers are used in a 
very low concentration to prevent aggregation of the polyelectrolyte complexes. 
Tiyaboonchai and colleagues studied the role of concentration of cross-linker (ZnSO4) 
on the physicochemical properties of PEI-DS [122]. It was found that a concentration 
of 15–25µM ZnSO4 was optimal in producing stable PEI: DS (1.5:1, pH 9 PEI 
solutions). It was also shown that as the amount of ZnSO4 was increased, the particle 
size decreased [122]. Precipitation was observed at higher concentrations of ZnSO4 
(35µM). Formulations prepared without ZnSO4 showed a mean particle size twice as 
large as before lyophilisation [122].  
Umerska et al. prepared polyelectrolyte complexes composed of hyaluronic acid and 
chitosan which were found stable in the absence of cross-linker [290]. It was shown 
that chitosan (CL213 and G213) with a higher molecular weight produced larger and 
fast sedimenting chitosan-hyaluronic acid particles than the low MW chitosan. The 
authors attributed this effect to the presence of more amino groups on the long polymer 
chain of high MW polymer than low MW polymer which interacted with carboxyl 
groups of hyaluronic acid leading to large particles and aggregates [290]. 
A number of researches have shown the ability of polyelectrolyte complexes to 
protect protein conformation and activity from enzymatic degradation and at low pH 
[73, 122, 295]. PEG-graft-trimethyl chitosan-insulin nanocomplexes were shown to 
protect insulin from enzymatic degradation [295]. Similarly, PEI-DS have been 
reported to protect DNA [269] and insulin structures [122]. Tiyaboonchai and 
colleagues have shown that the structurally altered insulin, completely dissociates from 
PEI in higher (153mM NaCl) ionic strength medium and returns to a native-like 
conformation [122]. The insulin- poly(methylaminophosphazene-DS (Insulin-PMAP-
DS) complexes have not only been shown to protect the insulin in the acidic conditions 
but also to preserve the insulin conformation [136]. Sarmento et al. reported that 
chitosan-DS complexes showed the preservation of immunogenic bioactivity of insulin 
[296]. This is the reason that all novel polyelectrolyte systems should be characterised 
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to determine their physicochemical properties such as particle size and surface charge 
to elucidate their formation and stability at various conditions.   
3.3 CHARACTERISATION OF POLYELECTROLYTE COMPLEXES   
The properties of polyelectrolyte complexes such as particle size, size distribution 
(PDI) and surface charge (ZP) have been identified as essential parameters for their 
characterisation [297, 298].  
3.3.1 Particle size and size distribution 
Particle size determination is the key step in the characterisation of polyelectrolyte 
complexes [297, 299]. It is a very useful indicator for determination of many properties 
of particulate materials. The colloidal particles have a size in the range between 1 to 
1,000 nm which allows them to remain dispersed in the aqueous environment whereas 
larger particles ˃1 micron are susceptible to sedimentation [115, 300].  
The colloidal dispersions rarely exist as monodisperse systems (one size) [301]. The 
more similar the size of particles in a particular system, the narrower is the size 
distribution [302]. On the other hand, a broad size distribution results from a wide range 
of particle sizes. A PDI closer to 0.1 on a scale from 0 to 1 is considered to have a 
homogenous particle population [302, 303]. A high PDI reflects a dispersion 
comprising of a number of different particle sizes. Each particle size may show different 
functionality such as uptake, biodistribution, immune generation and elimination 
(Table 3.1). The different particle sizes in a colloidal dispersion prevent the 
demarcation of size dependent functionality of particles. This makes the low PDI an 
essential requirement for a formulation [298].  
Slight differences in particle size have significant implications on the cellular uptake, 
mechanisms of uptake process, biodistribution  and bioavailability of the nanocarriers 
(Table 3.1) [297, 304]. The nanocarriers of size ≤200nm have shown efficient 
biodistribution and targeted delivery [302, 305, 306]. They have been shown to avoid 
uptake by reticuloendothelial system (RES) and mononuclear phagocytic system 
(MPS) and thus attain an extended circulation time as compared to the particles with 
larger diameter [305]. The smaller particles (20-30nm) undergo rapid renal excretion 
whereas large particles (˃200nm) are phagocytized by the MPS of the lung, liver, 
spleen, and bone marrow [302, 305, 306]. Large particles (˃200nm) have also been 
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reported to activate human complement system, and are rapidly cleared by Kupffer cells 
[305].  
Numerous studies have reported that the uptake of particles increases with decreasing 
particle size [304, 305]. He et al. reported a size-dependent uptake of Rhodamine B 
labeled carboxylated chitosan grafted- bovine serum albumin nanoparticles where 
particle size ˂300 nm demonstrated higher uptake by gut enterocytes and M cells; and 
higher systemic biodistribution than the larger particle sizes (600 and 1000 nm) [304].  
Table 3.1 A summary of the effects of nanocarriers’ size on bio-functionality  
 
Size of 
nanocarriers  
Functionality 
<500nm Endocytosis (Kulkarni et al.,2013) 
≥200nm Efficient phagocytosis [307] 
 Activation of complement system (Paur et.al., 2011) 
≤200nm Efficient uptake (Hartig et al., 2007; Yin Win et al., 2005) 
 Efficient bio-distribution (M. Gaumet et al., 2008; He et al., 2012) 
 Avoid RES and MPS (X-M. Liu et al.,2004; Kulkarni & Feng, 2013) 
 Extended circulation time (Kulkarni & Feng, 2013) 
60-100nm Receptor medicated uptake   (Zhang et al., 2009) 
<50nm Paracellular transport (Kulkarni & Feng, 2013; Goldberg et al., 2003) 
20-30nm Rapid renal clearance       (Kulkarni & Feng, 2013) 
 
It has been reported by Kulkarni et al. that small sized polystyrene nanoparticles 
modified with the d-α-tocopheryl polyethylene glycol with a diameter of 100 nm 
demonstrated the highest uptake among range of particles tested [305]. These properties 
make the small particles 100-200 nm, more favourable delivery systems owing to their 
higher uptake and biodistribution [115, 308]. However, nanoparticles with large 
hydrodynamic sizes (600 and 1000 nm) have been shown to be phagocytized more 
efficiently by murine macrophages [304]. 
 The size of particles also governs the route of particle uptake by the gut enterocytes 
such as paracellular passage (size < 50 nm) and endocytosis (size ≤500 nm) [305]. 
Zhang et al. has shown an upper limit of particle radii (60 nm) for receptor-mediated 
endocytosis [309]. All these investigations point towards the fundamental importance 
of measurement and control of the particle size of all delivery systems [88]. It is equally 
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important to determine the surface charge of particle which has been considered as the 
major factor in controlling the stability of the polyelectrolyte complexes. 
3.3.2 Particle surface charge 
ZP is an estimate of the surface charge of particles in colloidal dispersion [310]. The 
chemical groups on the surface of polyelectrolytes ionise in an aqueous solution to give 
a residual negative or positive charge on the particle surface, referred as the surface 
charge [310]. The oppositely charged ions form a counter-ion cloud around the ionised 
particles forming an electrical double layer (Figure 3.4) [311]. The net charge is thus 
derived not only from the surface charge but also from the surrounding counter-ions 
and reduced coions [280]. The inner region of the electrical double layer is known as 
the stern layer where the ions are strongly bound to the interfacial groups; whereas the 
outer region is called diffuse layer where the ions are less firmly associated [312]. There 
is an imaginary boundary in the diffuse layer called the hydrodynamic shear in which 
the ions and particles form a stable entity. The potential at this boundary is known as 
the zeta potential. 
 
 
Figure 3.4 Schematic illustration of electrical double layer of a particle 
(Adapted from nanoComposix, 2012) 
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ZP is used to predict and control the colloidal stability [308, 313]. It is an indirect 
measure of the magnitude of the electrostatic repulsion between the particles [314]. ZP 
has an impact on a particle’s tendency to associate with oppositely charged 
protein/polyelectrolyte [309]. A strong positive or negative charge is beneficial for 
electrostatic interactions with oppositely charged molecules, therefore large zeta 
potentials above (+/-) 30mV prevent aggregation and form an electrostatically stable 
dispersion [115, 315]. By contrast, the low ZP leads to a decrease in repulsive forces 
resulting in flocculation [314, 316].  
ZP is often measured as a function of pH. A change in pH alters the degree of 
ionisation of polyelectrolytes and hence the ZP of particles. Dissociation of the acidic 
groups gives rise to a negatively charged particle surface whereas basic groups ionise 
to acquire a positively charged surface. 
ZP also influences the uptake of particles by the cells and penetration of particles 
through the mucus layer of the GIT (de Campos, 2004). He et al. has shown that 
rhodamine B (RhB) labeled carboxymethyl chitosan grafted nanoparticles (RhB-
CMCNP) and chitosan hydrochloride grafted nanoparticles (RhB-CHNP) bearing 
higher positive or negative surface charges are more attractive to macrophages than the 
nanoparticles with low surface charge [317]. The cellular uptake of positively charged 
RhB-CHNP-CPT increased with the increase in surface charge [317]. It was considered 
that nanoparticles with a higher positive charge exhibited a stronger affinity for the 
negatively charged cell membrane, accounting for its higher cellular uptake [317]. RhB-
CMCNP of 150 nm in diameter displayed surface-charge-dependent cellular uptake, in 
the order -15 > -25 > -40 mV which was assumed to be due to the weakened electrostatic 
repulsion forces between the nanoparticles and the cell membranes. 
Internalisation of NPs formed of cationic chitosan and its derivatives appeared to 
occur predominantly by adsorptive endocytosis [67, 205]. Harush-Frenkel and group 
has shown a low rate of endocytosis of the negatively charged (mPEG–PLA) 
nanoparticles which did not utilize clathrin-mediated endocytosis pathway [208]. On 
the other hand, positively charged (mPEG–PLA) NPs formed with cationic lipid 
stearylamine were internalized rapidly via the clathrin-mediated pathway [208].  
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3.3.3 Techniques for the physicochemical and morphological 
characterisation of PECs 
Light scattering techniques are commonly used for the analysis of particle size and 
ZP [298]. In this study, dynamic light scattering (DLS) was employed to determine 
these physicochemical properties of the polyelectrolyte complexes. In addition, 
transmission electron microscopy (TEM) was used to characterize the morphological 
appearance of the polyelectrolyte carrier systems. 
3.3.3.1 Dynamic Light Scattering  
DLS, also called photon correlation spectroscopy or quasielastic light scattering is a 
valuable analytical technique for the analysis of submicron particulate systems (Figure 
3.5) [299, 318]. It is used to determine the hydrodynamic size, PDI and ZP of particles. 
DLS determines these parameters by measuring the speed of motion of particles in a 
fluid medium referred to as “Brownian motion” (the erratic random movement of 
microscopic particles in a fluid, resulting from the continuous bombardment of the 
surrounding molecules).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5  Schematic illustration of a Dynamic Light Scattering spectrophotometer 
Colloidal dispersion 
Helium laser 633nm     Focusing lens 
 
Auto-correlator 
 
Photomultiplier tube  
Detector 
Computer 
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A DLS spectrophotometer is equipped with a 633nm helium-neon laser which is used 
as a standard light source. A monochromatic light from this laser passes through the 
nano-dispersed system and scatters in all directions upon interaction with the particles 
in the dispersion [319]. Since the particles undergo Brownian motion, significant 
intensity fluctuations are produced which are detected and analysed by an auto-
correlation function which then yield the hydrodynamic radius of the particles [319]. 
These determinations are made on the basis of how fast the particles move within a 
system, due to the Brownian motion [299]. Generally, small particles move faster than 
larger particles at the same temperature.   
ZP cannot be measured directly; however, it can be calculated from the 
electrophoretic mobility (the velocity of the particle in an electric field) of particles in 
a solution by DLS. When an electric field is applied, particles move towards the 
oppositely charged electrode [320]. As the amount of charge is proportional to the 
velocity of the particles, the ZP is estimated by measuring the velocity of the particles 
[314].  
3.3.3.2 TEM 
TEM is a very powerful tool used to study the morphological properties of nanoscale 
materials [321]. As the name indicates the principle of the technique is based on the 
transmission of a beam of electrons through the specimen via the condenser lens system 
to form an image [322]. The negatively charged electron beam passes through multiple 
electromagnetic lenses down the column and is focussed at a point. These focused 
electrons strike the specimen on the stage and bounce off, creating X-rays in the process 
which are converted into light signals [298].  These signals form an image which is 
focussed by the objective lens to a point and subsequently magnified by projector lenses 
onto an imaging device [322].  
TEM produces high-resolution, two-dimensional, black and white images which 
allow direct visualisation of nano and microstructures [321]. It allows precise 
measurement of particle size and shape and can provide clear structural information. 
These properties make TEM a very reliable part for the characterisation of 
nanomaterials.  
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3.3.4 Quantification of protein complexation: 
The protein association efficiency of the polyelectrolyte complexes is generally 
defined as the amount of protein bound to the polymer and is expressed as percentage 
association efficiency. Protein are complexed to the polyelectrolytes by electrostatic 
interaction. The amount of protein associated in polyelectrolyte complexes can be 
quantified by techniques such as high performance liquid chromatography (HPLC) 
[323] and enzyme linked immunosorbent assays (ELISA) [324]. 
3.3.4.1 High Performance Liquid Chromatography  
HPLC is a chromatographic technique for quantitative and qualitative analysis of 
analytes in a sample. Among different types of chromatography, reverse phase high 
performance liquid chromatography (RP-HPLC) is commonly employed for 
identification and detection of peptide and proteins. It involves separation of molecules 
on the basis of their hydrophobicity [325].  
RP-HPLC typically includes a sample injection device, high pressure pumps, column 
and a detector. The sampler takes the sample into the mobile phase stream which then 
transports it into the column. The pump provides the desired flow and composition of 
the mobile phase to the column [326]. The detector generates a signal which is 
proportional to the amount of sample coming out from the column, thus allows the 
quantitative analysis of the sample components. A digital microprocessor and user 
software provides the data analysis [326].  
RP-HPLC is characterised for its excellent reproducibility and resolution. However, 
the main drawback is the irreversible denaturation of protein samples which reduces 
the biological activity of protein. For this reason the use of RT-HPLC for protein 
detection and quantification is discouraged and ELISA is preferred over it [327]. 
3.3.4.2 Enzyme Linked Immunosorbent Assay  
ELISA is a commonly used biochemical technique for the detection of specific 
antigens in samples. It offers a simple and convenient method for the quantitative 
determination of proteins such as insulin in the samples [328]. The main advantage of 
ELISA is that it preferentially detects the active forms of protein and thus provides a 
good correlation to the bioactivity of protein [329]. 
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A sandwich ELISA is a solid phase two-site enzyme immunoassay which is based 
on the direct sandwich technique [330]. The technique utilizes two antigen specific 
antibodies, i.e., a capture antibody bound to a solid phase and an enzyme linked 
detection antibody. The two monoclonal antibodies are directed against separate 
antigenic determinants on the protein molecule e.g., insulin [331]. The capture 
antibodies (peroxidase-conjugated anti-protein antibodies) first bind to the antigen 
(insulin) in the sample. Later on, anti-insulin antibodies are added which bind to 
antigen-antibodies conjugate. The bound conjugate is detected by reaction with a 
florescent marker such as 3, 3´-5, 5´-tetramethylbenzidine (TMB). The reaction is 
stopped by the addition of an acid, giving a colorimetric endpoint that is read 
spectrophotometrically.  
3.4 AIM AND OBJECTIVES  
3.4.1 Aim 
Fabrication and characterisation of NIL and IL APECs for oral insulin delivery. 
3.4.2 Objectives 
 Preparation and characterisation of polycation solutions.  
 Fabrication and characterisation of IL PECs. 
 Fabrication and characterisation of NIL and IL APECs. 
 Quantification of insulin in the PECs and APECs 
 Determination of effect of pH (7.4, 6.6 and 1.2), temperature (25ᵒC, 37ᵒC and 
45ᵒC), and ionic strength (68mM, 102mM, and 145mM of NaCl solution) on 
the stability of IL PECs and IL APECs. 
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3.5 MATERIALS AND METHODS 
3.5.1 Materials 
Materials Supplier 
0.8µM syringe filter (Millipore) Fisher Scientific, UK 
Amberlite 96 resin Fluka, UK 
Bovine insulin Sigma Aldrich, UK 
Bovine Insulin ELISA Kit Meracodia, Sweden 
Dansyl chloride Sigma Aldrich, UK 
Deionised water milliq apparatus Millipore, UK 
Dextran Sulfate (6-10KDa) Sigma Aldrich, UK 
Dialysing membrane (7 and 12-14kDa cut-
off limit) 
Medicell international Ltd, UK 
Diethyl ether Fisher Scientific, UK 
Dioxane Fisher Scientific, UK 
Ethanol Fisher Scientific, UK 
Hydrochloric Acid Fisher Scientific, UK 
Methanol Fisher Scientific, UK 
Methyl Iodide (Sigma Aldrich, UK 
Palmitic acid N hydroxy succinimide ester Sigma Aldrich, UK 
Polyacrylic acid (1.8KDa) Sigma Aldrich, UK 
Polyallyllamine Hydrochloride (MW= 
15KDa) 
Sigma Aldrich, UK 
Sodium Carbonate Sigma Aldrich, UK 
Sodium Hydrogen Carbonate Sigma Aldrich, UK 
Sodium hydroxide Fisher Scientific, UK 
Sodium Iodide Sigma Aldrich, UK 
Tris (hydroxymethyl) aminomethane (Invitrogen) Fisher Scientific, UK 
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3.5.2 Method 
3.5.2.1 Fabrication of PECs  
3.5.2.1.1 Fabrication of polycation solutions (control) 
Polycation solutions (8mgmL-1) were prepared by dissolving 16mg of the polycation 
(PAH, Pa2.5, QPa2.5 or Da10) in 2mL of Tris buffer pH 7.4, under gentle magnetic 
stirring. The solutions were sonicated at maximum amplitude for 5min, using Soniprep 
150 sonicator (MSE Ltd., UK) and were allowed to cool for 10min. 
3.5.2.1.2 Fabrication of insulin loaded PECs (control) 
The polycation solutions (4mgmL-1) (PAH, Pa2.5, QPa2.5 or Da10) were prepared 
as described in section 3.5.2.1.1. Insulin stock solution (2mgmL-1) was prepared by first 
dissolving the insulin powder in an acidic environment (150µL of 0.01 M HCl), 
followed by dilution with 0.1 M Tris buffer [332]. 
PECs were prepared by method reported by Thompson et al. [120]. Briefly, 2mL of 
2mgmL-1 insulin solution in Tris buffer pH 7.4 was added drop wise into 2mL of 
4mgmL-1 polycation solution under gentle magnetic stirring. The mixture was stirred at 
room temperature for 2h to form PECs. A final 2:1 polymer: insulin mass ratio was 
achieved. The following three PECs namely, IL Pa2.5, IL QPa2.5 and IL Da10 were 
produced spontaneously. Figure 3.6 depicts the schematic illustration of fabrication of 
PECs and APECs. 
3.5.2.2 Fabrication of APECs  
3.5.2.2.1 Fabrication of NIL APECs 
Briefly, APECs were prepared in Tris buffer at pH 7.4 by adding 0.75mL of 8mgmL-
1 of polyanion solution (DS or PAA) drop-wise into 1.5mL of 8mgmL-1 polycation 
solutions (PAH, Pa2.5, QPa2.5, and Da10) at a mass ratio 2:1 of Polycation:Polyanion. 
It was followed by addition of 250µL of 100µM ZnSO4. The final volume was made 
up to 6mL with Tris buffer pH 7.4. APECs were spontaneously formed after stirring 
the solutions for 2h at room temperature. The following eight NIL APECs were 
produced namely, PAH–DS, PAH–PAA, Pa2.5–DS, Pa2.5-PAA, QPa2.5–DS, QPa2.5–
PAA, Da10–DS and Da10–PAA. 
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Figure 3.6 Schematic illustration of fabrication of PECs and APECs 
 
3.5.2.2.2 Fabrication of IL APECs 
1.25mL of insulin solution (2mgmL-1) was added drop wise into 1.5mL of a 
polycation solution (8mgmL-1) to achieve a polycation-insulin solution, which was 
stirred for 5 minutes under gentle magnetic stirring. 0.75mL of 8mgmL-1 of polyanion 
solution (DS and PAA) was added drop-wise into the polycation-insulin solution 
followed by addition of 250µL of 100µM ZnSO4. The samples were stirred for 2h at 
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room temperature to allow formation of IL APECs. A final 2:1:0.42 of polycation: 
polyanion: insulin mass ratio was achieved.  All solutions were filtered with a 0.8µM 
pore size filter. The following eight IL APECs were produced namely, IL PAH–DS, IL 
PAH–PAA, IL Pa2.5–DS, IL Pa2.5-PAA, IL QPa2.5–DS, IL QPa2.5–PAA, IL Da10–
DS and IL Da10–PAA.   
3.5.2.3 Characterisation of PECs and APECs  
3.5.2.3.1 Measurement of particle size and zeta-potential 
DLS measurements of the particle hydrodynamic size, ZP and PDI were performed 
at 25 ˚C on freshly prepared samples with a zetasizer 6.12 series (Malvern Instruments 
Limited, UK). Each measurement is representative of three distinct sets of data, given 
as mean± S.E (n=3). 
3.5.2.3.2 Transmission electron microscopy analysis 
A drop of PEC/APEC solution was mounted onto Formvar/carbon coated 200 mesh 
copper grid. It was dried down to a thin layer on a hydrophilic support film at room 
temperature. 1% aqueous methylamine vanadate (Nanovan; Nanoprobes, Stony Brook, 
NY, USA) stain was applied and the mixture air-dried. Specimens were zero-loss 
imaged with a LEO 912 energy filtering transmission electron microscope at 120 kV. 
Contrast optimised, zero-loss energy filtered digital images were recorded with a 14 bit 
/2K Proscan CCD camera [120]. 
3.5.2.3.3 Quantification of insulin association efficiency 
The insulin was quantified by using bovine insulin ELISA immunoassay in 
accordance with the manufacturer’s protocol as given below (Mercodia, Sweden).  
i. Preparation of Enzyme Conjugate solution:  
The required volume of enzyme conjugate solution 100µL/well was prepared by 
mixing enzyme conjugate in enzyme conjugate buffer (1:10). The solution was stirred 
gently to allow homogenous mixing. 
ii. Preparation of Wash Buffer: 
Wash buffer was prepared by diluting 40mL wash buffer in 800 mL distilled water. 
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iii. Preparation of Samples: 
The IL PECs and APECs were prepared following the protocol stated previously 
(section 3.5.2.1.2 and 3.5.2.2.2). As the detection range of the ELISA test falls between 
0.025-3µgL-1, the samples were diluted serially to achieve a concentration of 1µgL-1 of 
insulin in samples. 
iv. ELISA Plate Preparation: 
Figure 3.7 displays the schematic illustration of the steps involved in the ELISA 
assay. 25μL of insulin calibrators and PEC/APEC samples were pipetted into 
appropriate wells of 96 well plate containing anti-insulin mouse monoclonal antibodies 
(mAB). 100μL of enzyme conjugate solution was added into each well. The plate was 
incubated on a plate shaker (Titramax, Heidolph, Germany) at 750 rpm for 2h at room 
temperature. The plate was washed 6 times with 700μL wash buffer per well to remove 
unbound insulin and enzyme conjugate solution. After the final wash, the plate was 
inverted and tapped against an absorbent paper. 200μL of substrate TMB was added 
into each well to act as a substrate for the enzyme conjugate solution. The plate was 
incubated for another 15 min at room temperature. Finally, 50μL of stop solution 
(sulphuric acid 0.5M, 50µL) was added to each well which changed the sample colour 
from blue to yellow. The plate was placed on the plate shaker for approximately 5 sec, 
to ensure appropriate mixing. The optical density was read at 450 nm, using a 
microplate reader (Synergy H4, Vermont, USA) and results were calculated as below. 
v. Determination of association efficiency of the PECs and APECs: 
The absorbance of the known insulin samples (1 mgmL-1 and 0.42mgmL-1) which 
were diluted to achieve 1µgL-1 of insulin, were used as positive control (100%) and the 
absorbance of the sample containing no insulin was taken as a negative control. The 
value of the background absorbance of the negative control well was deducted from all 
the subsequent sample absorbance. The association efficiency was determined relative 
to the amount of insulin in the corresponding known insulin stock solution by the 
following equation: 
%Association efficiency = Amount of insulin in unknown sample   x 100 
                                 Amount of insulin in corresponding known sample 
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Figure 3.7 Schematic representation of quantification of insulin by Bovine Insulin ELISA 
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3.5.2.4 Stability studies 
3.5.2.4.1 Effect of temperature 
The IL PECs and APECs were prepared as described in section 3.5.2.1.2 and 
3.5.2.2.2. They were incubated at 37˚C & 45˚C for 30mins and particle size, ZP and 
PDI were determined by DLS. 
3.5.2.4.2 Effect of ionic strength 
The influence of ionic strength on the stability of IL PECs and APECs was studied 
by incubating 6mL of the PECs/APECs solution with 338µL, 507µL and 721µL of 
1.206M NaCl solution for 30min, to achieve final concentrations of 68mM, 102mM, 
and 145mM respectively. Particle size, ZP, and PDI were determined by DLS. 
3.5.2.4.3 Effect of pH 
The stability of IL PECs and APECs was investigated by incubating 2mL of sample 
at pH 1.2 and 6.6 for 4h and 6h respectively. The chosen pH reflects the pH in the 
stomach and small intestine respectively and the incubation time reflects the average 
residence time of a dosage form in these two regions. The samples were titrated to the 
respective pH by addition of required volume of 0.1M HCl (100-200μL/mL). The effect 
of pH on size and ZP was determined by DLS.  
3.5.2.5 Statistical analysis 
The samples were analysed for normal distribution. Statistical analysis was carried 
out using SPSS 20. One way analysis of variance (ANOVA) was performed using 
post hoc tukey’s test. The values p ≤ 0.05 were considered significant.  
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3.6 RESULTS 
3.6.1 Characterisation of PECs and APECs 
3.6.1.1 Dynamic light scattering 
Table 3.2 represents the average size, ZP and PDI of polymer, PECs and APECs as 
determined by DLS. All formulations were obtained in a nanoscale range i.e., NIL 
polycation solutions (200-468nm), IL PECs (92-141nm), NIL APECs (78-435nm) and 
IL APECs (72-388nm). The introduction of polyanion (DS, PAA) in polycations 
(Pa2.5-200nm, Da10-208nm and QPa2.5-468nm) to form NIL APECs reduced the size 
of polycations. Polycations also demonstrated reduction in size upon complexation with 
insulin in PECs. However, the presence of insulin in APECs increased the size of 
APECs (except QPa2.5-DS and Pa2.5-PAA) compared to their NIL counterpart.  
The general trend was a decrease in ZP of all PECs and APECs upon complexation 
with insulin. As expected, the introduction of polyanion was also able to reduce the ZP 
of all NIL and IL APECs. Among all APECs, the effect of reduction in ZP upon addition 
of polyanion was more pronounced in NIL QPa2.5 APECs (2.5 folds). 
Table 3.2 Hydrodynamic size, ZP and PDI of NIL and IL PECs and APECs. The data represents 
the mean± SE of 3 experimental determinations. 
                   NIL polycation and APECS IL PECs and APECs 
 Size(nm) ZP PDI Size(nm) ZP PDI 
PAH-DS 119±1 39±2 0.2±0.2 334±20 25±3 0.3±0.1 
PAH-PAA 78±0.2 29±2 0.1± 0.0 94.2±0.4 0.06±3 0.1±0.0 
Da10 208±0.2 32±3 0.1±0.0 92±1.2 26± 2 0.3±0.0 
Da10-DS 91±3 23±2 0.1±0.08 96±1.2 22±3 0.2±0.2 
Da10-PAA 101±2 29±4 0.1±0.02 106±0.8 25±4 0.2±0.0 
Pa2.5 200±9 35±4 0.2±0.01 141±0.3 29±2 0.2±0.0 
Pa2.5-DS 117±6 29±3 0.1±0.01 160±1.9 25±2 0.2±0.0 
Pa2.5-PAA 122±15 29±2 0.1±0.02 101±2.7 25±2 0.2±0.0 
QPa2.5 468±12 52±3 0.5±0.09 117±2.4 20±3 0.1±0.0 
QPa2.5-DS 435±4 19±2 0.4±0.1 72±0.9 16±3 0.5± 0.0 
QPa2.5- 
PAA 
228±1 17±2.4 0.2±0.01 388± 29 7±2 0.5±0.0 
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3.6.1.2 Transmission electron microscopy analysis 
Figure 3.8 displays the negatively stained TEM micrographs of various APECs. All 
APECs were found to be smooth and spherical structures. The sizes obtained were 
slightly smaller than the size achieved from DLS. Most of the APECs appeared as 
multicore structures (PAH-DS, Da10-PAA, Pa2.5-DS, Pa2.5-PAA and QPa2.5-PAA) 
surrounded by an outer layer.  
             
      
                    
              
Figure 3.8 TEM micrographs of freshly prepared IL APECs insulin (a) PAH-DS (b) PAH-PAA 
(c) Da10-DS (d) Da10-PAA (e) Pa2.5-DS (f) Pa2.5-PAA (g) QPa2.5-DS (h) QPa2.5-PAA 
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3.6.1.3 Association Efficiency of PECs and APECs 
Different PEC and APEC formulations exhibited different association efficiencies 
(Figure 3.9). There were no significant differences between association efficiencies of 
hydrophobically modified PECs (Pa2.5 and Da10) and their respective APECs (≥80%). 
However, introduction of polyanion in QPa2.5 significantly reduced the association 
efficiency of QPa2.5 PECs from ≥80% - ≤40%. 
Among all APECs, the complexes formed by hydrophobically modified PAH i.e., 
Pa2.5 and Da10 displayed higher insulin complexation efficiency (>75%) than PAH-
PAA and QPa2.5 based APECs (≤60% and ≤40%) respectively. These findings indicate 
that the type of polycation had an impact on the degree of insulin complexation. Pa2.5-
DS, Da10-DS and PAH-DS demonstrated higher insulin association efficiency than 
their PAA based counterparts, substantiating the role of DS in mediating higher 
association efficiency.  
 
Figure 3.9 Percentage association efficiency of insulin in PECs and APECs. The data is 
expressed as mean± SE (n=3). Statistically significant differences (p < 0.05) APECs with PECs 
are indicated by asterisks. 
3.6.1.4 Stability Studies 
There are several factors which influence the formation of polyelectrolyte 
complexes. Notably, factors like pH, ionic strength and temperature are of paramount 
importance for the polyelectrolyte formation and stability. Therefore, the stability of 
PECs and APECs was investigated at various temperatures (25 ˚C, 37˚C & 45˚C), ionic 
strengths (68mM, 103mM & 145mM NaCl) and pH (1.2, 6.6 & 7.4). 
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3.6.1.4.1 Effect of temperature 
The effect of temperature (37˚C and 45˚C) on size and ZP of IL PECs and APECs 
was studied by DLS (Figure 3.10a & b). All PECs and APECs displayed no significant 
change in size except QPa2.5 based APECs. QPa2.5-DS demonstrated approximately 
2 fold, and QPa2.5-PAA 3 fold increase in size at 45˚C (Figure 3.10a). 
The increased temperature affected the ZP of all APECs except Pa2.5 based APECs. 
Pa2.5-PAA demonstrated the least fluctuation in ZP (≤2mV) indicating the highest 
stability at the temperatures tested. In contrast, QPa2.5-PAA APECs demonstrated the 
greatest decline in ZP of up to 20mV at 37ᵒC and 45ᵒC.  
 
 
Figure 3.10 Effect of temperature on (a) Size (b) ZP of PECs and APECs incubated at 
37˚C and 45˚C for 30 minutes. Each value represents mean± SE of three 
experimental determinations. 
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3.6.1.4.2 Effect of Ionic Strength  
The influence of various salt concentrations (68mM, 102mM and 145mM NaCl) on 
the size and ZP of IL PECs and IL APECs is shown in Figure 3.11a & b. PAH-DS 
displayed a dramatic increase in hydrodynamic sizes at all molarities of NaCl tested, 
indicating destabilisation of these complexes. PAH-PAA displayed a progressive 
increase in size with increasing salt concentration, reaching up to 2 order of magnitude 
in size at the highest i.e., 145mM NaCl, indicating the initiation of destabilisation of 
complexes. This shows that type of polyanion had no favourable effect on the stability 
of PAH based APECs.  
Once again, the PECs and APECs formed by hydrophobically modified PAH (Pa2.5 
and Da10) displayed only minor fluctuation in size (≤180nm) at various NaCl 
molarities, as compared to PAH and hydrophilically modified Pa2.5 (i.e., QPa2.5). This 
shows that type of polycation had an effect on the stability of PECs and APECs at 
various ionic strength conditions. All the PECs and APECs formed by hydrophobically 
modified polycations (except Pa2.5-DS) presented a reduction in ZP at high salt 
conditions. This shows that type of polyanion had minimum effect on size of Pa2.5 and 
Da10 based PECs and APECs at various salt conditions, however, had considerable 
effect on ZP of APECs. 
IL QPa2.5 PECs displayed a 2 fold increase in size at 102mM NaCl, and a 4 fold 
increase at 145mM NaCl signifying destabilisation of the complexes with increasing 
NaCl concentration. However, QPa2.5 based APECs displayed an increase in size at 
68mM NaCl followed by a decrease in size at 102mM and 145mM NaCl concentration, 
irrespective of polyanion used. This behaviour indicates that polyanion had a 
favourable effect on the stability QPa2.5 based APECs at higher NaCl conditions. 
However, the reduction in ZP at different NaCl concentrations was more marked in 
QPa2.5-PAA than QPa2.5-DS indicating that DS prevented changes in the ZP.  
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Figure 3.11 Effect of Ionic strength on (a) Size (b) ZP of PECs and APECs incubated 
at 68mM, 102mM and 145mM NaCl for 30 minutes. Each point represents mean± 
SE of three experimental determinations. 
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3.6.1.4.3 Effect of pH 
The stability of various PECs and APECs was investigated at physiological pH in 
GIT by incubating them for 4h in pH 1.2 (in stomach) and 6h in pH 6.6 (small intestine) 
[333]. The integrity of complexes at the above mentioned pH was compared with the 
formulation pH 7.4 (Control). Figure 3.12a & b shows the effect of various pH on the 
size and ZP of IL PECs and IL APECs. All PECs showed minor fluctuation in size apart 
from QPa2.5 PECs. Similar to the effect of ionic strength (3.6.1.4.2), once again, PAH 
based APECs, whether formed with PAA or DS encountered fluctuation in size. PAH-
PAA displayed a 3 fold increase in size at pH 1.2, suggesting the initiation of 
dissociation of complexes, whereas PAH-DS demonstrated reduction in size at the 
tested pH implying the stability of complexes.  
All the hydrophobically modified APECs (i.e., Da10 and Pa2.5 based APECs), 
except Da10-PAA, maintained or reduced in size at pH 6.6 and 1.2, with minor 
fluctuations in ZP. Pa2.5 based PECs and APECs displayed less fluctuation in size and 
ZP than Da10 based APECs. Among Pa2.5 based APECs, Pa2.5-DS maintained their 
size while Pa2.5-PAA demonstrated a reduction in size from 137-73 indicating their 
stability at pH 1.2 and 6.6. Pa2.5-PAA produced less fluctuation in ZP (25-28mV) than 
Pa2.5-DS, signifying higher stability. On the other hand, Da10-DS exhibited less 
fluctuation in size and ZP than their corresponding Da10 PECs, indicating their stability 
over Da10 PECs. However, Da10-PAA displayed a 2 fold increment in size and a 2 
fold reduction in ZP (23-12mV) at pH 1.2 indicating destabilisation of complexes.  
QPa2.5 based PECs maintained their size and ZP at pH 1.2 and 6.6. Among QPa2.5 
APECs, QPa2.5-PAA reduced in size whereas QPa2.5-DS increased in size at pH 6.6 
and 1.2. Similar to behaviour in ionic strength (section 3.6.1.4.2), once again, the 
fluctuation in ZP was more marked in QPa2.5-PAA than QPa2.5-DS. These results 
show that the type of polyanion had an impact on the size and ZP of APECs. PAH-PAA 
and Da10-PAA also showed more fluctuation in size and ZP than DS based APECs, 
implying reduced stability at pH 1.2. All DS based APECs presented less fluctuation in 
size, signifying the role of DS in contributing stability to the complexes at low pH.  
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Figure 3.12 Effect of pH on (a) Size (b) ZP of PECs and APECs incubated at pH 1.2 for 
4hrs and pH 6.6 for 6hrs. Each point represents mean± SE of three experimental 
determinations 
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3.7 DISCUSSION 
It is well established that nanoparticles made of polyelectrolyte complexation hold 
tremendous promise as drug delivery systems [72]. This study describes the formation 
of eight NIL APECs and eight IL APECs as carrier for insulin. The NIL and IL APECs 
were fabricated by complexing a polycation (PAH, Pa2.5, Da10 or QPa2.5) with a 
polyanion (DS or PAA) in the presence of a low MW ionic cross-linker ZnSO4. ZnSO4 
ionises in aqueous environment to give two bivalent ions i.e., Zn+2 and SO4
-2, which 
cross-link the polymeric chains via electrostatic interactions [334]. In comparison to 
the monovalent ions, the bivalent ions (Zn+2 and SO4
-2) play role in the formation and 
stabilisation of polyelectrolyte complexes, as they hold twice the charge of monovalent 
ions. Unlike the monovalent ions, the bivalent ions have higher affinity for charged 
polymer units. They form ionic cross links by interacting electrostatically with the 
charged polymer units in the proteins and polyelectrolyte and thus provide stability to 
the complexes as shown in Figure 3.13 [122, 335]. The MW of such ionic cross likers 
is much smaller than the MW of the polymeric chains [336]. The smaller the molecular 
size of the cross-linker, the faster is the crosslinking reaction, since it eases the diffusion 
of molecules in the complex [336].  
 
 
 
 
 
 
 
 
Figure 3.13 Interaction of cross-linker with insulin in APECS 
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sizes (˂450nm) were achieved in the presence of 4µM ZnSO4. The ionic crosslinking 
between the chains allowed tight stacking of the chains resulting in a decrease in the 
size of complexes [113]. Similar findings were achieved by Tiyaboonchai et al. who 
reported that ZnSO4 stabilised the PEI-DS-insulin particles through electrostatic 
interactions with these particles [122]. They also showed that the mean particles size of 
Amphoericin B nanoparticles formed by using ZnSO4 <25µM was larger than the mean 
particle size of complexes formulated with 25µM ZnSO4 [55]. This indicates that the 
cross-linker and its concentration plays an important role in the formation of APECs. 
The Zn2+ and SO4
2- ions promoted ion pairing interaction between unpaired charges on 
the polymeric chains [113]. The amino groups on the polycation and insulin, linked 
with the SO4
2- of ZnSO4, while COO
- groups of insulin and PAA, and SO4
2- of DS, 
linked with the Zn2+ to form electrostatically stable complexes as shown in Figure 3.13 
[55].  
There was a reduction in the size and ZP of PECs upon complexation with insulin. 
The polymeric chains in a solution, in the un-complexed state remain in an expanded 
form due to the electrostatic repulsion between the like charges on the chains [116]. 
The like charges on the polymer backbone oppose each other and tend to prevent the 
chains from coiling or acquiring a self-assembled structure, leading to large sized self-
assemblies [115]. However, upon complexation, the negatively charged insulin units 
(COO-) bind electrostatically to the amino groups of the polycation. This behaviour 
reduces the number of positively charged units on the polymer chains thereby 
decreasing the intra-complex electrostatic repulsion between the like charges, leading 
to a decrease in size. Chen et al. has shown a similar trend whereby the introduction of 
a negatively charged polymer (DS) in the system was associated with a decrease in 
particle size and zeta potential [258]. It was shown that as the charge of chitosan was 
reduced by addition of DS, the chitosan molecules started to fold, resulting in the 
formation of condensed particles with a small size [258]. It has recently been shown 
that hyaluronan-chitosan nanoparticles either showed a slight decrease in size or did 
not change significantly upon introduction of a hyaluronan content [290]. 
On the other hand, unlike PECs, the IL APECs (except Pa2.5-PAA and QPa2.5-DS) 
displayed an increase in the hydrodynamic size, upon complexation with insulin. This 
effect may be attributed to the alteration in the +/- charge ratio due to the addition of 
two negative charges i.e., polyanion and insulin in APECs. The polycation: polyanion 
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charge ratio is an important factor affecting the particle size [258]. An increase in the 
charge ratio of polycation: polyanion above 1 is associated with a decrease in the 
particle size resulting from an increase in the magnitude of net charge on the particles 
[290]. On the other hand, as the charge ratio approaches closer to 1 by addition of 
polyanion, the particle mean size increases because of the reduction in charge ratio 
[337]. In the first step of the formation of IL APECs, the polycation was complexed 
with insulin which led to a significant reduction in the number of charged amino groups 
on the polymer backbone. This behaviour reduced the intra-complex repulsion between 
polymeric chains leading to a reduction in the complex size. However, in the second 
step, addition of polyanion led to the occupancy of the remaining un-paired charges on 
the polymer backbone and increased the intra-complex repulsion between the two 
polyanions resulting in an increased size. This effect has previously been reported by 
Chen et al. who showed that incorporation of bovine serum albumin (BSA) into the 
chitosan-DS nanoparticles led to an increase in the particle size which gave a good 
indication of the incorporation of BSA into chitosan-DS nanoparticles [258]. The 
authors indicated the role of the positively charged BSA to compete with chitosan to 
interact with DS electrostatically [258]. Similarly, the incorporation of anti angiogenic 
hexapeptide (ARH peptide) was also shown to increase the size of nanoparticles, 
compared to the empty nanoparticles [270]. Likewise, the incorporation of MTX into 
the glycol chitosan-DS nanoparticles [273] and of 5-aminosalicylic acid (5-ASA) into 
the chitosan–DS hydrogel [291] have also been shown to cause a sharp increase in the 
particle size of the nanoparticle dispersion.   
It is well know that the association of protein in complexes alters the surface charge 
of complexes. Insulin is negatively charged above its isoelectric point i.e., pH 5.2, [338] 
therefore, complexation of insulin in PECs and APECs was expected to reduce the ZP 
of IL complexes. For this reason, a reduction in the ZP of PECs and APECs upon 
complexation with insulin indicated the association of insulin in the complexes (refer 
to Table 3.2). The incorporation of anti angiogenic hexapeptide (ARH peptide) in CS-
DS nanoparticles has previously shown a similar trend to change the ZP of peptide-
loaded nanoparticles from positive to negative, compared to the empty nanoparticles 
indicating that almost all the ARH peptide was incorporated into the nanoparticles 
[270]. Insulin is amphoteric in nature, i.e., comprises of both positively and negatively 
charged moieties [118]. Ionisation of these charged moieties in the insulin molecule are 
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responsible for the complexation of insulin in PECs and APECs by electrostatic 
interactions [272]. The COO- of insulin interact electrostatically with the amino group 
of polycation (Figure 3.14a).  The amino groups in the insulin molecule interacts with 
COO- of PAA or SO4
2- of DS (Figure 3.14 b & c). In this way, several different forms 
of electrostatically driven interaction are possible. Additionally, hydrophobic 
interactions, Van der Waal’s associations and hydrogen bonding also contribute in the 
association of proteins with polyelectrolytes [121].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Schematic illustration of interaction between polycation, polyanion and 
insulin in (a) IL PEC (b) IL DS based APEC (c)  IL PAA based  APEC 
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The reduction in ZP of both NIL and IL APECs in the presence of a polyanion again 
indicates the complexation between polyanion and polycation. Introduction of 
polyanion such as DS has previously been found to reduce the cationic charge related 
to polycations such as PEI [55] and chitosan [296].  
APECs formed by PAH and modified PAH displayed significant differences in their 
properties indicating that the type of polycations have an influence on the properties of 
polyelectrolyte complexes. Apart from NIL QPa2.5, NIL QPa2.5-DS and IL PAH-DS, 
all the other PECs and APECs exhibited a size ˂ 230nm. In this way, APECs formed 
by hydrophobically modified PAH i.e., Pa2.5 and Da10 exhibited smaller 
hydrodynamic sizes and relatively higher ZP as compared to the APECs formed by 
QPa2.5 which displayed considerably larger sizes and low ZP values. These effects can 
be explained by the ability of hydrophobic grafts i.e., Pa2.5 and Da10 to allow stronger 
hydrophobic association with insulin leading to formation of smaller self-assemblies 
[121]. In contrast, the bulky nature of quaternary ammonium moieties and increased 
electrostatic repulsion between permanently charged quaternary ammonium moieties 
appeared to have driven the formation of large size PECs and APECs [129]. In addition, 
the hydrophilic quaternary moieties might have prevented the hydrophobic interactions 
due to inter-chain repulsion which further reduced the tight packing of polymer chains 
[119]. As a consequence, the polymer chains were set apart resulting in the large sized 
complexes [119]. A similar effect has been shown by Guo et al. who prepared ternary 
complexes by introduction of polyanion polyglutamic acid-graft-poly(ethylene glycol) 
(PGA-g-mPEG) into amphiphilic polycation polycaprolactone-graft-poly(N,N-
dimethylaminoethyl methacrylate) (PCL-g-PDMAEMA). The electrostatic interaction 
between PGA and PDMAEMA chains led to compaction of the complexes and at the 
same time the hydrophilic mPEG chains increased the size of the complexes. As a 
result, the ternary complexes nearly maintained the constant and suitable sizes of about 
130 nm [127]. 
The insulin association efficiency of complexes was generally found to be polymer 
structure dependent. In relation to the polycations, the degree of association efficiency 
is graded as Pa2.5>Da10>PAH>QPa2.5. Thus the PECs and APECs formed by 
hydrophobically grafted PAH (Pa2.5 and Da10) demonstrated higher insulin 
association efficiency (80%) than PAH (60%) and QPa2.5 (40%) based APECs. 
Among the hydrophobically grafted APECs, Pa2.5 demonstrated higher percentage 
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association efficiency than Da10 based APECs. The difference in the association 
efficiency of the two may be attributed either to (i) the difference in percentage grafting 
of the two, where the higher hydrophobic load of Da10 could not cope with the greater 
amount of insulin or (ii) the bulkier and rigid dansyl moeities might have caused some 
steric hindrance resulting in limited complexation. However, a detailed investigation of 
the underlying concepts of the complexation process is very crucial, since the overall 
yield of insulin strongly depends on the efficiency of the complexation process. Pa2.5-
DS demonstrated the highest ability to complex insulin, i.e., 100%, which suggest that 
all of the insulin was complexed with polymers. In addition, PAH-DS and Da10-DS 
also demonstrated higher insulin association efficiency than their PAA based 
counterparts. These results indicate higher insulin association by DS based APECs. DS 
possesses a higher molecular weight (60-10KDa) than PAA which may be responsible 
for high association efficiency. The highly charged SO4
-2 of DS might have strongly 
interacted with NH3
+ of insulin and trapped more insulin molecules than the less 
charged COO- of PAA, allowing higher AE. Our findings correlate with the findings 
achieved by Sarmento et al. who prepared complexes between polyanions (dextran 
sulphate or alginate) with chitosan and reported a higher insulin association efficiency 
of DS based complexes than alginate based complexes [126]. In addition, Silvia et al. 
have also demonstrated high insulin complexation in the presence of dextran sulphate 
[339]. 
QPa2.5 APECs demonstrated 2 fold lower association efficiency than QPa2.5 PECs. 
The presence of bulky groups in the side chain of the polycation has been reported to 
have a notable effect on the complexation with the highly charged polyanion. The 
presence of bulky side chains on chitosan have been reported to have steric hindrance 
effects that reduced the cooperativity of the charge based interactions [292]. The 
addition of polyanion in IL QPa2.5 PECs might have created a competition between 
insulin and polyanion to complex with the bulky N+(CH3)3. Since the complexation of 
insulin and polyanion with quaternary ammonium moieties resulted in a significant 
decline in ZP, this shows that the polyanion might have impeded the interaction of 
insulin with QPa2.5 and itself superseded in complexing with the QPa2.5. This might 
indicate a higher binding affinity of QPa2.5 for polyanion than insulin. This effect has 
previously been demonstrated by Tiyaboonchai et al. who reported a competitive 
interaction between Amphotericin B and DS with the positively charged chitosan [73].  
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The stability studies showed that the hydrophobically formed PECs and APECs were 
more stable at varying temperature, ionic strength and pH than PAH and QPa2.5 based 
complexes. They showed less fluctuation in size and minor changes in ZP at varying 
condition (apart from Da10 PECs and Da10-PAA APECs which displayed increase in 
size at pH 1.2 and fluctuation in ZP). The higher stability of complexes formed by 
hydrophobically modified PAH has been attributed to the generation of hydrophobic 
associations between hydrophobic grafts of polycation and insulin. Previously Reschel 
et al. has also shown that hydrophobic nature of poly[N-(2-aminoethyl)methacrylamide 
trifluoroacetate] conferred higher stability to (PAEMA)/DNA complexes than 
PLL/DNA complexes, [282].  
Since PAH has flexible chain architecture, its chains can move about with sufficient 
degree of freedom. The modification of PAH with hydrophobic grafts (i.e., C16 long 
alkyl chain of Pa2.5 and aromatic group of Da10) tend to reduce the polymer chain 
flexibility [120]. The destabilisation experienced by PAH-DS at high ionic strength, 
and PAH-PAA at the tested pH is therefore ascribed to the flexible linear architecture 
of PAH and lack of hydrophobic association which was unable to provide sufficient 
strength to the complexes. It is assumed that the addition of salt created a counter-ion 
environment which screened the positive charges on the surface of PAH-DS. This effect 
led to the loss of electrostatic attraction between the PAH-DS and insulin, subsequently 
leading to an increase in the size and hence dissociation of the complexes [79, 113]. 
Similarly, at pH 1.2 the carboxylic acid groups of PAA are protonated and hence did 
not interact with positively charged amino groups (NH3
+) leading to destabilisation of 
PAH-PAA. The PAH based APECs are not formed by additional hydrophobic 
associations which could stabilise these complexes. However, the hydrophobic grafting 
on the PAH backbone provided additional hydrophobic interactions which conferred 
stability to the hydrophobically modified complexes [120]. Filippov et al. showed that 
the colloid stability of P17 based polyplexes increased with increasing the hydrophobic 
cholesterol content in polycations [251]. The complexes prepared with the lowest 
content of cholesterol showed the highest coagulation rate, whereas the rate of 
coagulation was lower for complexes prepared with polycations bearing higher 
amounts of cholesterol [251]. Thus it was shown that the colloid stability of complexes 
increases with increasing content of side-chain cholesterol moieties which is related to 
the hydrophobicity of polycations [251].  
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The increase in temperature up to 45˚C brought no significant change in size and 
minor fluctuation in ZP of hydrophobically formed PECs and APECs. It is known that 
the hydrophobic interactions increase in strength with the increasing temperature [287]. 
These increasing hydrophobic associations are considered to have maintained the 
complex integrity. The results are consistent with the findings achieved from Mao et 
al. who reported that the increased temperature facilitates PECs formation [79]. 
However, on the other hand, QPa2.5 based APECs, in particular QPa2.5-PAA, 
demonstrated moderate increase in size and reduction in ZP at increased temperatures. 
The hydrophilic segments of QPa2.5 might have undergone dehydration of polymer 
chains caused by the desolvation of water molecules upon increase in temperature. This 
behaviour might have led to impairment or loss of hydrogen bonding between the 
polymer and water molecules resulting in the increased sizes of the self-assemblies and 
hence destabilised the complexes [112]. The breakage of hydrogen bonds might have 
caused displacement of positive surface charges which is obvious from the very low ZP 
of QPa2.5 based APECs. In the case of QPa2.5-insulin PECs, any breakage of the bonds 
upon increase in temperature appeared to have been compensated by new bond 
formation via hydrophobic association between reorganised QPa2.5 chains and insulin 
chains. The non-polar aliphatic side chains of insulin are thought to have mediated the 
hydrophobic associations with palmitoyl graft in QPa2.5, which maintained the 
integrity of QPa2.5 PECs [121]. However, this effect was essentially absent in the case 
of QPa2.5 based APECs as the presence of polyanion interfered with the intra-complex 
hydrophobic associations.  
The hydrophobically modified PECs and APECs were found stable at high ionic 
strength conditions. It is assumed that, the addition of salt produced a counter ions 
environment. Since the surface of hydrophobically modified PECs and APECs was 
positively charged, the counter-ions bound to the surface and reduced the surface charge 
which is clear from the obvious reduction in ZP, however, the concentration of counter-
ions was not enough to neutralise the surface charge of the complexes which could 
subsequently cause destabilisation of the complexes. Alternatively, QPa2.5 PECs 
displayed a progressive increase in size with increasing ionic strength. It is thought that 
the PECs formed by polyamines with bulky quaternised amine groups are less stable 
due to loosely coupled charges by weak electrostatic interaction [340]. This effect is 
ascribed to the increased distance between charges in the ion pairs.  The presence of 
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counter-ions caused neutralisation of surface charge of QPa2.5. Since the surface 
charge of QPa2.5 PECs was already below (≤20mV), as compared to the 
hydrophobically modified PECs and APECs ≥22mV. This caused the counter ions to 
effectively neutralise the surface charge leading to the destabilisation of QPa2.5 PECs 
which clearly appeared from the progressive increase in size and decrease in ZP.  
On the other hand, the presence of polyanion in QPa2.5 APECs decreased the steric 
hindrance and reduced the distance between the charged units, allowing stronger ion 
pairing. QPa2.5 APECs, although experienced the same effect of loss of surface charge 
by charge neutralisation at low ionic strength due to the small positive surface charge 
(≤16mV), however, when the small monovalent ions (Na+ and Cl-) penetrated deeper 
into the expanding complexes, they might have generated ion pairing effect with the 
free negative charges (SO4
+2 and COO-) on the polyanion chains in the complexes 
which is considered to have restored the surface charge and hence provided stability to 
the QPa2.5 APECs at high ionic strength conditions [340]. These effects can be noticed 
from the compaction of size and increase in ZP at high ionic strength conditions 
(102mM and 145mM).  
Generally, PECs and APECs formed by modified polycations (except Da10 PECs 
Da10-PAA APECs) were found stable at varying pH. QPa2.5 based PECs and APECs 
maintained or reduced in size suggesting their stability. However, slight variation in ZP 
was observed. All modified APECs except Da10-PAA and QPa2.5-DS displayed 
increase in the ZP at pH 1.2. At pH 1.2, the amino groups of polycation and insulin are 
predominantly protonated, thus generate a positive charge. The sulfonate groups of DS 
are partially ionised at pH 1.2, giving predominantly a negative charge while carboxylic 
group of PAA and insulin remain unionised. PAH is a weak base, PAA a weak acid and 
DS a strong acid [253]. The pKa of PAH and modified PAH is approximately 8.8 [341]. 
This means that their amino groups will be highly protonated at pH values below their 
pKa and de-ionised at pH above its pKa [279]. On the other hand, the pKa of polyanions 
DS and PAA are 1.2 and 4.75 respectively [253, 342]. The polyanions are fully ionized, 
at pH values higher than their pKa, however, the degree of ionization decreases 
rationally with the decrease in pH below their pKa [343]. DS benefits from its low pKa 
(pH 1.2), in complexing with polycation over a broad pH range above its pKa, which 
is essentially indicative of a permanently charged state. This is the reason that all DS 
based APECs, demonstrated considerably higher stability at the pH tested, irrespective 
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of the polycation used. However, since PAA has a pKa of 4.75, the degree of ionized 
units decreases clearly below its pKa. This is the reason that in an acidic medium (pH 
1.2), PAH-PAA and Da10-PAA displayed 3 and 2 folds increase in size respectively, 
which is indicative of the destabilisation of these complexes. However, a reverse trend 
was observed for Pa2.5-PAA (145-73 nm) and QPa2.5-PAA (350-150), whereby they 
displayed considerable reduction in size, indicating their stability at low pH. This 
behaviour of how PAA conferred stability to these complexes is not fully known. These 
findings indicate that PEC and APEC systems can retain their therapeutic cargo in the 
acidic environment of the stomach and the intestine and therefore can be taken up in 
the intact form by the intestinal enterocytes. 
3.8 CONCLUSION 
APECs were formed in nano-sized range by complexing a polyanion, a polycation 
and insulin. Pa2.5 based APECs were found to be the most stable systems at all the 
conditions tested. They demonstrated higher stability at varying temperature, ionic 
strength, pH, and higher insulin association efficiency than unmodified, Da10 and 
QPa2.5 APECs. The findings imply that the hydrophobic modification of PAH had a 
favourable effect on the stability of PECs and APECs. In addition, DS conferred greater 
stability and higher insulin complexation than PAA indicating that type of polyanion 
also plays a role in stabilising APECs.   
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4 INTRODUCTION  
Despite being efficient delivery systems, a major challenge to nanocarriers is the 
understanding of potential harmful effects caused by them to the cells [157, 344]. 
Nanocarriers can disrupt certain activities within the cells which alter the cellular 
metabolism and cell proliferation [344, 345]. They may cause structural damage to the 
cells which can even result in cell death. In addition, nanocarriers have been shown to 
cause increased production of inflammatory cytokines and reactive oxygen species 
(ROS)  [148, 346]. For this reason, it is essential to investigate the potential adverse 
effects related to all polymeric nanostructures to evaluate their ‘biocompatibility’ 
profile (suitability for human use) [347]. The in vitro cell culture systems provide an 
efficient primary means to screen the drug delivery systems [166, 345]. However, there 
is a need to optimize and standardize the in vitro approaches for the detection of 
nanocarrier toxicity [345].  
4.1 IN VITRO CELL CULTURE SYSTEMS 
The cell based in vitro models play a very important role in analysing the toxic effects 
of nanomedicine on the cell lines. There are techniques to measure endpoints such as 
cytotoxicity, haemocompatibility, immunotoxicity and inflammatory potential to 
understand the underlying toxicity [166, 345, 348, 349]. Such models offer many 
advantages over the use of animal models. They are simple, quick and less expensive 
to use than animal models [166]. Additionally,  in vitro cell culture models based on 
human cell lines may better represent the human cellular functions than the in vivo 
studies done on animals [350]. However, it is difficult to assess and analyse the multiple 
complex biological effects solely by in vitro cell culture models. Therefore, the 
accuracy and predictability of these tests is validated by comparing with the in vivo 
studies [158, 351, 352].  
An essential part of in vitro toxicity evaluation is the selection of appropriate end 
points and cell types for simulating the original biological environment [160]. The cell 
lines are selected for their similarity to the in vivo phenotype. Some of the common cell 
types used in in vitro testing include phagocytic (monocyte and macrophage 
phenotypes), neural, hepatic, epithelial, endothelial, red blood cells (RBC’s) and 
various cancer cell lines [157, 353-355]. The two cancer cell lines used in this study are 
described below. 
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4.1.1 Cell lines 
4.1.1.1 CaCo2 Cell line 
CaCo2 is a continuous cell line which is derived from the human epithelial colorectal 
adenocarcinoma [220]. It was chosen for this study because it mimics intestinal 
enterocytes both morphologically and functionally which serve as initial line of contact 
for the oral drug [356]. CaCo2 cells express many in vivo characteristics such as TJs, 
microvilli, several enzymes and transporters (peptidases, esterases, P-glycoprotein) 
(Gad, 2008; Yee, 1997), and uptake transporters for amino acids, cobalamine, and bile 
acids which are classically representative of ileal enterocytes [357]. One limitation of 
using this cell line is the absence of mucus lining. Although this limitation can typically 
underestimate the interaction between the carriers and mucin, but is still commonly 
used because it provides an alternative for ileal cells.  
4.1.1.2 J774 Cell Line: 
J774 cell line originated in 1968 from a female mouse suffering from plasmacytoma 
[358]. It is a finite cancerous cell line obtained from peritoneal lavage of the mouse. It 
is a rapidly growing cell line and comprises of murine macrophage-like mononuclear 
cells which grow with a doubling time of 22h [358]. Macrophages are the first line 
defence in generation of early immune responses and an essential part of the 
mononuclear phagocyte system [359, 360]. They take part in primary immune 
regulation by phagocytosis, antigen presentation and production of cytokines such as 
interleukin IL-6, IL-10, IL-12 and tumour necrotic factor-α (TNF α) [361, 362]. This 
cell line has been used in a variety of experiments such as elucidation of immune 
responses, macrophage function and cytotoxicity [363].  
4.1.2 Cytotoxicity  
An important initial aspect of biomaterial screening is the investigation of in vitro 
cytotoxicity [349]. The term cytotoxicity refers to the toxic effects mediated by a 
substrate on the cells [349]. There are numerous properties of nanomaterials such as 
size, shape, biodegradability and molecular weight which are involved in mediating 
toxicity, however, cationic nature is of prime importance in causing toxicity (Fischer et 
al., 2007). A large number of polycations such as PLL, polyethyleneamine (PEI) 
polyamidoamine (PAMAM) are known to be cytotoxic which has been established in 
vitro by using a variety of cell lines and cell cytotoxicity assays (Fischer et al., 2007). 
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The primary amine functional groups on polycation are considered as the key factor for 
causing cytotoxicity [153]. They are known to interact with negatively charged 
proteoglycans on the surface of cell membrane by electrostatic interaction [364, 365]. 
The conversion of primary amines to safer tertiary or quaternary amine or addition of a 
steric coating such as polyethylene glycol (PEG), renders them non-toxic [67, 151, 
366]. In addition, approaches which can reduce the surface charge such as by 
complexing with a polyanion have also been shown to reduce the toxicity associated 
with polycations [131]. Wang et al. used four types of biocompatible polyanion 
containing carboxyl groups or sulfonic acid groups to prepare polyanion/PEI complexes 
[127, 131]. These complexes produced a sharp reduction in the PEI associated toxicity 
such that the cell viability for all polyanion-PEI complexes was more than 95% 
compared to only 12% of PEI alone [131].  
In addition to charge density and type of amine, the polymer architecture, three-
dimensional arrangement and molecular weight of polycations have also been shown 
to influence the cytotoxicity [157, 367]. Recently, Mao et al. reported a concentration 
and MW dependent effect of trimethyl chitosan (TMCs-400 kDa and TMCs-5kDa) and 
PEG grafted-TMC (PEG(5k)-g-TMC(400) on the cytotoxicity of CaCo2 cells by using 
3-4,5 dimethyl thialzol2,5 diphenyl tetrazolium bromide (MTT) and lactate 
dehydrogenase (LDH) assay [227]. The cytotoxicity of polycation such as 
diethylaminoethyl-dextran (DEAE-dextran), PLL and PEI was shown to increase with 
the increase of their molecular weights. However, these findings applied only to the 
polymers having similar chemical structure and not for different types of polycations 
[157].  
Cationic polymers comprising of a globular structure such as PAMAM have been 
found to be more biocompatible than linear or branched polymers  (diallyl-dimethyl-
ammonium chloride (DADMAC), PLL, PEI) [157]. Despite having high charge, 
PAMAM has been reported to produce low cytotoxicity which is attributed to its low 
molecular weight. Polymers with a rigid architecture e.g. DADMAC have displayed 
comparatively lower toxicity than flexible chain polymers [157]. It has been 
hypothesised that the chain stiffness makes the attachment of DADMAC to the cell 
surface more difficult resulting in reduced interaction and hence decreased cytotoxicity 
[157]. There may be many more factors responsible for causing polymeric toxicity. 
Further research in nanotoxicology will allow understanding of the underpinning 
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concepts leading to toxicity. The in vitro assays are essential screening tests which 
provide information of the structure-toxicity relationship for optimizing and 
standardizing the biocompatibility of polymeric delivery systems. 
4.1.2.1 In Vitro Cytotoxicity assays 
Cytotoxicity assays determine the loss of cell viability occurring from the distortion 
of structure or function of the cell membrane or cellular organelles [349, 368]. The 
evaluation of basal cytotoxic potential of a substrate is made by determination of its 
IC50 [160]. Exposure of cells to cytotoxins initially causes structural, biochemical or 
metabolic alterations in cells which act as markers for the assessment of degree and 
type of cell damage.  The  changes in cellular morphology, mitochondrial function, 
membrane leakage of LDH, reduced glutathione (GSH) levels, oxidative stress, 
haemoglobin release from erythrocytes and adenosine triphosphate (ATP) depletion are 
the most common endpoints used to assess the in vitro cytotoxicity [349, 368].  
The commonly employed cytotoxicity assays include tetrazolium salt based assays 
particularly MTT [157, 227], 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS), (2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium 
hydroxide) (XTT) [160, 345] which assess the cytotoxicity by measuring the metabolic 
activity of mitochondrial enzymes. Other common assays include LDH assay [157, 
227], neutral red (3-amino-6-dimethylamino-2-methyl-phenazine) uptake assay and 
ATP [144]. LDH is a cytoplasmic enzyme present in all cells. It is released into the cell 
culture supernatant upon damage to the cell membrane. This forms the basis for 
determination of cell membrane integrity and hence the cell damage [369].  
Neutral red determines the number of vital and uninjured cells in the cultures. The 
neutral red dye is taken up exclusively by viable cells and subsequently accumulates in 
the lysosomes [355]. The assessment of the dye content determines the number of live 
and undamaged cells.  
ATP is present in all metabolically active cells. Determination of ATP content by 
bioluminescent measurement is directly related to the number of metabolically active 
cells [369]. The tetrazolium salt based colorimetric assays determine the metabolic 
activity of viable cells. MTT is the most widely used assay, discussed in detail in the 
section below.  
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4.1.2.1.1 MTT Assay 
MTT assay is a quantitative calorimetric assay employed for measuring the effect of 
a substrate on the activity of the living cells [370, 371]. In other words, it studies the 
substrate-induced impairment of mitochondrial function [371]. MTT is a yellow water 
soluble tetrazole which is reduced to purple water insoluble formazan crystals in 
metabolically active cells by mitochondrial reductases [160, 371]. The insoluble 
formazan is solubilised by adding dimethyl sulfoxide (DMSO), an acidified ethanol 
solution, or isopropanol to form a purple solution [157, 371]. The amount of purple 
formazan produced by treated and untreated control cells is used as a measure of the 
viability of the cells. The fluorescent intensity of the coloured solution is determined at 
a certain wavelength (usually between 500 and 600 nm) by a spectrophotometer [370, 
371]. The absorbance level reflects the amount of the reduced product which in turn is 
an indicator of the number of metabolically active and functionally viable cells [160]. 
 The in vitro cytotoxicity assays can give a relative but not absolute index of potential 
toxicity of a polymeric carrier, however can set out the suitability for further 
investigation and subsequent in vivo use. MTT assay is chosen in this study due to its 
sensitivity and reproducibility. A number of researchers compared MTT assay with 
other cytotoxicity assays such as LDH assay, neutral red assay and trypan blue and have 
found comparable results [157, 227]. In this study, MTT assay was combined with ROS 
and haemolysis assay to assess the degree of cytotoxicity on CaCO2 cells and 
erythrocytes.  
4.1.3 Haecompatibility 
Haemolysis assay is a common test for the analysis of nanocarrier interaction with 
the blood components. It is a very easy, rapid and sensitive method [372]. Haemoglobin 
serves as a biomarker for the detection of haemolysis. Free haemoglobin concentration 
is determined spectrophometrically in the erythrocyte supernatants which is 
proportional to the degree of haemolysis [373]. Haemolysis can lead to serious 
disorders e.g., anaemia, haemocytosis and jaundice [373]. For this reason, the 
haemolytic potential of all nanocarriers must be evaluated as a necessary part of the 
development of drug delivery systems [373]. 
The physicochemical properties of nano-drug carriers such as cationic charge  [374, 
375] high molecular weight, flexible architecture and branched or linear structure [157, 
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376] trigger their interactions with erythrocytes leading to haemagglutination (cell 
aggregation)  or haemolysis (destruction of red blood cells) [376, 377].  
Haemagglutination is thought to occur due to non-specific ionic interactions between 
the positively-charged polycation and negative charges of the erythrocytes, mainly by 
sialic acid units located in the glycocalyx of the cell membrane [374, 378]. These 
interactions may also cause haemolysis via permeabilization of the lipid bilayer of 
erythrocytes [373, 378].  
The hydrophobic subunits of quaternized tertiary polyamine have been shown to 
have a tendency to dissolve in the lipid membrane and destabilise erythrocyte leading 
to haemolysis [378]. The MW of PLL has also been shown to have an impact on 
haemolysis and aggregation of erythrocyte [377]. Kaminski et al. reported the same 
behaviour of the polymethacrylate derivatives to cause haemolysis with the increase of 
hydrophobicity and MW [376]. Fischer et al. reported an increase in haemolysis with 
the increase in the number of primary amine group in polycation [157].  
Despite the cytotoxicity associated with polycations, numerous polycations have 
reached the clinics for drug delivery purposes such as Eudragit derivatives, chitosan 
and protamine [379]. A number of approaches are being used to prevent the toxicity of 
polycations. The efficient but toxic polycations are modified to produce safer 
nanocarriers such as polyethylene glycol (PEG) grafted nanocarriers to prevent their 
interaction at the biological surfaces, by masking their antigenic sites [92, 380, 381]. 
Zhu et al. prepared chitosan-N-trimethylaminoethylmethacrylate chloride–PEG which 
were able to reduce the haemolytic activity of the unmodified counterpart up to 50% 
[92]. In addition, Kamiński et al. synthesised cationic derivatives of dextran and 
hydroxypropylcellulose which have been reported to be free from haemolytic effects 
[376].  
4.1.4 Oxidative Stress 
Oxidative stress is caused by an imbalance of the redox state of cells which occurs 
under conditions such as exposure to radiations or toxic chemicals [160, 382]. It 
primarily occurs due to the overproduction of ROS and free radicals by the cells [383]. 
Although, both free radicals and ROS are naturally produced in the body as 
intermediates in several different metabolic reactions, however, a balance is maintained 
by simultaneous production of antioxidants such as glutathione (GSH) [383, 384].  
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ROS species are either electrophilic molecules (e.g. H2O2) that attract electrons or 
are free radicals (e.g. OH-) containing an unpaired electron [160, 383]. Such species 
have substantial ability to damage DNA, proteins, and lipids by binding covalently and 
irreversibly to these biomolecules [385]. There are several different types of ROS such 
as superoxide (O2
-), hydroxyl radical (HO-), peroxy radical (ROO-), and hydrogen 
peroxide (H2O2) and reactive nitrogen species (RNS) [166, 383, 385, 386].  
ROS generation is one of the primary mechanisms of nanocarrier toxicity. There have 
been large numbers of instances when toxicity has been attributed to ROS production 
and oxidative stress [148, 159, 382, 387]. A diverse range of nanomaterials including 
carbon fullerenes, carbon nanotubes and nanoparticle metal oxides have been 
implicated to produce ROS [159]. ROS generation has been reported to be the plausible 
mechanism for the cellular apoptosis induced by the chitosan/polyoxometalate nano-
complex nanocarriers [388]. It has been reported that carrageenan (a sulphated 
polysaccharide) produces inflammation as a consequence of free radical generation 
[382]. The generation of ROS by fullerenes nano-C60 has shown to produce toxic 
effects by causing lipid peroxidation of cell membranes [387, 389]. Lipid peroxidation 
is characterised as an oxidative deterioration of polyunsaturated lipids of cell membrane 
which is involved in causing toxic effects such as DNA damage leading to cancer [383] 
It has been shown that ROS production varies with the physicochemical properties 
of nanocarriers. One good example is PEI-DS microparticles which produced 
significantly high levels of ROS with the increase of MW of PEI [390]. Recently, 
Nabeshi et al. reported that silica particles induced intracellular ROS generation which 
increased with decreasing particle size to less than 100 nm [391]. These findings 
indicate the role of high MW and small size in the ROS generation.  
It is considered that the surface area to volume ratio of nanocarriers is the key factor 
responsible for production of ROS. The higher the ratio, the higher is the chemical 
reactivity and hence the biological activity of the nanocarriers, resulting in more ROS 
production [160, 368, 392].  
Despite great advances in polymer cytotoxicity testing, the relation of the 
physicochemical properties of polymeric nanocarriers to the generation of ROS has not 
been fully explored [393]. This is the reason that the assays determining the production 
of ROS and free radicals hold great importance in the evaluation of toxicity generated 
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by polymeric systems. There are a number of assays used to measure oxidative stress 
such as ROS assay, lipid peroxidation assay, glutathione: oxidized glutathione assay, 
cytochrome C reduction assay and probe based assays such as 2′,7′-dichlorofluorescein 
diacetate (DCFDA) and 5-(and 6-)-chloromethyl-2',7'-dichloro-dihydrofluorescein 
diacetate (CM H2DCFDA) ROS assay   
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Schematic representation of probe based detection of intracellular ROS 
 
4.1.4.1 ROS assay 
The ROS assays are employed to determine the inflammatory and oxidizing potential 
of nanocarriers by measuring intracellular ROS. ROS production is measured using 
probes e.g. 2′,7′-dichlorofluorescein diacetate (DCFDA) or 5-(and 6-)-chloromethyl-
2',7'-dichloro-dihydrofluorescein diacetate (CM H2DCFDA). These fluorescent based 
probes can permeate the cell membrane where they are deacetylated to form 2,7-
dichlorodihydrofluorescein (DCFH) [166]. In the presence of ROS, DCFH is oxidized 
to a fluorescent product, 2,7-dichlorofluorescein (DCF)  (Figure 4.1) [166]. The 
evaluation of intracellular oxidative stress is made by measuring the presence of 
fluorescence of DCF in the sample by a fluorometer [160]. It gives an indication of 
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inflammation and irritation. The degree of inflammation and irritation can also be 
measured by evaluating the immunotoxicity profile. 
4.1.5 Immunotoxicity  
Immunotoxicity assessment is an important aspect of biomaterial screening of 
nanocarriers for their inflammatory potential. Inflammation occurs as a result of an 
immune response set in against the foreign antigens. It is mediated by a complex 
regulatory network of cells. Macrophages are activated on exposure to foreign bodies 
and secrete cytokines such as interleukin-6 (IL-6), IL-8 and TNFα which further 
generate immune response and inflammation [361, 362, 394].  
Cytokines are small soluble proteins or glycoproteins which act as messengers 
between adjacent or distant cells particularly of hematopoietic origin [395]. They act as 
markers of inflammation or disease process [396].  Among the many cytokines some 
function as proinflammatory (TNF-α, IL-2 and IL-6 ) while other as anti-inflammatory 
bodies (IL-10) [396, 397]. TNF-α and IL-6 were chosen for the in vitro cytokines assay 
because they are produced by activated macrophages and monocytes. They are involved 
in acute phase pro-inflammatory reactions [396, 398]. TNF-α can induce the production 
of IL-6 [396] and is able to initiate a cascade of other cytokines which further mediate 
an inflammatory response [399]. IL-2 is predominantly produced by antigen-activated 
T cells [400].  In addition to TNF-α and IL-6, IL-2 was employed for in vivo cytokine 
generation assay to assess the role of second line immune cells (T cell) in immune 
regulation. It has both positive and negative effects on the immune response and can 
stimulate a cascade of cytokines that involve various interleukins, interferon and TNF-
α [401].  
The type and degree of cytokine production has been found to be different between 
different cell lines. Tryoen-To´th and coworkers cultured osteoblast-like cells (SaOS-
2) and human periodontal ligament (PDL) cells on the surface of polyelectrolyte films 
with different terminating layers i.e., PEI, poly(sodium 4-styrenesulfonate) (PSS), 
PAH, poly(L-glutamic acid) (PGA), or PLL. They found significantly high levels of 
IL-8 (45 and 35%) than TNF-α in the culture supernatant of SaOS-2 cells grown on 
PAH and PEI-terminating films respectively, indicating the influence of type of 
polycation on cytokine production. The stimulating effect of PAH and PEI surfaces on 
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IL-8 production was more pronounced on PDL cells indicating cell type specific 
production [402].  
Chellat et al. found that exposure of the THP-1 macrophages to different 
concentrations of chitosan-DNA nanoparticles did not induce proinflammatory 
cytokine (IL-1β, IL-6 and TNFα) at 1, 6 and 24h incubation time [361]. Similar findings 
have been reported by Semete et al. who reported that chitosan and polyethylene glycol 
(PEG) coated-PLGA nanoparticles were taken up by macrophages following in vivo 
exposure via oral and intraperitoneal routes but did not produce significant level of 
cytokine [403]. These studies indicate non-immunogenicity of these polymeric 
nanoparticles. 
 Researchers have identified the relationship of cytokine production with cytotoxicity 
which may adversely affect their use. A study done by Olbrich et al. investigated the 
effect of D114- solid lipid nanospheres (SLN) prepared using different surfactants on 
the production of pro-inflammatory cytokine IL-6, IL-12 and TNFα by RAW 264.7 
cells. They reported that the IL-6 and TNFα generation reduced with the increase in 
concentration of formulation (from 0.00001 to 0.1%) such that no cytokine were 
detected at higher concentrations [404]. These findings indicated an inverse 
relationship of the cytokine generation with cytotoxicity. Similar findings have been 
reported by Scholer et al. who studied the generation of IL-6, IL-12 and TNFα on 
exposure to solid lipid nanoparticles (SLN) coated with P908, P407, P188, HS15 and 
T80 at 0.001% or lower concentrations. It was shown that IL-6 generation following 
incubation with all the above mentioned SLN formulations was reduced from 0.0001% 
to 0.1% in a concentration dependent manner indicating an inverse relationship of 
cytokine generation with cytotoxicity [405].  
There may be an association of physicochemical properties of nanocarriers such as 
size, surface charge, biodegradability, hydrophilicity and hydrophobicity with 
generation of cytokines, however, the effect of these properties on the cytokine 
generation has not been fully explored for polymeric nano-structures. There are two 
important techniques of analysing and quantifying cytokines in biological fluids and 
tissue culture supernatant namely flow cytometric and ELISA based detection. 
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4.1.5.1 Enzyme linked immunosorbent assay (ELISA) 
 ELISA is a highly specific and sensitive method for quantifying cytokines in 
biological samples [406]. However, they are restricted to detection and quantification 
of a single cytokine per assay. Simultaneous detection of a number of cytokines can be 
performed by using flow cytometry [406]. The principle of sandwich ELISA is detailed 
in chapter 3, section 3.3.4.2.  
4.2 AIM 
The aim of the present study was to investigate the biocompatibility of various 
polycations and NIL APECs. 
4.2.1 Objectives 
To investigate the effect of various polycations and APECs on  
 Cytotoxicity 
 ROS generation 
 Haemocompatibility 
 In vitro and in vivo Immunotoxicity 
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4.3 MATERIALS AND METHODS 
4.3.1 Materials 
Materials used Supplier 
3-4,5 dimethyl thialzol2,5 diphenyl 
tetrazolium bromide (MTT) 
Sigma Aldrich 
CaCo2 Cells European Collection of Cell Cultures 
Cytokine ELISA kits Bioscience 
Dimethyl Sulfoxide (DMSO) Sigma Aldrich 
Dulbecos Minimal essential media Invitrogen, UK 
Dulbecos Modified Eagles Media Invitrogen, UK 
Eagles Minimal Essential Media Sigma Aldrich 
Foetal bovine serum Sigma Aldrich 
Hydrogen peroxide (H2O2) Sigma Aldrich 
J774 cells European Collection of Cell Cultures 
L Glycine Sigma Aldrich 
L-Glutamine Sigma Aldrich 
Lipopolysacchride (LPS) Sigma Aldrich 
Non-essential amino acids Sigma Aldrich 
Penicillin Streptomycin Sigma Aldrich 
Phosphate buffer saline 10X (PBS) Sigma Aldrich 
ROS detection assay kit Invitrogen, UK 
Triton-X Sigma Aldrich 
Trypan Blue Sigma Aldrich 
Trypsin 10X Sigma Aldrich 
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4.3.2 Methods 
4.3.2.1 Thawing of frozen CaCo2 cells 
The media was warmed by placing in a 37°C water bath for 15min. On every 
occasion when the cells were thawed, the cryo-tube was taken out from the liquid 
nitrogen and partially immersed in the water bath at 37°C for 1-2min until the cells 
fully thawed. The tube was then wiped with 70% IMS to avoid contamination. The 
contents of the tube were slowly pipetted into a T25 flask (75cm2). 9mL of pre-warmed 
complete medium (Eagles minimal essential medium (EMEM) supplemented with 1% 
non- essential amino acids (NEAA), 1% 2nM Glutamine, 10% heat inactivated foetal 
bovine serum (FBS) and 1% Penstrep) was added into the flask to promote the growth 
of cells. The flask was incubated in 5% CO2 at 37°C. 
4.3.2.2 Cell line maintenance: 
CaCo2 cells grown in EMEM were examined every alternate day for their confluency 
and media was replaced with 10mL of fresh pre-warmed media. The cells were re-
incubated in 5% CO2 at 37°C. They were generally found to be 80-90% confluent in 3-
4 days and ready for subculture. For all experiments the confluent flasks were first 
washed 3 times with 5mL 0.01M PBS. 3mL of 0.25% w/v trypsin was added to the 
CaCo2 cell flask to dislodge cells from the bottom of the flask. The flask was then 
swirled few times to allow contact of trypsin with all the cells. 2mL of trypsin was 
aspirated and the flask was incubated in 5% CO2 at 37°C for 30sec. The flask was then 
gently shaken and tapped to separate cells from each other. Subsequently, the cells were 
examined under the microscope to confirm cell detachment from the surface of the 
flask. 5mL of media was then added into the flask to inactivate the trypsin. The cell 
suspension was transferred to a 15mL centrifuge tube and centrifuged at 1500 rpm for 
5min at ambient temperature. The supernatant was aspirated by vacuum suction and the 
pellet was re-suspended in 1mL of fresh media. The cells were counted as detailed 
below (section 4.3.2.3) and transferred to new T75 flasks to grow again. The remaining 
cells were used for the required assay. The thawed cells were sub-cultured three times 
before using for an experiment. 
J774 cells were cultured in dulbeco’s modified eagles medium (DMEM) which was 
supplemented with 10% FBS and 1% penicillin/streptomycin and incubated in 5% CO2 
at 37ᵒ C. Macrophages adhere strongly to the tissue culture plastic and hence cannot be 
easily trypsinized. Therefore, the cells were passaged by scraping. Once confluent 
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(usually within 24h) the cells were gently scraped with a cell scraper. The harvested 
cells were centrifuged at 1500 rpm for 5min at room temperature. The pellet was re-
suspended in media and used as required. 
4.3.2.3 Cell counting 
100µL of cell suspension was mixed with 100µL trypan blue in an eppendorf (1:1 
dilution). 10 µL of this suspension was pipetted into the haemocytometer chamber and 
was covered with a moist cover slip. 
The number of cells were counted in the neubauer’s chamber and the average number 
of viable cells in the suspension was determined as shown in equation 4.1.  
Average number of cells/chamber =
Total number of viable cells
Number of chambers
  
Equation 4.1 
The original number of cells/mL were calculated as in equation 4.2.  
 
Equation 4.2 
The volume of the original cell suspension required to achieve desired number of 
cells to grow in a flask was calculated using equation 4.3.  
 
 
                               Equation 4.3 
 
4.3.2.4 In vitro cytotoxicity assay 
4.3.2.4.1 MTT assay 
MTT assay was conducted on two different cell lines to determine the cytotoxicity 
of various formulations. CaCo2 cells (passage 40-70) and macrophage J774 cell line 
(passage 86-97) were grown at a density of 2 X 103 cells/well in 96 well plates under 
identical experimental conditions. The method described here is based in principle on 
the method described by Mosmann et al. [407].  
Original number of cells/mL= Average number of cells X 104 X dilution factor 
 
Volume of original suspension= Desired number of cells X Total volume 
        Original number of cells  
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% Cell viability
=
  Average sample absorbance − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
  Average absorbance of negative control − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
 X 100 
200µL of the cell suspension (2 X 103cells/well) was added to the 96 wells plates. 
The plates were incubated at 37°C, 5% CO2 until the desired confluency (80-90%) was 
achieved (usually within 1-2 days). The polymer (PAH, Pa2.5, Da10, QPa2.5) and 
APEC (PAH-DS, PAH-PAA, Pa2.5-DS, Pa2.5-PAA, Da10-DS, Da10-PAA, QPa2.5-
DS and QPa2.5-PAA) solutions were prepared (as described in chapter 3, section 
3.5.2.1.1 & 3.5.2.2.1) and were serially diluted with growth media to achieve required 
concentrations. The media in the 96 well plate was replaced with 200µL of each 
concentration into the wells (n=5). Triton X was used as a positive control while 
untreated media was used as a negative control. Plates were incubated in 5% CO2 at 
37°C. After 24h incubation, the polymer/APEC solutions were replaced with 200µL of 
fresh media and plates were incubated for another 24h. 50µL of sterile filtered MTT 
solution (0.5 mg/mL) prepared in distilled water was added into each well containing 
media. The unreacted dye was aspirated after 4h. The insoluble formazan crystals were 
dissolved by adding 200µL of DMSO, followed by addition of 25µL of 0.05 M glycine 
buffer (made up by dissolving 3.75g glycine and 2.93g NaCl  in 500mL distilled water 
and pH adjusted to 10.5)  in each well. The absorbance was read spectrophotometrically 
at a wavelength of 540nm with a UV plate reader (Synergy H4, Vermont, USA). The 
percentage cell viability was calculated using equation 4.4.  
 
 
 
Equation 4.4 
The IC50 was calculated as the concentration at which the cell viability decreased to 
50% of maximum cell viability (negative control cells). The experiments were 
performed in triplicates. 
4.3.2.5 Haemolysis assay 
4.3.2.5.1 Erythrocyte preparation 
Fresh rat blood was kindly provided by the biological service unit (BSU) of the 
University of Hertfordshire. Blood was collected in a heparinized tube and washed with 
phosphate buffered saline (PBS buffer 0.01 M). 15mL of PBS was added to 3 - 5mL of 
fresh rat blood and centrifuged at 2500 rpm for 10min at 4˚C. The supernatant was 
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discarded and the process was repeated until the supernatant was clear. The final 
erythrocyte pellet was isolated and weighed. A 3% w/v dilution was made with PBS. 
4.3.2.5.2 Assay procedure 
Haemolysis assay was adopted from the method described by D Fischer et al. [157]. 
80µL of the erythrocyte suspension was pipetted into each well of round bottomed 96 
well plates. 20 mgmL-1 stock solution of each polymer or APEC was made up in Tris 
buffer and the pH was adjusted to pH 7.4 with NaOH / HCl. Serial dilution was 
performed to achieve various concentrations ranging from (0.05- 10mgmL-1) of 
polymer and APEC solutions by using 0.01M PBS as a diluent.  80µL of various 
formulation concentrations (n=5) were added into a 96 well plate. The negative control 
was prepared by mixing blood and PBS solutions (1:1), while the positive control was 
prepared by mixing blood solution and triton X (1:1). The plates were incubated at 37˚C 
for 4h and then centrifuged at 2500 rpm for 10min at 4˚C. 100µL of supernatant from 
each well was transferred to a flat bottom 96 well plate. The amount of haemoglobin 
released in the samples was determined spectrophotometrically at 540nm. The 
experiments were performed in triplicate and the percentage haemolysis was calculated 
in relation to the positive controls by using equation 4.5. 
Equation 4.5 
4.3.2.6 Reactive oxygen species (ROS) assay  
The ROS production was investigated in the CaCo2 cells incubated with various 
polymers and APECs. The CaCo2 cells (2 X 103cells/well) were seeded into a 96-well 
plate and incubated for 24h. The generation of ROS was monitored by using ROS 
detection kit (Molecular Probes/Invitrogen) following the manufacturer’s protocol. 
100µL of polymer or APEC at the IC90 concentration (concentrations (PAH 3µgmL
-
1, PAH-DS 3µgmL-1, PAH-PAA 5µgmL-1, Pa2.5 7µgmL-1 Pa2.5-DS 10µgmL-1, Pa2.5-
PAA 14µgmL-1, Da10 7µgmL-1, Da10-DS 10µgmL-1, Da10-PAA 14µgmL-1, QPa2.5 
11µgmL-1, QPa2.5-DS 14µgmL-1, QPa2.5-PAA 14µgmL-1) determined by the MTT 
assay) were added to each well of 96 well plate (n=5) and plates were incubated at 37˚C 
% Haemolysis =
  Average sample absorbance − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
  Average absorbance of positive control − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
 X 100 
 
138 
 
for 4h. A 10µM stock solution was prepared by first dissolving in 50µg of carboxy 
methyl- di-fluoro di-hydro fluorescein di-acetate (CM-H2DCFDA- 577.8 g/mol) in 
0.5mL DMSO while protected from light, followed by subsequent dilution with 11.5 
mL of 0.01M PBS.  
The cells were washed 3 times with PBS and incubated with 100μM CM-H2DCFDA 
(100μL/well) at 37°C. After 30min, the cells were washed 3 times with PBS and 
incubated with serum free medium (100μL/well). The medium was removed after 
30min and replaced with PBS. Production of the oxidation product was determined by 
measuring the fluorescent intensity of the samples at 560 nm (excitation) and 590 nm 
(emission) on a fluorescent microplate reader (Techan M200 microplate reader). The 
background reading of negative control (PBS) was subtracted from the actual 
fluorescent reading. Tert-Butyl hydrogen peroxide (TBHP- (CH3)3COOH), 100µM was 
used as a positive control for ROS production, as it is an inducer of a number of ROS. 
The ROS generation induced by the positive control was considered as 100%. The 
percentage of ROS production by cells incubated with various formulations was 
calculated in respect to the positive control cells as shown in equation 4.6.  
% ROS production =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠−𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒
𝑋100 
Equation 4.6 
4.3.2.7  Cytokine Assay: 
4.3.2.7.1 In vitro cytokines assay  
The macrophages were harvested from a confluent flask and centrifuged at 1500 rpm 
for 5min at room temperature. The pellet was re-suspended in media and seeded in 96 
well plates (2 X 103 cells/well) for 24h. The cells were incubated with 200µL/well of 
polymers, NIL APECs at the IC90 concentrations (refer to section 4.3.2.6) based on the 
results from MTT assay. Lipopolysaccharide (LPS) was used as a positive control 
(1µg/mL) to induce cytokines associated with activated macrophages. 
After 2-4 h incubation of the cells with the samples, the supernatants were collected 
for cytokine determination. The concentrations of cytokines (TNF-α and IL-6) in cell 
culture supernatants were determined by enzyme-linked immunosorbent assay (ELISA) 
according to the manufacturer’s protocol (Bioscience ELISA kits).  
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Briefly, the plates were coated with cytokine capture antibodies (IL-6, TNF- α). The 
plates were sealed and kept at 4ᵒC for 16-18h. The coated plates were washed 4 times 
with 300µL wash buffer per well. Afterwards, the plates were washed 4 times with 
300µL wash buffer per well between all the subsequent steps.  200µL of assay diluent 
was added to each well to reduce the non-specific binding and the plates were re-
incubated. After 1h reaction period, 100µL per well of standards and cell culture 
supernatants incubated with IC90 concentration of polymer and APECs diluted in assay 
diluent were added to the wells of 96 well plates and incubated for 2h on a plate shaker 
(200 rpm) at RT. Thereafter, the plates were incubated with 100µL per well of detection 
antibodies. After 1h reaction time, 100µL per well of freshly prepared TMB substrate 
solution was added and plates were incubated in the dark for 20min. The wells 
containing cytokine turned blue. 100µL per well of stop solution (1M H2SO4) was 
added to each well to stop the reaction. The amount of IL-6 and TNF-α present in each 
well was determined by using a microplate spectrophotometer (Synergy H4, Vermont, 
USA) at a wavelength of 540nm. A standard calibration curve was constructed between 
absorbance and known concentration (7.8-500 pgmL-1) of cytokines (IL-6 and TNF). 
The cytokine concentration in unknown samples was calculated from the calibration 
curve. The measurements were performed in triplicates.  
4.3.2.7.2 In Vivo cytokine assay 
Male wistar mice were maintained in the BSU at UH, and used at 6-8 weeks of age. 
They weighed between 18 - 22g each. To examine the in vivo effect of the formulations, 
half of the mice were injected intravenously with sterile LPS (100µg/mouse) and 100-
200µg/mouse of formulations prepared in 5% dextrose via the tail vein while rest half 
were given the formulations orally via intra gastric gavage to ensure delivery of an exact 
dose. The mice were bled and 100-200µL aliquots of blood were retrieved via the 
arterial catheter at 12h after i.v. administration and 24h of oral administration of 
formulations. Blood samples were centrifuged at 6000 rpm for 5 min at 4ᵒC. The serum 
was aliquoted and stored at -20ᵒC until assayed for the presence of cytokines. The serum 
cytokine concentrations were determined by ELISA immunoassay as described above 
in section 4.3.2.7.1.  
4.3.2.8 Statistical analysis 
  All the experiments were performed in triplicates and data presented as mean ±S.E. 
Statistical analysis was performed using one way analysis of variance (ANOVA) 
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followed by post hoc, tukey’s test for comparison with the control group. The statistical 
significance was determined at a p<0.05. 
4.4 RESULTS  
4.4.1 In vitro cytotoxicity analysis by MTT assay 
MTT assay was performed to determine the viability of CaCo2 and J774 cells after 
24h treatment with polycations or NIL APECs formulations.  The principle of this assay 
is based on the assessment of cellular mitochondrial activity [407]. The percentage of 
viable cells was used as an indicator of polycation and APECs response.  
4.4.1.1 MTT analysis on CaCo2 cells 
The treatment of cells with DS and PAA at (0.01-10mgml1) concentrations did not 
affect the cell viability or morphological characteristics of cells (data not shown). The 
polycations (PAH, Pa2.5, Da10, QPa2.5) produced a more significant decrease in the 
cell viability than APECs (Figure 4.2 & 4.3). The IC50 values of the polycations were 
calculated to be PAH-37.5µgmL-1, Pa2.5-63µgmL-1, Da10-63µgmL-1, and QPa2.5-
500µgmL-1 (Table 4.1).  
A substantial increase in IC50 (p<0.05) was observed when the cells were incubated 
with APECs. The improvement in IC50 was more pronounced in the presence of PAA 
based APECs (p<0.001) than DS based APECs. The introduction of PAA was able to 
increase the IC50 of PAH by 2 fold (p≤0.01), Pa2.5 (14 fold- p≤0.001), Da10 (16 fold- 
p≤0.001) and QPa2.5 (2 fold- p≤0.01) compared to polycation alone (Table 4.1). On 
the other hand, DS based formulations i.e., Pa2.5-DS and PAH-DS did not exhibit 
improvement in IC50, whereas Da10-DS (p<0.01) and QPa2.5-DS (p<0.05) improved 
the IC50 by 2.2 and 2 fold respectively.  
Substantial changes in the morphology of the cells were noticed upon incubation with 
the polycations and APECs (Figure 4.4). The number of viable cells appeared 
significantly higher in the cells incubated with the PAA based formulations, particularly 
Pa2.5-PAA and Da10-PAA. The areas showing black patches on micrograph represent 
the dead cells.  
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Figure 4.2 Effect of (a) PAH and corresponding APECs (b) Da10 and corresponding 
APECs on viability of CaCo2 cells. Each value represents mean± SE of three 
experimental determinations. Statistical significance was determined at a p 
value<0.05*.  
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Figure 4.3 Effect of (a) Pa2.5 and corresponding APECs (b) QPa2.5 and 
corresponding APECs on viability of CaCo2 cells. Each value represents mean± SE of 
three experimental determinations. Statistical significance was determined at a p 
value<0.05*.  
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Figure 4.4 Effect of polycations and APECs on viability of CaCo2 cells (a) Untreated control, 
(b) PAH-DS (0.025mgmL-1), (c)PAH-PAA (0.025mgmL-1), (d) Da10 (0.05mgmL-1), (e) Da10-DS 
(0.05mgmL-1), (f) Da10-PAA (0.05 mgmL-1), (g) Pa2.5 (0.05mgmL-1), (h) Pa2.5-DS (0.05mgmL-
1), (i) Pa2.5-PAA (0.05mgmL-1), (j) QPa2.5 (0.5mgmL-1), (k) QPa2.5-DS (0.5mgmL-1), (l) 
QPa2.5-PAA (0.5mgmL-1). The black patches show dead cells which are indicated by 
arrows.   
a     b     c 
 
 
d     e     f 
 
 
g     h     i 
 
 
j     k     l 
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Table 4.1 A summary of cytotoxicity profile of polycations and APECs on CaCo2 and J774 
cells following 24h incubation. Each value represents mean± SD of three experimental 
determinations. 
Polycations/ 
APECs 
IC50 
(mgmL-1) 
on CaCo2 
cells 
Improvement in 
IC50 of APECs 
compared to 
related polycations 
IC50 (mgmL-1) 
on J774 cells 
Improvement in 
IC50 of APECs 
compared to 
related polycations 
PAH 3.75X 10-2       2.0X 10-2  
PAH-PAA 7.5X 10-2 2 folds 7.2X 10-2 3.6 folds 
PAH-DS 3.75X 10-2 - 2.4X 10-2 1.2 folds 
P2.5 6.3X 10-2  3.75X 10-2  
Pa2.5-PAA 9.0X 10-1 14.2 folds 3.5X 10-1 9.33 folds 
Pa2.5-DS 6.3X 10-2 - 1.5X 10-1 4 folds 
Da10 6.3X 10-2  3.75X 10-2  
Da10-PAA      1 15.8 folds 1.4X 10-1 3.73 folds 
Da10-DS 1.4X 10-1 2.2 folds 8.15X 10-2 2.17 folds 
QPa2.5 5X 10-1  1.15  
QPa2.5-PAA     1 2 folds 2.1X 10-1 - 
QPa2.5-DS     1 2 folds 1.7X 10-1 - 
 
4.4.1.2 MTT analysis on J774 cells 
J774 cells were found to be more susceptible to polycations and APECs induced 
cytotoxicity than CaCo2 cells. The IC50 values varied significantly between the two cell 
lines. The IC50 values in J774 cells were found to be much lower than those found in 
CaCo2 cells (Table 4.1). The degree of cytotoxicity on J774 cells is rated as 
PAH˃Pa2.5=Da10˃QPa2.5 which is similar to what was found in CaCo2 cells (Figure 
4.5 & 4.6). Once again, PAH was found to be more cytotoxic than its modified 
counterparts (Figure 4.5a) and QPa2.5 was the least cytotoxic (Figure 4.6b).  
Similar to CaCo2 cells, the addition of polyanions diminished the cytotoxicity of 
most of the polycations in J774 cells (except QPa2.5 based APECs), however, the 
improvement was not as great as found in the CaCo2 cells (Table 4.1). Pa2.5-PAA and 
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Da10-PAA improved the IC50 on J774 cells by 9.3 fold (p<0.01) and 3.73 fold (p<0.05) 
respectively, whereas 14 – 16 fold respectively on CaCo2 cells. On the other hand, 
Pa2.5-DS displayed 4 fold improvements in IC50 (p<0.05), in contrast to no 
improvement on CaCo2 cells. Like CaCo2 cells, Da10-DS produced 2 fold 
improvement in IC50 (p<0.05) on J774 cells. Substantial changes in the morphology of 
cells were noticed after 24h incubation with polycation or APECs (Figure 4.7). The 
number of dead cells was seen to be higher in the cells incubated with the polycations 
than APECs at identical concentrations.  
 
 
Figure 4.5 Effect of (a) PAH and corresponding APECs (b) Da10 and corresponding APECs 
on viability of J774 cells. Each value represents mean± SE of three experimental 
determinations. Statistical significance was determined at a p value<0.05*. 
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Figure 4.6 Effect of (a) Pa2.5 and corresponding APECs (b) QPa2.5 and 
corresponding APECs on viability of J774 cells. Each value represents mean± SE of 
three experimental determinations. Statistical significance was determined at a p 
value<0.05*. 
 
 
 
-5
15
35
55
75
95
115
0.005 0.01 0.025 0.05 0.075 0.1 0.2 0.5 1 1.5
%
 C
el
l v
ia
b
ili
ty
Concentration (mg/mL)
Pa2.5
Pa2.5-DS
Pa2.5-PAA
-5
15
35
55
75
95
115
0.025 0.05 0.075 0.1 0.2 0.5 1 1.25
%
 C
el
l v
ia
b
ili
ty
Concentration (mg/mL)
QPa2.5
QPa2.5-DS
QPa2.5-PAA
* 
* 
* 
* 
* 
* 
b 
a 
* 
* 
* 
* 
* 
* 
147 
 
   
                 
                  
                 
Figure 4.7 Effect of (a) Untreated control, (b) PAH-DS (0.025mgml-1), (c)PAH-PAA 
(0.025mgml-1), (d) Da10 (0.05mgml-1l) (e) Da10-DS (0.05mgml-1) (f) Da10-PAA (0.05mgml-1), 
(g) Pa2.5 (0.05mgml-1), (h) Pa2.5-DS, (0.05mgml-1), (i) Pa2.5-PAA, (0.05mgml-1), (j) QPa2.5 
(0.5 mgml-1), (k) QPa2.5-DS (0.5mgml-1), (l) QPa2.5-PAA (0.5mgml-1) on viability of J774 
cells (X 40 magnification).  
a      b c 
d     Dead cells e f 
g     Dead cells 
 
h i 
j k     Dead cells l     Dead cells 
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4.4.2 Haemolysis Assay 
Haemolysis assay was employed to investigate the degree of haemolysis on exposure 
to polycations and APECs. The haemolytic potential of APECs was evaluated in 
comparison to polycations alone. Less than 10% haemolysis was considered as no 
significant haemolysis which is in line with Fisher et al. [157].  Haemoglobin measured 
in the erythrocyte supernatants exposed to all formulation (≤ 5mgmL-1) was found to 
be less than 10%, except Da10 based formulations (Figure 4.8a). However, at higher 
concentrations (≥5mgmL-1) PAH and Pa2.5 were found haemolytic (Figure 4.8b & c).   
Among all polycations, Da10 appeared to be the most haemolytic. Da10 1mgml-1 
released 20% of haemoglobin, 8mgml-1 released approximately 34% and 10mgml-1 
released approximately 37% haemoglobin. However, Da10-DS and Da10-PAA 
(8mgmL-1 concentration) released 16% and 11% haemoglobin respectively, indicating 
significantly less haemolytic activity than Da10. Exposure of cells to non-haemolytic 
concentration of Da10 and corresponding APECs resulted in aggregation and clumping 
of cells (Figure 4.9j, k & l). PAH, PAH-DS, PAH-PAA, Pa2.5, Pa2.5-DS and Pa2.5-
PAA demonstrated no haemolytic activity up to 5mgml-1 (Figure 4.8b & C). Quaternary 
ammonium based polycations and APECs were found to be non-haemolytic at all 
concentrations tested in the study (10mgml-1) (Figure 4.8d).  
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Figure 4.8 Effect of (a) Da10 and corresponding APECs (d) PAH and corresponding APECs 
(a) Pa2.5 and corresponding APECs (a) QPa2.5 and corresponding APECs on 
haemocompatibility of erythrocytes. Each value represents mean± SE of three 
experimental determinations. Statistical significance was determined at a p value<0.05. 
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Figure 4.9 Morphology of wistar rat RBC’s incubated with (a) Untreated control (b) PAH-DS 
(c) PAH-PAA (d) Pa2.5 (e) Pa2.5-DS (f) Pa2.5-PAA (g) QPa2.5 (h) QPa2.5-DS (i) QPa2.5-PAA 
(j) Da10 (k) Da10-DS (l)Da10-PAA.  
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4.4.3 ROS assay 
Intracellular ROS generation was assessed in the supernatants of CaCo2 cells 
incubated with polycations and APECs (at IC90 as determined by the MTT assay). PAH, 
Pa2.5 and Da10 induced higher ROS (max 25%) in CaCo2 cells than QPa2.5 (max 
12%) (Figure 4.10).  
There was substantially lower ROS production on exposure of CaCo2 cells to APECs 
(p<0.05) than their corresponding polycations. APECs formed by Pa2.5 and QPa2.5 
produced more significant reduction in polycation associated ROS production (Figure 
c and d) than APECs formed by PAH and Da10 (Figure a & b). PAH and Pa2.5 based 
APECs reduced the ROS production of corresponding polycations by 2 fold and 3 fold 
respectively (p<0.05). Da10-DS did not reduce the ROS production compared to Da10. 
The QPa2.5-PAA produced 3 fold (p<0.01) and QPa2.5-DS 2 fold (p<0.05) lower ROS 
generation than QPa2.5 (p<0.05).  
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Figure 4.10 Effect of ROS production by CaCo2 cells on exposure to (a) PAH and 
corresponding APECs (b) Da10 and corresponding APECs (c) Pa2.5 and corresponding 
APECs (d) QPa2.5 and corresponding APECs. Each value represents mean± SE of three 
experimental determinations. Statistical significance was determined at a p 
value<0.05*. 
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4.4.4 In Vitro cytokine generation assay 
This study was performed to determine the ability of polycations and APECs to 
induce cytokine production (IL-6 and TNF α) in J774 cells. IL-6 and TNFα cytokines 
were chosen as they are produced by macrophages and serve as an indicator for 
activation of macrophages and hence an early immune response.  
All polycations and APECs demonstrated the ability to induce IL-6 and TNFα 
production (Figure 4.11). Generally, the formulations induced higher levels of IL-6 than 
TNFα (except QPa2.5 and QPa2.5-PAA). The IL-6 generation profile of polycations is 
rated as QPa2.5˃Pa2.5˃Da10˃PAH. On the other hand, TNFα generation profile is 
rated as QPa2.5˃Pa2.5˃PAH˃Da10.  
QPa2.5 and its APECs demonstrated higher generation of cytokines (≥90%) than 
unmodified and hydrophobically modified polycations (≤75%). QPa2.5 and Da10 
based APECs produced no significant reduction in corresponding polycation associated 
cytokine generation (except QPa2.5-PAA). The exposure of cells to Da10-DS resulted 
in higher levels of cytokines than their corresponding polycations.  
The cytokine generation was lower in the cell supernatants exposed to PAH and 
Pa2.5 based APECs. Similar to MTT and haemolysis assay, the result of PAH and Pa2.5 
based APECs showed more marked reduction in cytokine generation in the presence of 
PAA based APECs (PAH-PAA- 1.7 fold IL-6 reduction, p<0.01; Pa2.5-PAA 2 fold 
TNFα reduction and 3.5 fold IL-6 reduction, p<0.001) than DS based APECs (which 
did not show statistically significant difference in cytokine generation with their 
corresponding polycation). These results show that PAA based APECs, in particular 
Pa2.5-PAA produced the most significant reduction in cytokine generation, therefore, 
only PAA based APECs were selected for the in vivo cytokine generation study.  
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Figure 4.11 In vitro cytokine generation by J774 cells on exposure to polycations 
and APEC formulation. Each value represents mean± SE of three experimental 
determinations. Statistical significance was determined at a p value<0.05*. 
 
4.4.5 In Vivo cytokine generation assay  
The in vivo generation of three pro-inflammatory cytokines (IL-2, IL-6 and TNF-α) 
was investigated in serum samples of healthy mice treated with i.v. and oral doses of 
polycations or APECs. The polycations and APECs induced significantly lower levels 
of in vivo cytokines (Figure 4.12) compared to the high levels of in vitro cytokines 
(Figure 4.11) in macrophage culture supernatants. Among all the cytokines tested, the 
generation of IL-6 was more significant (maximum 27% i.v. administration; maximum 
18% oral administration) than other cytokines which is consistent with the in vitro data. 
The cytokine generation was found higher in mice sera treated with i.v. and oral QPa2.5 
than the hydrophobically modified polycations, which agrees with the in vitro data. 
There were no significant differences in the generation of IL-2 and TNFα by 
polycations and APECs. Pa2.5-PAA and QPa2.5-PAA brought a more marked 
reduction (P<0.05) in the polycation associated cytokine generation than Da10-PAA.  
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Figure 4.12 In vivo cytokine generation profile in serum samples of wistar mice treated 
with (a) i.v. polycation and APEC formulations (b) oral polycation and APEC formulations. 
Each value represents mean± SE of three experimental determinations. Statistical 
significance was determined at a p value<0.05*. 
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4.5  DISCUSSION 
It is well known that polyelectrolyte complexes are simple and quick to formulate 
but complexes formed from polycations may be toxic biologically [153]. There is a 
well-established relationship between toxicity and the polycationic nature of polymers 
[157, 408]. This study aims to evaluate the biocompatibility profile of various 
polycations and APECs. Briefly, this study investigated and compared the cytotoxicity, 
haemocompatibility, ROS generation and immunotoxicity of the polycations and 
APECs fabricated in chapter 3 section 3.5.2.1.1 & 3.5.2.2.1. 
The findings from MTT assay substantiate the contribution of polymer architecture 
in mediating the cytotoxic effects on CaCo2 and J774 cells (Table 4.1), whereby 
hydrophobically modified polymer (Pa2.5 and Da10) were more cytotoxic than the 
hydrophilically modified PAH (QPa2.5). The key trend of the polymer cytotoxicity 
remained the same i.e., PAH˃Pa2.5=Da10˃QPa2.5 on both the cell lines. However, 
J774 cells exhibited lower IC50 values indicating higher sensitivity to the polycations 
and APECs than CaCo2 cells. The varying IC50 on the two cell lines can be attributed 
to the differences in the physicochemical properties of the particles and the intrinsic 
difference in the properties of the two cell lines. It has been shown that different 
particles differ in their ability to interact with macrophages and hence in the induction 
of toxicity [353]. Macrophages have been shown to internalise 4 times more 
polystyrene-COOH than THP-1 cells which may be the reason for their higher 
sensitivity [307]. Recently, Calu-3 and CaCo-2 cells have also been reported to exhibit 
different degree of toxicity on exposure to chitosan indicating differential toxicity on 
different cell lines [409]. Clift et al. has shown significant toxicity of quantum dots 
(QDs) on J774 cells [353] which were found non-toxic on primary rat hepatocytes 
[410]. This might mean that macrophages are more sensitive to nanocarriers than other 
cell lines which may either be due to extensive uptake or different mechanism of uptake 
by them. However, unlike other formulations, QPa2.5 based complexes exhibited lower 
cytotoxicity to macrophage which may be due to their large size which prevented higher 
uptake of particles and hence the cytotoxicity.  
CaCo2 cells are derived from colon adenocarcinoma, which differentiate to adapt 
ileal enterocyte like properties [220]. They differ significantly from the macrophages 
both morphologically and physiologically. Their uptake mechanism is different from 
the uptake by macrophages. They preferentially internalise nanoparticles in the range 
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of 100-200 nm by endocytosis [411]. However, the particles that are internalised by 
cells may also undergo efflux [412]. Conversely, the uptake by macrophages occurs 
primarily via phagocytosis. The extent of uptake depends on the size and shape of 
nanoparticles [412].  
The internalisation of nanoparticles by macrophage cell lines does not behave the 
same as uptake by primary macrophage [412] as well as by other cell lines [413]. 
Macrophages have been shown to phagocytise the particles ≥200nm in diameter more 
efficiently than the smaller particles [307, 411].  It has been shown that macrophages 
were able to accumulate significantly higher level of oritavancin than the epithelial cell 
lines i.e., LLC-PK1 and CaCo2 indicating chances for higher cytotoxicity [413]. 
Therefore, it is very important to understand the molecular events leading to a higher 
uptake. It is also important to determine whether the uptake of nanoparticles by 
macrophages activates or halts the inflammatory response [412]. 
The unmodified PAH was more cytotoxic to both cell lines than the modified PAH. 
The higher cytotoxicity of PAH is attributed to the presence of a high density of primary 
amine groups. It is well known that polycations bearing –NH2 termini such as PEI, 
poly-l-lysine (PLL), chitosan [207] and polyallylamine (PAH) generate significant 
cytotoxicity [143, 153]. Modification of PAH reduces the number of primary amines 
on the PAH backbone which is the most likely reason for the reduction in cytotoxicity. 
It has previously been shown that modification of primary amines with hydrophilic 
methyl glycolates [154], PEG [414] and imidazolyl grafting [152] reduces the 
cytotoxicity. It has also been shown by Thompson et al. that the modification of PAH 
with palmitoyl group decreased the toxicity of PAH by 2-3 fold which agree well with 
our data [415]. Besides, they also reported that quaternisation of palmitoyl pendant 
groups on the polymer backbone significantly improved the cytotoxicity which again 
correlates with our data  [415].  
Based on studies with polycations, it has been observed that macromolecules with 
tertiary and quaternary amino groups exhibit a much lower cytotoxicity index than 
primary and secondary groups [227]. This is clear from the results where hydrophilic 
modification of Pa2.5 with a quaternary ammonium moiety brought a more significant 
improvement in IC50 i.e., CaCo2 cells -13 fold and J774 cells - 57.5 fold. This may be 
due to the conversion of primary amines on the polymer backbone to less toxic 
quaternised amines which carry a permanent cationic charge [151]. Brownlie et al. has 
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reported a similar response of more than four-fold reduction in the toxicity of PEI by 
the quaternised PEI, and eight folds upon quaternisation of palmitoyl grafted PEI [151]. 
The polyanions, PAA and DS are non-toxic hydrophilic polymers. They did not 
affect the cell viability up to 10mgmL-1 (data not shown). Owing to their negative 
charge they are able to complex with polycations and reduce their overall positive 
charge [258]. In this way, they are expected to diminish the polycation associated 
cytotoxicity. As expected, the addition of the polyanions in APECs significantly 
reduced the ZP and hence increased the IC50. Tiyaboonchai et al. has previously 
reported similar findings whereby PEI-DS complexes diminished the cytotoxicity 
associated with PEI [122]. Nimesh et al. also reported the ability of polyallylamine-
dextran sulphate-DNA (PAH-DS-DNA) complexes to reduce the cytotoxicity of PAH 
[153]. Guo et al. prepared ternary complexes by coating polyglutamic acid-graft-
poly(ethylene glycol)(PGA-g-mPEG) onto binary complexes of polycaprolactone-
graft-poly(N,N-dimethylaminoethyl methacrylate (PCL-g-PDMAEMA). These ternary 
complexes demonstrated lower in vitro cytotoxicity in CCK-8 cells than the binary 
complexes [127]. The ternary complexes (polycaprolactone-graft-poly(N,N-
dimethylaminoethyl methacrylate) (PCL-g-PDMAEMA) [256] and 
polyanion/pDNA/PEI [131] have also been shown to reduce the positive surface charge 
and hence toxicity associated with the corresponding binary complexes. 
Among the two polyanions, the increase in IC50 was more pronounced in the presence 
of PAA based APECs than DS based APECs. These findings indicate that different 
polyanions exert different effects on the cell viability when complexed with the 
polycations. This effect of polyanions may be attributed to the low MW of PAA 
(1.8kDa) in comparison to high MW of DS (6-10kDa). Numerous researchers have 
shown that high MW polycations such as PEI and TMC are more cytotoxic than low 
MW ones [157, 227, 367]. The high MW of polyanion may have similar implications 
on cytotoxicity as high MW polycations. In addition to MW, there are distinct 
architectural differences between the DS and PAA which may be responsible for the 
trend observed. DS is an anionic polysaccharide with a dense architecture whereas PAA 
is a weak polyacid [261, 267] They exhibit differences in ionisation state and number 
of charged groups. In addition, the anionic functional units of the two i.e., SO4
-2 of DS 
and COO- of PAA are also different. These differences may be responsible for causing 
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different degree of affinity for the cell membrane and leading to differences in 
mediation of cytotoxicity.  
The in vitro exposures of erythrocytes to the polycations (except Da10) and APECs 
showed low tendency to cause haemolysis (≤12%) over the concentration range (0.075-
5mgml-1). The microscopic observations showed that even non-haemolytic 
concentrations of Da10 caused a substantial clumping and aggregation of erythrocytes 
presumably due to the polymer cross linking (Figure 4.9j, k & l). Changes in RBC 
morphology have also been observed by Malik et al. after only 1h incubation with non-
haemolytic concentration of cationic polyamidoamine (PAMAM) and diaminobutane 
(DAB) dendrimers [408]. A higher haemolytic profile (37% at 10mg/mL-1) of Da10 has 
been linked to the hydrophobic modification of its backbone. However, since 
hydrophobically modified Pa2.5 was not haemolytic, the effects observed may be due 
to the difference in the structure of hydrophobic group or degree of hydrophobic load. 
Da10 comprised of higher hydrophobic load i.e., 10% hydrophobic grafting in 
comparison to 2.5% of Pa2.5 (which indicates haemolysis due to a higher hydrophobic 
load. The haemolytic effects may be due to the formation mixed micelles of the 
hydrocarbon chains with the phospholipid bilayers [416]. The hydrophobicity of the 
polymers has previously been linked with the membrane-disruptive activity by Liu et 
al. [417]. It was reported that the hydrophobicity of the polymer permits partitioning of 
the polymer into the cell membrane. This behaviour disrupts the packing of the lipid 
bilayer and causes haemolysis [417]. On the other hand, hydrophilicity of polymers has 
been shown to reduce the haemolytic effects which agrees well with the lowest 
haemolysis profile of the QPa2.5 based formulations [414]. Colak et al. incorporated a 
hydrophilic, biocompatible PEG pendant groups on amphiphilic polynorbornene 
derivative, Poly3, and found that increasing the hydrophilicity reduced the haemolytic 
activities of the polymer [414]. 
Da10-DS and Da10-PAA were able to significantly reduce the haemolytic activity 
associated with Da10. The improvement in haemolytic profile may be due to the 
reduction in positive charge density or addition of hydrophilicity to the complexes 
which subsequently prevented the adverse interaction of APECs with the erythrocyte 
membrane. Liu et. al. has previously shown that the haemolytic activity may reduce by 
reduction in positive charge density via surface modification of polymer [417]. It is also 
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believed that a balance between hydrophobic and hydrophilic load is required to prevent 
the haemolytic activity [376].  
Nanocarrier toxicity has been proposed to originate from oxidative stress induced by 
ROS and free radical formation [418]. There is substantial evidence that nanocarriers 
made from inorganic and metallic materials, such as carbon, iron, zinc and titanium 
dioxide (TiO2) are potent generators of  ROS [418]. However, very few polymeric 
nanocarriers have been explored for their ROS generation profile. Exposure of 
polycations and APECs to CaCo2 cells induced low levels of ROS (˂26%) at IC90 
concentration. The trend of ROS generation (PAH˃Pa2.5=Da10˃QPa2.5) agreed well 
with the cytotoxicity profile indicating a correlation between ROS production and 
cytotoxicity. Cationic particles have been shown to localise in mitochondria and 
produce a cytotoxic response via the mitochondrial injury pathway which leads to 
production of additional O2 species [419]. Naha et al. has shown that ROS production 
in J774 cells exposed to PAMAM dendrimers linearly correlated with the number of 
surface primary amino group [420]. The higher intracellular ROS generation under the 
effect of PAH may also be due to the higher number of primary amino groups which 
caused a disruption of the mitochondrial electron transduction chain leading to higher 
cytotoxicity [421]. 
Modification of PAH led to a reduction in the number of primary amino groups and 
hence a reduction in ROS production and cytotoxicity. The small size (≤100nm) of 
nanocarriers is considered to exhibit higher reactivity, which increases their adverse 
effects [422]. This may also be the reason for lower ROS generation in cells exposed 
to QPa2.5 based formulations which exhibited larger particle sizes (≥250nm) compared 
to other formulations. 
APECs demonstrated a significant reduction in ROS production compared to the 
corresponding polycations. No significant differences were observed in alleviation of 
ROS induction between PAA and DS. These findings suggest that reduction in positive 
charge turned down the production of ROS. These findings are in line with the study of 
Yang et al. who also demonstrated the role of positively charged poly-l-lactide 
glycolide in higher ROS production [393].  
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Oxidative stress has also been implicated in the activation of cytokine production 
[421]. The effect of various polycations and APECs on the induction of cytokine 
generation (IL-6 and TNF α) from the J774 cells was investigated by in vitro cytokine 
assay. The in vitro investigations was facilitated by in vivo cytokine production (IL-6, 
IL-2 and TNF α) assessed in healthy mice treated with oral and i.v. doses of polycations 
and APECs. All formulations demonstrated the ability to induce cytokines both in vitro 
and in vivo, however, there were significant differences in cytokine production between 
the polycations and their respective APECs and between in vivo and in vitro situations. 
The in vivo serum cytokine levels (≤27%) were found to be significantly lower than 
the in vitro levels ≥90% (Figure 4.11 & 4.12). This disparity in the data may have been 
due to the difference in the in vitro and in vivo situations such as short half-life or 
localised in vivo cytokine production leading to their reduced systemic availability 
[423, 424]. The difference in the incubation time between the in vitro (2-4h) and the in 
vivo (12h following i.v. and 24h following oral administration) cytokines production 
may also have contributed to the disparity in data. There is a possibility that the in vivo 
cytokine levels reached a peak any time before or after they were analysed. Besides, in 
vitro assays provide only cell type-specific responses, however, do not capture 
intercellular effects such as cross-talk between cells which can alter the cytokine levels. 
One such example is of the in vivo stimulation of anti-inflammatory cytokines e.g., IL-
10 which might have caused the down regulation of pro-inflammatory cytokines [361]. 
The down regulation of cytokines (IL-6, TNFα and IL-2) by IL-10 might have been 
responsible for low in vivo cytokine level. 
Generally, in vitro and in vivo IL-6 generation on exposure to polycations and APECs 
was higher than other cytokines, except Pa2.5-PAA, QPa2.5 and QPa2.5-PAA. The 
differences in the cytokine generation profile between IL-6 and TNFα are attributed to 
the different reactivity of cells towards the different formulations. Exposure of 
macrophages to phorbol myristate acetate (PMA), and Phytohemagglutinin (PHA) has 
previously shown to induce significantly different levels of 5 different cytokine at 
similar experimental conditions employed [424]. It was also shown that there was no 
correlation between the productions of one cytokine with the other, nor was there any 
association between response to one stimulus or the other [424].  
The degree of in vitro TNFα production is rated as QPa2.5˃Da10˃Pa2.5=PAH 
whereas in vitro IL-6 generation is rated as QPa2.5˃Pa2.5=PAH˃Da10. QPa2.5 
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showed the highest cytokine production in both in vitro and in vivo situations. This 
shows that cytokine generation followed a reverse trend to the cytotoxicity and ROS 
assay. Previously, Scholer et al. has also shown an inverse relationship of the cytokine 
generation to the cytotoxicity on exposure to solid lipid nanoparticles [405]. They also 
reported that cytokine generation is particle size dependent [397]. Similar finding have 
been reported by Zolnik et al. indicating that particle size is a major factor governing 
the type of immune response [163]. This might mean that large particle sizes of QPa2.5 
(468 ±12nm) and its APECs (435 and 228 nm), compared to the unmodified and 
hydrophobically modified polycations may be responsible for higher cytokine 
generation. There may also be an association of the surface properties of QPa2.5 such 
as hydrophilicity or particle size with the generation of cytokine. Previously, Jones et 
al. has also linked hydrophilicity of particles with the generation of cytokines [362].  
Pa2.5-PAA showed the most pronounced reduction (≤25%) in cytokine generation 
in cell culture supernatants. A similar trend was observed in in vivo study whereby 
Pa2.5-PAA produced ≤12% cytokine generation. Unlike in vitro study, QPa2.5-PAA 
also reduced the in vivo cytokine generation (P<0.05) indicating the role of PAA in 
reducing the cytokine production. However, Da10-PAA was unable to significantly 
reduce the in vitro cytokine generation. QPa2.5-DS and Da10-DS were also unable to 
reduce the in vitro cytokine production indicating no role of DS in reducing the cytokine 
production. Polyanions have previously been implicated in stimulation of immune 
system which is in agreement with the above findings [425]. These findings indicate 
that the type of polyanion plays a significant role in altering cytokine generation.  
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4.6 CONCLUSION 
APECs significantly reduced the polycation associated cytotoxicity. The reduction 
in cytotoxicity and polycation induced ROS production was more pronounced on 
exposure to PAA based APECs particularly Da10-PAA and Pa2.5-PAA than DS based 
APECs. The polycations and APECs (except Da10 based formulations) showed no 
significant haemolytic activity up to 5mgml-1. Both in vitro and in vivo data 
demonstrated reduction in cytokine generation on exposure to APECs particularly in 
the presence of PAA based APECs (Pa2.5-PAA). There was little correlation between 
in vitro and in vivo cytokine generation which is assumed to be either due to localised 
in vivo release of cytokines or in vivo production of anti-inflammatory cytokines such 
as IL-10 which down regulated the in vivo cytokine levels. 
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5 INTRODUCTION 
The success of oral administration of protein is dependent on a number of factors, 
out of which one crucial factor is their uptake and transport by enterocytes in the gut. 
Nanocarriers have shown unique potential to facilitate the cellular uptake and transport 
of proteins. However, differences in the physicochemical properties of nanocarriers 
such as size, surface charge and hydrophobicity have significant implications in their 
cellular uptake and transport [308, 317]. Considerable efforts have been devoted to 
elucidate the effects of these properties on the cellular uptake and transport mechanism 
of nanocarriers. Some of the recent progress is briefly discussed below. 
5.1 MECHANISM OF UPTAKE AND TRANSPORT 
5.1.1  Paracellular Transport 
Due to poor permeation of macromolecules via TJs, research is being conducted to 
explore approaches to improve the paracellular permeability of macromolecules [173]. 
The potential of nanocarriers to allow reversible opening of the TJs represent a 
promising way to facilitate the absorption of hydrophilic drugs across the intestinal 
epithelium [426]. Recently, Thompson et al. has shown the potential of amphiphilic 
PAH based polyelectrolyte nano-complexes to reversibly open the TJs and increase 
insulin transport through the monolayers [427]. It is also known that the paracellular 
permeability of proteins and peptides can be enhanced by using polymers such as 
chitosan and its derivatives [428, 429]. 
 Chitosan acts by binding to the epithelial cells and causing transient reversible 
opening of the TJs. It is proposed that this effect is due to structural reorganization of 
the tight junction-associated proteins and morphological changes in F actin 
cytoskeleton [183]. A number of chitosan derivatives such as trimethyl chitosan and 
thiolated chitosan have been designed to reversibly open the TJs and hence increase the 
permeability of nanocarriers across the intestinal cells [430-432]. It is thought that the 
cationic nature of chitosan and its derivatives is responsible for their interaction with 
the junctional proteins leading to transient reversible opening of TJs. Recently, Sadeghi 
et al. studied four partially quaternised derivatives of chitosan - trimethyl chitosan 
(TMC), dimethylethyl chitosan (DMEC), diethylmethyl chitosan (DEMC) and triethyl 
chitosan (TEC) to evaluate their effect on the permeability of insulin across intestinal 
CaCo2 monolayers. It was found that all four chitosan derivatives decreased the TEER 
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value in the same order (TMC > DMEC > DEMC = TEC > chitosan) as was observed 
for the cationic charge of the various polymers. These finding indicated that the higher 
the cationic charge, the higher is the reduction in the TEER.  It was also shown that 
reduction in TEER was not due to the cytotoxic effects but due to transient opening of 
the TJs [431].  
There are reports which provide evidence that not only cationic charge but also 
anionic charge mediates opening of TJs. One such investigation was conducted by 
Kitchens et al. who studied the influence of surface charge of PAMAM dendrimers on 
the transport of 14C-mannitol across CaCo2 cells [433]. It was reported that the 
PAMAM dendrimers with neutral surface groups (PAMAM–OH) did not significantly 
influence TEER or 14C-mannitol permeability across CaCo2 monolayers. However, 
PAMAM dendrimers with negatively charged surface groups (PAMAM–COOH) had 
a generation-dependent effect on the TEER and 14C-mannitol permeability [433].  
Studies have reported the effect of physicochemical properties such as viscosity on 
the TJ opening and enhancement of paracellular permeation. Thanou and coworkers 
studied the effect of 3 different viscosity grades 20, 40 and 60 cps of N-sulfonato-N,O-
carboxymethylchitosan (SNOCC), on the rate of the intestinal permeation of low 
molecular weight heparin (LMWH) and reviparin. The higher viscosity formulation 
decreased the TEER more readily and was found 51 fold more effective in enhancing 
the permeation of the 14C-mannitol compared to the low viscosity formulation. These 
findings indicate the role of the higher viscosity of the nanocarrier formulation in 
enhanced permeation across intestinal epithelia [432].  
A number of studies have implicated particle size and surface properties in enhancing 
paracellular transport [433-435]. Li et al. has shown that treatment of Calu-3 cells with 
carbopol polymer gel formulations resulted in molecular size-dependent permeability 
enhancement of desmopressin  a model peptide, with a concomitant drop in the TEER 
[187]. The permeation enhancement ability was related to the chelation of extracellular 
or tight-junctional Ca2+ by carboxylate groups of charged polymer which led to 
temporary disruption of tight-junctions, thereby facilitating paracellular transport [187].  
The understanding of the mechanism of opening of TJs is very crucial. Dorkoosh et 
al. studied the mechanism of opening of TJs in CaCo2 cell monolayers using 
superporous hydrogel (SPH) and SPH composite (SPHC) polymers as permeation 
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enhancers for octreotide drug delivery [436]. It was reported that the junctional proteins 
including actin, occludin and claudin-1 were influenced by application of SPH and 
SPHC polymers to the CaCo2 cell monolayers. SPH and SPHC induced noticeable 
changes in the staining pattern of all three proteins. There was increased expression of 
these proteins in the TJs which  was assumed to be due to the mechanical pressure of 
the polymers on the junctional proteins leading to opening of the TJs  [436].  
There are reports which have indicated the opening of TJs under the influence of 
polymers, however, only a subtle passage of nanocarriers across the paracellular 
junctions has been observed [188, 437]. This may be due to the fact that TEER has 
to decrease below a threshold level of about 50% of the original values for the 
paracellular passage of large molecules to occur [183]. Since the TJs represent only 
<1% of the mucosal surface area (pore diameter between 10-50 Å ) of the intestine, 
the passage of macromolecules will still be limited despite the opening of TJs [141, 
172, 220, 438, 439].  
There are studies which have reported that uptake of nanocarriers occurred via both 
the paracellular and transcellular pathway. El-Sayed studied the mechanism of 
uptake of PAMAM and found that internalisation occurred via a combination of both 
paracellular and transcellular transport by adsorptive endocytosis [434]. However, it 
is still believed that the contribution of paracellular transport is significantly lower 
than the transcellular transport [205]. Therefore, efforts should be made to increase 
the potential of nanocarriers for transcellular transport. 
5.1.2  Transcellular Transport 
The transcellular internalization of particles is thought to be influenced by 
physicochemical properties of particles such as the size, shape, surface charge and 
surface chemistry [304, 308, 317, 440-443]. Recently, Gratton et al. designed three 
distinct series of cationic poly(ethylene glycol)-based particles with varying sizes and 
shapes but similar surface charge i.e., a micrometer-sized series of cubic-shaped 
particles (cube side length 2 µm, 3µm and 5µm); a micrometer-sized cylindrical series 
with identical heights but varying diameters; and a cylindrical shaped nanoparticle 
series of 200 nm, 100 nm and 150 nm in diameter [440]. The cellular internalization of 
particles by HeLa cells was found to be particle size and shape dependent. The HeLa 
cells readily internalized non-spherical particles with dimensions as large as 3µm via 
several mechanisms of endocytosis. There was also a marked effect of charge on the 
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cellular internalization of particles. The positively charged nanoparticles were 
internalized (84%) to a significant extent within 1h, whereas the identically shaped, 
negatively charged particles were not internalized to any significant amount (<5%). 
These findings strongly support the role of particle size, shape and surface charge in 
the cellular internalization of particles [440].  
A plethora of research has demonstrated that polycations are taken up more readily 
by cells than polyanions. However, there is evidence that particles containing both 
polyanion and polycation demonstrate efficient internalisation [131]. Woitiski et al. 
formulated multilayered nanoparticles by encapsulating insulin within a core consisting 
of alginate and DS, interacting with poloxamer and stabilized by layering with chitosan 
and subsequently coated with albumin. These nanoparticles increased the insulin 
permeation by 2.1 fold through CaCo2 cell monolayer, 3.7 fold through a mucus-
secreting CaCo2/HT29 co-culture, and 3.9 fold through excised intestinal mucosa of 
Wistar rat, as compared to insulin alone [444]. Hornoff et al. has shown that coating a 
DNA/PEI polyplexes with low molecular weight anionic hyaluronan (<10 kDa) 
facilitated CD44 receptor-mediated uptake, leading to increased transfection efficiency 
[445]. Wang and co-workers have shown that polyanions/DNA/polycation ternary 
polyplexes exhibited significantly higher transfection efficiencies than the original 
DNA/polycation binary polyplex [131]. Similarly, Xu’s research group showed that a 
DNA/crosslinked PEI/hyaluronate ternary polyplexes achieved remarkably higher 
transfection efficiency than other polycation systems [446]. These investigations 
indicate that the novel ternary complexes formed by combination of polycation and 
polyanion may show higher uptake than the conventional binary systems. 
 In addition to surface charge, surface chemistry of nanocarriers is known to 
influence the uptake via the transcellular pathway [441]. Yin Win and colleagues 
showed that the cellular uptake of nanoparticles can be improved by surface 
modification with vitamin E [308]. They reported that the vitamin E coated PLGA 
nanoparticles showed 1.4 fold higher uptake than the polyvinyl alcohol -coated PLGA 
nanoparticles and 4-6 fold higher than that of nude polystyrene nanoparticles [308]. 
A large number of polymeric nanocarriers have been reported to be internalised via 
endocytosis. Internalization of cationic PEG-graft-trimethyl-chitosan copolymer–
insulin nanocomplexes has been reported to occur predominantly by adsorptive 
endocytosis [67]. Jevprasesphant and coworkers reported the endocytosis-mediated 
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cellular internalisation of G3 PAMAM and surface-modified (with lauroyl chains) G3 
PAMAM dendrimer nanocarriers across CaCo2 cell monolayers [447]. They reported 
the presence of early endosomes containing electron-dense nanocomposites 
immediately below the apical surface. In addition, endosomes were seen to aggregate 
to produce multivesicular bodies found throughout the cell. These findings supported 
the notion that nanocomposites transported through the cells in these vesicular 
structures [447].  
Studies have identified several different types of endocytic pathways such as classical 
clathrin mediated endocytosis, caveolae-mediated endocytosis, clathrin- and caveolae-
independent endocytosis as detailed in chapter 1 [201, 202]. These endocytic 
mechanisms are distinguished by the composition of coat, size of detached vesicles, 
and fate of the internalized material [201]. Recently, Dombu and colleagues reported 
that cationic nanoparticles made of maltodextrin were quickly internalised within 3 min 
by clathrin mediated endocytosis and that their exocytosis was cholesterol dependent 
[448]. It has been shown that particles can be taken up via a combination of clathrin 
and caveolae mediated endocytosis or clathrin and caveolae independent pathways 
depending on their physicochemical properties [208, 449]. Jin et al. indicated the ability 
of insulin loaded TMC nanoparticles modified with a CSKSSDYQC (CSK) targeting 
peptide to be internalised via clathrin and caveolae mediated endocytosis by goblet cell-
like HT29-MTX cells [449]. Harush-Frenkel and co-workers studied the differential 
endocytic internalisation of positively versus negatively charged nanoparticles. They 
showed that unlike negatively charged nanoparticles, the positively charged particles 
were seen to be internalised via clathrin- and caveolin pits, predominantly in the 
perinuclear region [208]. Qaddoumi and colleagues reported that PLGA nanoparticles 
are internalised in primary cultures of rabbit conjunctival epithelial cells by endocytosis  
mainly via clathrin- and caveolin-1- independent pathways [450]. Rejman et al. 
reported that particles size itself can determine the pathway of entry. The clathrin 
mediated pathway of endocytosis shows an upper size limit for internalization of 
approx. 200 nm. The kinetic parameters have determined almost exclusive 
internalization of such particles along this pathway rather than via caveolae mediated 
pathway [214]. 
Nanocarriers may be absorbed in small quantities via membranous epithelial cells in 
the GALT called M cells [215]. M cells have the capability of transporting 
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nanoparticles via transcytosis from the gut lumen to the underlying mucosal immune 
system. Rajapaksa’s group investigated the uptake mechanism of sub-micron size 
PLGA particles, incorporating a recombinant protein, with or without a c-terminal 
peptide which had a high binding affinity for a protein (claudin 4) associated with M 
cell endocytosis [451]. These particles exhibited enhanced uptake by intestinal M cells 
[451]. However, since the number of M cells in FAE is very low, the potential for 
uptake via this pathway is very limited [220]. Beloqui and co-workers studied the 
potential of three different nanostructured lipid carriers (NLC) formulations to enhance 
the oral bioavailability of poorly soluble compounds using saquinavir (SQV). It was 
found that SQV transport across the CaCo2 monolayers enhanced up to 3.5-fold by 
NLCs compared to the SQV suspension. However, M cells did not enhance the 
transport of NLCs loaded with SQV [452]. The probability of nanocarriers not being 
internalised or being internalised to a negligible extent, draws attention to the need to 
characterise the uptake and mechanism of uptake of all novel nanocarriers. This chapter 
elucidates the potential of uptake and transport of the polymers, PECs and APECs 
(fabricated in chapter 3), using in vitro cell culture models, flow cytometry and 
fluorescent microscopy. 
5.2 CHARACTERISATION OF NANOCARRIERS UPTAKE 
5.2.1  In vitro cell culture model 
The transport of drug across epithelial lining is studied using in vitro cell culture 
models (Figure 5.1). CaCo2 cell culture models are the most widely used in vitro 
models. CaCo2 cells form a confluent monolayer which serves as an in vitro tool to 
predict the absorption of orally administered drugs [220, 426, 453].  The intrinsic ability 
of CaCo2 cells to form TJs assist in the uptake and transport studies [454, 455].  
Transport studies are simple and convenient procedures and provide reproducible 
data. They provide rapid assessment of the intestinal permeability of drug candidates 
[170]. These studies require only small quantities of drugs for absorption screening 
[426]. However, such models are laborious as they require 3-4 weeks to generate a 
confluent layer (Gad, 2008). Drug transport studies involve the culture of CaCo2 cells 
on porous filters in multi-well cell culture plates. The wells comprise of apical or 
basolateral compartments. The transport of drug is measured from the apical to 
basolateral direction or vice versa [426].  
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 In vitro models can be used to monitor changes in the integrity of TJs (leaky to 
moderately leaky epithelium) by measuring the TEER [220, 426]. The efficiency of the 
opening of TJs is usually monitored by using high molecular weight paracellular 
markers such as mannitol and FITC-Dextran [426]. The paracellular permeability of 
the macromolecules essentially depends on their molecular size. Therefore, paracellular 
markers of different molecular sizes can be used to assess the opening of TJs [426]. 
This allows CaCo2 cell models to be used to investigate the mechanism of transport of 
drug [173]. However, they do not provide information about cellular localisation of 
nanocarriers, which can be obtained from techniques such as fluorescent microscopy. 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 In vitro cell culture model of transport study showing cell monolayer in a 
transwell 
 
5.2.2 Fluorescent Microscope:  
Fluorescence microscopy is a powerful technique for live-cell imaging at a sub-
second time scale  [456, 457]. It provides opportunity not only to study the cellular 
structure, distribution of cellular organelles, cell health and performance but also 
provide insights into the cellular uptake and localisation of the nanocarriers [458]. In 
order to study the uptake of particles, the specimen of interest is labelled with 
fluorophores which reveal the locations of the particles in the cell. The cellular 
organelles can also be stained to elucidate the differential localisation of particles. Nam 
et al. visualised the uptake of Glycol chitosan (GC) and GC-5β- cholanic acid conjugate 
nanoparticles (HCG) by HeLa cells under fluorescent microscope by labelling them 
with carboxy succinimidyl ester cyanine 5.5. At 5 min post-incubation, the fluorescence 
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signal from the HGC nanoparticles was detected primarily near the cellular membrane. 
As the incubation time increased, the HGC fluorescence became more intense inside 
the cells and evenly dispersed in the cytosol. However, entry of HGC into the nucleus 
was somewhat unclear even at a prolonged incubation time. Evidently, some particles 
formed aggregates which appeared as large and strongly fluorescent red spots under the 
microscope [201]. Although, fluorescent microscopy generates a large amount of data, 
it is essentially qualitative. Other techniques such as flow cytometry are more useful in 
providing quantitative data.  
5.2.3  Flow cytometry 
Flow cytometry is a rapid, simple and sensitive method for analysing a large number 
of cells individually using light-scattering, fluorescence, and absorbance measurements 
[141, 459]. It has the ability to analyse many properties of the cells in a moving liquid 
stream at thousands of events per second, with simultaneous measurement of light 
scatter and fluorescence of each event [460, 461]. It is able to perform a broad range of 
functions like cell and particle sizing and sorting, determination of cell biology and 
pathology [462]. However, in this study, flow cytometry has been used to analyse 
cellular uptake of particles to elucidate the percentage internalisation of PECs and 
APECs. 
Particle uptake is commonly determined by using intracellular markers like 
fluorescently labelled particles such as DiI, rhodamine or fluorescein labelled particles 
[190]. In a flow cytometer, the cells are transported in a fluid stream which is positioned 
in the centre of the laser beam. The cells flow one-by-one into the cytometer for single 
cell analysis which is accomplished through a pressurized laminar flow system. The 
sample specific lasers focus on the cell suspension, scatter light forward and on the 
sides and emit fluorescence [463]. The side-scattered light is proportional to cell 
granularity or internal complexity whereas forward scatter determines the size of 
particles [464]. The amount of fluorescent signal detected is proportional to the number 
of fluorochrome molecules in the cells [462]. Park et al. found that the N-acetyl 
histidine-conjugated glycol chitosan (NAcHis-GC) nanoparticles, were detected as 
green fluorescence after 10 minutes treatment of the cells with nanoparticles. DiI is 
virtually non-fluorescent until incorporated into lipid membranes, was seen as red 
fluorescence which is indicative of its entrapment into lipid membranes such as plasma, 
endosome, and lysosome membranes [190]. 
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5.3 AIM 
The aim of the study was to investigate the potential uptake and transport of 
polycations, PECs and APECs across CaCo2 cells. 
5.3.1 Objectives  
 Determination of the effect of free insulin, polycations, PECs and APECs on 
TEER of the CaCo2 cell monolayers. 
 Determination of the effect of free insulin, IL PECs and IL APECs on transport 
of a paracellular marker i.e., FITC-Dextran (10kDa) across CaCo2 cell monolayer. 
 Determination of the transport of free insulin and insulin loaded in IL PECs and 
IL APECs across CaCo2 cell monolayer.  
 Evaluation of transcellular uptake of polycations, PECs and APECs by flow 
cytometry and fluorescent microscopy. 
5.4 MATERIAL AND METHODS 
5.4.1 Materials 
Materials Supplier 
Bovine insulin ELISA kit Mercodia, Sweden 
Diamino-2-phenylindole (DAPI) Sigma Aldrich, UK 
Dimethyl sulfoxide (DMSO) Sigma Aldrich, UK 
FITC-insulin Sigma Aldrich, UK 
Foetal bovine serum (activated) Sigma Aldrich, UK 
Hank’s balanced salt solution with sodium 
bicarbonate, magnesium and calcium 
(HBSS) 
Sigma Aldrich, UK 
Insulin from bovine pancreas (27 U/mg) Sigma Aldrich, UK 
L-Glutamine (200 mM) Sigma Aldrich, UK 
Minimum essential media eagle media 
(EMEM) 
Sigma Aldrich, UK 
Non-essential amino acids Sigma Aldrich, UK 
Penicillin/Streptomycin (10000 UmL−1/ 
10000 μLmL−1) 
Invitrogen 
Phosphate buffer tablets (PBS) Sigma Aldrich, UK 
Rhodamine Β isothiocyanate (RBITC) Sigma Aldrich, UK 
Transwell plates Corning, UK 
Trypan blue Sigma Aldrich, UK 
Trypsin-EDTA Sigma Aldrich, UK 
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5.4.2 Method 
5.4.2.1 Rhodamine Labelling of Amphiphilic Polymers  
Rhodamine Β isothiocyanate (RBITC) grafting of amphiphilic polymers (Pa2.5 and 
QPa2.5) was carried out using a method adapted from Thompson et al. [427]. Briefly, 
50mg Pa2.5 was dissolved in 95mL of double-distilled water to achieve a 0.05% (w/v) 
solution of Pa2.5. RBITC (5mg) was initially dissolved in 5mL DMSO to achieve 
1mgmL-1 solution which was then added drop-wise to the above prepared Pa2.5 
solution over 10 min with gentle magnetic stirring. The solution was stirred for one 
hour at room temperature followed by dialysis against 5L of double-distilled water with 
a visking tube (12–14 kDa cutoff; Medicell, UK). The dialysis was carried out over 48 
h, with six water changes in 24h to ensure removal of all non-bound RBITC. The 
dialysate was lyophilized for 24h to obtain rhodamine labelled Pa2.5 (Pa2.5R) as a deep 
pink fluffy solid. Pa2.5R was further quaternised as described in chapter 2, section 
2.4.2.2.2 to produce RBITC-labelled QPa2.5 (QPa2.5R).  
5.4.2.2 Transport Study 
5.4.2.2.1 Cell culture 
The CaCo2 cells were grown at a density of 2×104 cells/well on Transwell® filters 
with a pore size of 0.4 mm in 12-well polycarbonate plates. The cells were cultured for 
at least 15-21 days until a confluent monolayer was formed. Fresh media was added to 
the apical (0.5mL) and the basal compartments (1.5mL). The media was replaced from 
the apical compartment every alternate day until 9 days and then from both apical and 
basal compartments until the day when the experiment was conducted. The cell 
confluency and the monolayer formation were assessed by measuring the TEER with a 
Millicell-ERS (Millipore). 
5.4.2.2.2 Monolayer integrity 
Cells were grown in Transwell plates as detailed above. TEER measurements were 
taken routinely by using Millicell-ERS ohmmeter chopsticks (Millipore, USA) before 
and after media addition to assess the monolayer integrity. The transport study 
experiments were conducted when the resistance was within 350-650 Ω.cm2, usually 
within 15-21 days. [465] 
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5.4.2.2.3 TEER measurements and permeation of insulin and FITC-Dextran 
transport across CaCo2 monolayer  
The transport study was carried out by replacing the media (EMEM ) from apical 
(0.5 mL) and basal chambers (1.5 ml) of each well with HBSS (supplemented with 1% 
(v/v) non-essential amino acids and 1% (v/v) L-glutamine) followed by equilibration 
of plates for 30 min at 37 ºC before conducting TEER measurements. The polycations, 
PECs and APECs were prepared in 0.01 M HCl: 0.1 M Tris buffer 87:13% (v/v) as 
described in chapter 3, sections 3.5.2.1 and 3.5.2.2. The samples were subsequently 
diluted in HBSS to their respective IC90 concentrations (PAH 3µgmL
-1, PAH-DS 
3µgmL-1, PAH-PAA 5µgmL-1, Pa2.5 7µgmL-1 Pa2.5-DS 10µgmL-1, Pa2.5-PAA 
14µgmL-1, Da10 7µgmL-1, Da10-DS 10µgmL-1, Da10-PAA 14µgmL-1, QPa2.5 
11µgmL-1, QPa2.5-DS 14µgmL-1, QPa2.5-PAA 14µgmL-1) determined by MTT. The 
free insulin (5µgmL-1) was used as a control.  
0.5mL/well of IC90 concentrations of samples were added to the apical 
compartments. The media (200µL) was collected from the basal compartment at 0.5, 1, 
1.5 and 2 h and replaced with fresh HBSS to measure the apical to basolateral flux of 
insulin. After 2h, the cells were washed with HBSS (three times) and samples were 
replaced with fresh EMEM. The plates were incubated for another 2 h. The samples 
(200µL) were again collected from the basal compartment of each Transwell at 3 and 
4h and replaced with fresh media. The insulin concentrations of the samples collected 
at different time points were determined using a Mercodia bovine insulin ELISA kit 
(Meracodia Ltd., Sweden). 
The paracellular permeability of a paracellular marker FITC-dextran (10kDa) across 
the cell monolayer was also monitored in the presence and absence of IL PECs and 
APECs. A FITC-Dextran solution (20mgmL-1) was prepared in HBSS. 250µL of 
20mgmL-1 was added to the apical side of the monolayer to achieve a final concentration 
of 10mgmL-1 and the plates were incubated at 5% CO2, 95% humidity and 37°C. The 
FITC-Dextran concentration in samples from each basal chamber was determined at 
different time points (at 0.5, 1, 1.5 and 2 h before sample removal; at 3 and 4h after 
sample removal) by using a Fluorescence Multi-well Plate Reader (Perkin Elmer, LS 
55) with excitation and emission wavelengths of 485 nm and 530 nm, respectively. 
TEER measurements were recorded at 0 h (before addition of polycations, PECs and 
APECs), at 0.5, 1, 1.5 and 2 h (before removing polycations, PECs and APECs) and at 
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3 and 4 h (after removing polycations, PECs and APECs). The resistance of HBSS 
alone (10 Ω.cm2) was considered as background resistance and subtracted from each 
TEER value. 
5.4.2.3 Uptake study 
5.4.2.3.1 Determination of CaCo2 cell uptake by fluorescent imaging 
The CaCo2 cells were grown and maintained as described in chapter 4 section 4.3.2. 
For the uptake experiments, the CaCo2 cells were seeded in 12-well polycarbonate 
plates at a density of 2×104 cells/well. The fluorescently labelled polycations (Pa2.5R, 
QPa2.5R); and IL PECs and APECs which were fabricated using fluorescently labelled 
polycations were diluted in EMEM to achieve their IC90 concentration reported 
previously in section 5.4.2.2.3. The confluent cell culture plates were washed with 
serum free EMEM and the cells were incubated with 2mL of IC90 concentrations of 
various polymer, PECs or APECs samples at 5% CO2, 95% humidity and 37°C. After 
2 h, the cells were washed (three times) with pre-warmed 0.1M PBS and stained with 
DAPI (300 nM for 5 mins) to detect and localize the cellular nuclei. The cells were 
stained with 4% trypan blue for 1 min to identify the presence of dead cells. 
Subsequently, the wells were washed (three times) with PBS and the plate was re-
incubated at 5% CO2, 95% humidity and 37°C for 0.5 h prior to imaging by 
fluorescence microscopy  with Olympus IX2 series, inverted fluorescent microscope 
1X71 Ltd., UK. The fluorescence images were acquired with the IX-TVAD TV camera, 
Olympus Instruments and processed using image analysis software (C*). Each 
experiment was carried out in triplicates. 
5.4.2.3.2 Quantitative Measurement of the CaCo2 cell uptake by Flow cytometry 
The cells were grown in 12 well plates at a density of 1×105 cells/well as detailed in 
chapter 4, sections 4.3.2. The IL and NIL PECs and APECs were prepared at IC90 
concentrations as given above in section 5.4.2.2.3) using rhodamine labelled polymers 
(Pa2.5R and QPa2.5R). The IL PECs and APECs were prepared using fluoresceine-
isothiocyanate labelled insulin (FITC-insulin). The cells were incubated with various 
formulations for 2h at 5% CO2, 95% humidity and 37°C. The plates were then sub-
cultured as described in chapter 4 section 4.3.2.2. The cell pellets (≥105cellmL-1) were 
re-suspended in 0.1M PBS and analysed by flow cytometery (Attune® Acoustic 
Focusing Cytometer). The flow cytometer was equipped with a violet laser (excitation 
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515 nm and emission 545 nm) and a blue laser (excitation 540 nm and emission 590 
nm) for detection of fluorescein and rhodamine respectively. The cells were 
appropriately gated by forward and side scatter and 30 000 events per sample were 
collected. The fluorescence was detected in BL1 channel for fluorescein and BL2 
channel for rhodamine. Each experiment was carried out in triplicates. 
5.4.2.4 Statistical analysis 
A normality test on the data was performed to confirm the normal distribution of 
data. All data were compared by one-way analysis of variance (ANOVA), Post Hoc 
tukeys test using the SPSS 20 software. P<0.05 was considered to denote significance. 
Statistical differences were compared between the polycations, PECs and APECs. In 
addition, statistical differences were also compared between control i.e., free insulin 
samples and polycations, PECs and APECs. 
 
5.5 RESULTS 
5.5.1 Transport study 
5.5.1.1 Effect of the formulations on TEER across the CaCo2 cell monolayer 
The effect of various formulations on the integrity of CaCo2 cell monolayer was 
investigated by monitoring TEER across the CaCo2 cell monolayers (Figure 5.2 and 
5.3). The CaCo2 cells incubated with free insulin exhibited no apparent variation in 
TEER compared to the initial values at any time point. In comparison to the free insulin, 
the polycations, PECs and APECs significantly decreased the original TEER (p<0.001) 
within 0.5h which signifies the opening of CaCo2 cell TJs. The reduction in TEER 
compared to the initial values was more significant in the presence of PECs than their 
respective APECs. The samples were replaced with fresh media at 2h to investigate the 
reversibility of opening of the TJs. All PECs and APECs (with few exceptions) 
demonstrated restoration of TEER to around ≥80% of their initial values within 24h. 
This behaviour indicates that the effect of formulations was reversible and rules out the 
possibility of permanent damage to the TJs. However, TEER did not recover 
completely for IL Pa2.5 PECs and Da10 based complexes which retained 20-40% of 
the original values.  
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Figure 5.2 Effect of (a) PAH based formulations and (b) QPa2.5 based formulations 
(IC90 concentration) on percentage TEER of CaCo2 cells (n=3 ±SE). Values represent 
average percentage reduction in the original TEER. Each point represents the 
mean± SD of 3 replicate experiments. Insulin (5 μgmL−1) demonstrated no 
significant decrease in original TEER. All samples were significantly different from 
insulin (p<0.05). Differences between PECs and respective APECs are expressed as 
p<0.05*. 
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Figure 5.3 Effect of (a) Da10 based formulations and (b) Pa2.5 based formulations 
(IC90 concentration) on percentage TEER of CaCo2 cells (n=3 ±SD). Values represent 
average percentage reduction in the original TEER. Each point represents the mean± SE 
of 3 replicate experiments. Insulin (5 μgmL−1) demonstrated no significant decrease in 
original TEER. All samples were significantly different from insulin (p<0.05). Differences 
between PECs and respective APECs are expressed as p<0.05*. 
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The NIL PAH displayed greater tendency to reduce the original TEER value than 
their IL counterparts (Figure 5.2a). NIL PAH and NIL PAH-PAA displayed a more 
marked reduction of the original TEER (5 fold, p<0.01) than NIL PAH-DS (2 fold). 
Conversely, IL PAH-DS produced greater reduction of original TEER (40-70%) than 
IL PAH-PAA (80%).  
Similar to PAH based complexes, QPa2.5 based complexes produced greater 
reduction in original TEER than their IL counterparts (Figure 5.2b). The NIL QPa2.5-
DS produced a more significant reduction in original TEER (5 fold, P<0.001) than NIL 
QPa2.5 and QPa2.5-PAA (2.5 fold). There were no significant differences in TEER 
reduction profile between the three IL QPa2.5 complexes.  
The IL and NIL Da10 and Da10-DS produced significantly greater reduction in 
original TEER (P<0.05) than corresponding Da10-PAA (Figure 5.3a). The greater 
reduction in original TEER by NIL QPa2.5-DS, IL PAH-DS and Da10-DS indicate the 
role of DS in a more significant TEER reduction than PAA.  
In comparison to PAH and QPa2.5 based complexes, IL Pa2.5 based complexes 
(except IL Pa2.5-DS) followed a reverse trend (Figure 5.3b). There was a more marked 
reduction in the original TEER by IL Pa2.5 and Pa2.5-PAA (40% of original- p<0.001) 
than IL Pa2.5-DS (60% of original, p<0.05). There was no significant difference in the 
TEER reduction between the NIL Pa2.5 PECs and APECs.  
5.5.1.2 Effect of formulations on the permeability of FITC-Dextran (10KDa) 
across CaCo2 monolayers 
The permeability of an otherwise impermeable marker, FITC-Dextran (10KDa) in 
the presence and absence of free insulin, polycations, PECs and APECs was 
investigated across CaCo2 cell monolayer (Figure 5.4).  
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Figure 5.4 Effect of various IL PEC and APEC formulations on permeability of FITC-
Dextran across CaCo2 monolayer at different time points (h) (n=3 ±SE). All samples 
demonstrated significant differences p<0.05 when compared with free insulin p<0.05. 
The statistically significant differences in FITC-Dextran permeation between PECs and 
their respective APECs is expressed as p<0.05*. 
 
In the presence of free insulin, no substantial flux of FITC-Dextran was observed 
across the CaCo2 cell monolayer indicating that free insulin has no role in opening the 
TJs which correlates with the TEER findings. Likewise, cells exposed to media alone 
demonstrated no flux of FITC-Dextran across CaCo2 cells signifying no uptake of 
FITC-Dextran in the absence of PECs and APECs (data not shown). It was observed 
that cells exposed to PECs and APECs demonstrated statistically significant (p<0.05) 
permeation of FITC-Dextran across CaCo2 cell monolayer compared to free insulin. 
However, the amount of FITC-Dextran in donor chamber was found to be <0.01%, 
indicating no appreciable paracellular transport.  
There was only a subtle difference observed in the permeability of FITC-Dextran in 
the cells exposed to various PECs which is graded as Da10≥QPa2.5≥Pa2.5 (0.82, 0.78, 
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incubated with PECs than APECs (p˂0.05). These findings are consistent with the 
TEER data where IL PECs (except QPa2.5 PECs) demonstrated a higher reduction in 
TEER than their respective APECs. These findings indicate that PECs had a greater 
ability to open the TJs and to facilitate the paracellular transport than APECs.  
The paracellular flux of FITC-Dextran across CaCo2 cells exposed to IL APECs is 
ordered as QPa2.5-DS ≥ Da10-DS ≥Da10-PAA ≥Pa2.5-DS ≥QPa2.5-PAA ≥PAH-PAA 
≥PAH-DS ≥Pa2.5-PAA (Figure 5.4). Notably, IL QPa2.5-DS demonstrated a higher 
flux of FITC-Dextran across the CaCo2 monolayer (p≤0.01) than the corresponding IL 
QPa2.5 PECs, despite there being no significant difference in the TEER reduction 
between them (Figure 5.2b).  
Altogether, the findings show that DS based APECs formed by complexation with 
modified PAH facilitated a higher paracellular permeability of FITC dextran than PAA 
based APECs. These results are in line with the TEER study where DS based 
formulations exhibited greater reduction in TEER.  
5.5.1.3 Transport of insulin across CaCo2 cell monolayer 
The cumulative transport of insulin across CaCo2 cell monolayers on exposure of 
cells to IL PECs and IL APECs is shown in Figure 5.5 and 5.6, and summarised in 
Table 5.1. The findings show that there was only a minor transport of free insulin across 
CaCo2 cells compared to insulin complexed in PECs and APECs (p≤0.001). All IL 
PECs and APECs increased the permeability of insulin across the epithelial barrier. 
These findings correlates well with the findings achieved from the TEER and FITC-
Dextran permeability study which demonstrated the opening of TJs and facilitation of 
FITC-Dextran absorption.  
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Figure 5.5 Cumulative insulin concentration in the basal compartment of transwell 
plates at different time points following incubation of CaCo2 cells with (a) PAH 
based IL PEC and APEC formulations (b) Da10 based IL PEC and APEC formulations 
(n=3 ±SE). All PEC and APEC formulations demonstrated significantly higher insulin 
permeation than free insulin (p<0.001).  APEC formulations exhibited significantly 
lower insulin permeation than their respective PECs, expressed as p<0.05*. 
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Figure 5.6 Cumulative insulin concentration in the basal compartment of Transwell 
plates at different time points following incubation of CaCo2 cells with (a) Pa2.5 
based IL PEC and APEC formulations (b) QPa2.5 based IL PEC and APEC 
formulations (n=3 ±SE). All PEC and APEC formulations demonstrated significantly 
higher insulin permeation than free insulin (p<0.001).  APEC formulations 
exhibited significantly lower insulin permeation than their respective PECs, 
expressed as p<0.05*. 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
2.2
0 0.5 1 1.5 2
In
su
lin
 C
o
n
ce
n
tr
at
io
n
 (
n
g/
m
L)
Time (h)
Pa2.5
Pa2.5-PAA
Pa2.5-DS
insulin
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
2.2
0 0.5 1 1.5 2
In
su
lin
 C
o
n
ce
n
tr
at
io
n
 (
n
g/
m
L)
Time (h)
QPa2.5
QPa2.5-PAA
QPa2.5-DS
insulin
a 
b 
185 
 
Table 5.1 Cumulative insulin concentration in basal chambers of Transwell plates 
following incubation with IL PEC and APEC formulations for 2h 
PECs and APECs Insulin concentration 
(µgmL-1) in basal 
chamber of wells of 
Transwell plate at 2h 
incubation with samples 
Number of folds 
reduction in insulin 
transport by APECs 
as compared to 
PECs 
Free insulin 0.4  
PAH-PAA 1.3  
PAH-DS 1.4  
Pa2.5 1.6  
Pa2.5-PAA 0.9 1.8 
Pa2.5-DS 1.2 1.3 
QPa2.5 2.2  
QPa2.5-PAA 0.9 2.4 
QPa2.5-DS 1.5 1.5 
Da10 1.9  
Da10-PAA 1.1 1.7 
Da10-DS 1.6 1.2 
 
The cells incubated with PECs demonstrated higher transport of insulin than APECs 
(p˂0.001) (Table 5.1). The degree of insulin transport by cells incubated with PECs is 
graded as QPa2.5 ≥Da10 ≥Pa2.5 (Figure 5.5 and 5.6, Table 5.1). These findings relate 
to the FITC-Dextran permeability study in view that both studies demonstrated higher 
flux in the presence of QPa2.5 and Da10 and lowest flux in the cells exposed to Pa2.5. 
The findings are also consistent with the TEER data except for the IL QPa2.5 PECs 
which demonstrated a lower ability to open the TJs and facilitate FITC-Dextran 
transport compared to QPa2.5-DS.  
The uptake of free insulin across CaCo2 cells was found to be ˂0.01% of the total 
amount of insulin in the apical chamber of transwell plates. The reduced uptake of free 
insulin may be attributed to the enzyme activity on the apical membrane of CaCo2 cells 
which might have degraded it prior to its uptake by cells. On the other hand, the insulin 
transport across CaCo2 cells incubated with PECs and DS based APECs was found to 
be ≥0.01%, indicating a considerably higher uptake than free insulin. The insulin 
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transport profile of the APECs is graded as Da10-DS ≥QP2.5-DS ≥Pa2.5-DS ≥PAH-
DS = PAH-PAA ≥Da10-PAA ≥Pa2.5-PAA = QPa2.5-PAA (Figure 5.5 and 5.6). This 
ranking substantiates the role of DS based APECs in generating higher insulin transport 
than PAA based APECs. The transport of insulin across CaCo2 cells incubated with 
PAA based APECs was found to be ≤0.01%. This low insulin transport across cells 
agree well with the low TEER reduction profile, reduced permeability of FITC-Dextran 
and reduced uptake of complexes in cells exposed to PAA based APECs. Conversely, 
the high insulin transport across cells exposed to DS based APECs correspond well to 
the high TEER reduction profile, higher permeability of FITC-Dextran and higher 
uptake of complexes in cells exposed to DS based APECs. 
5.5.2 Uptake study 
5.5.2.1 Determination of the CaCo2 cell uptake by fluorescent imaging 
The fluorescent microscopy was employed to confirm the uptake of IL PECs and 
APECs by CaCo2 cells. QPa2.5 and Pa2.5 based complexes were chosen for this study. 
Since the fluorescent microscope was not equipped with a UV filter, therefore, uptake 
of Da10 based complexes was not studied. Figure 5.7 and 5.8 show the fluorescent 
microscopy images of CaCo2 cells where internalised IL Pa2.5-R and IL QPa2.5-R 
based PECs and APECs are shown by arrows. The complexes are seen as red 
fluorescence whereas the cellular nuclei appear as blue fluorescence due to staining 
with DAPI nuclear stain. No fluorescence was detected in the control cells which were 
not exposed to the rhodamine labelled complexes, implying that there was no auto-
fluorescence of the cells which could cause misinterpretation of the data (figure not 
shown). The complexes appeared as punctuated red spots. The Pa2.5 PECs (red 
fluorescence) were found predominantly close to the cell membrane (Figure 5.7-1b) 
while Pa2.5 APECs were found further in the cytosol (Figure 5.7-2b & 3b). On the 
other hand, QPa2.5 based complexes (red fluorescence) mainly localised in the 
cytoplasm and perinuclear areas (Figure 5.8-1b) whereas QPa2.5 Co- localised in the 
cytoplasm (Figure 5.8-2b & 3b). Dead and damaged cells appeared as black patches in 
bright field due to the treatment of cells with trypan blue. The bright field images 
revealed no substantial black/blue staining of cells signifying the viability of the CaCo2 
cells after treatment with PECs and APECs.  
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Figure 5.7  Fluorescent microscopy images (40X magnification) of CaCo2 cells incubated 
with various IL PECs and APECs at IC90 concentration (1) IL Pa2.5 (2) IL Pa2.5-DS (3) IL 
Pa2.5-PAA (a) Bright field image (b) Fluorescent image (c) overlay of a & b. The 
complexes are visualised as red fluorescence indicated by arrows and the nucleus as 
blue fluorescence due to staining with DAPI nuclear stain. 
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Figure 5.8 Fluorescent microscopy images (40X magnification) of CaCo2 cells incubated 
with various IL PECs and APECs at IC90 concentration (1) IL QPa2.5 (2) IL QPa2.5-DS (3) IL 
QPa2.5-PAA (a) Bright field image (b) Fluorescent image (c) overlay of a & b. The 
complexes are visualised as red fluorescence indicated by arrows and the nucleus as blue 
fluorescence due to staining with DAPI nuclear stain. 
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5.5.2.2 Quantitative measurement of the CaCo2 cell uptake by Flow 
cytometry 
In order to determine the efficiency of uptake, a quantitative uptake study was carried 
out using flow cytometer (Attune® Acoustic Focusing Cytometer). Figure 5.9 and 5.10 
display the plots showing the internalisation of R-Pa2.5 and R-QPa2.5 based PECs and 
APECs by CaCo2 cells. Each plot presents four quadrants specific to the cells i.e. left 
lower quadrant (cell with no uptake i.e., negative), left upper quadrant (cells presenting 
uptake of only rhodamine labelled complexes), right lower quadrant (cells presenting 
uptake of only FITC-insulin) and right upper quadrant (cells presenting uptake of both 
rhodamine labelled complexes and FITC-insulin).  
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Figure 5.9 Flow cytometry plots showing the uptake profile of CaCo2 cells incubated with 
(1a) Pa2.5 (1b) IL Pa2.5 (2a) NIL Pa2.5-DS (2b) IL Pa2.5-DS (3a) NIL Pa2.5-PAA (3b) IL Pa2.5-
PAA. 
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Figure 5.10 Flow cytometry plots showing the uptake profile of CaCo2 cells incubated with 
(1a) QPa2.5 (1b) IL QPa2.5 (2a) NIL QPa2.5-DS (2b) IL QPa2.5-DS (3a) NIL QPa2.5-PAA (3b) IL 
QPa2.5-PAA. 
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Table 5.2 Percentage uptake of polycations, PECs and APECs by CaCo2 cells determined by 
flow cytometry (n=3 ±SE) 
PECs and APECs % Uptake of non-
loaded complexes 
% Uptake of insulin loaded 
complexes 
Pa2.5 89±2.3 44±6.8 
Pa2.5-DS 25±5.4 43 ± 8.7 
Pa2.5-PAA 42±6.8 29± 3.2 
QPa2.5 10±2.2 73± 7.4 
QPa2.5-DS 8±1.7 67± 6.2 
QPa2.5-PAA 5±2.4 12± 4.2 
 
The data in Table 5.2 summarises the uptake of NIL and IL QPa2.5 and Pa2.5 
complexes by CaCo2 cells achieved from the flow cytometry study. The findings show 
that the uptake of Pa2.5 and QPa2.5 PECs was higher than the uptake of respective 
APECs. 
 
 
Figure 5.11 Intracellular uptake of IL and NIL complexes versus ZP (n=3 ±SE). 
 
Overall, the uptake of the NIL Pa2.5 PECs and APECs was significantly higher than 
the uptake of respective IL Pa2.5 complexes (except Pa2.5-DS). The IL Pa2.5 PECs 
demonstrated 2 fold lower uptake (44%) than the NIL Pa2.5 PECs (89%) whereas IL 
Pa2.5-PAA demonstrated 1.4 fold lower uptake (29%) than NIL Pa2.5-PAA (42%). On 
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the other hand, the IL Pa2.5-DS (43%) followed a reverse trend i.e., 1.7 fold higher uptake 
by CaCo2 cell than NIL Pa2.5-DS (25%).  
The uptake of IL QPa2.5 complexes (12-73%) was found higher than the respective 
NIL QPa2.5 complexes (5-10%). Among all QPa2.5 complexes, NIL and IL QPa2.5-PAA 
presented the least uptake i.e., 5% and 12% respectively. On the contrary, the IL QPa2.5 
and QPa2.5-DS demonstrated considerably higher uptake. IL QPa2.5 presented 7.3 fold 
higher uptake (73%) than NIL QPa2.5 (10%). IL QPa2.5-DS demonstrated 8.3 fold higher 
uptake (67%) than NIL QPa2.5-DS (8%).  
5.6 DISCUSSION  
Understanding the mechanism of cellular uptake and transport of polymeric 
nanocarriers is critical for designing effective carriers for protein delivery [466]. It is 
known that certain properties of polymeric nanocarrier systems such as size surface 
charge, molecular weight and hydrophilicity affect their intestinal absorption [308, 317]. 
Each specific property may impact differently on the uptake behaviour depending on the 
cell type [201]. The aim of this study was to characterize the cellular uptake and transport 
of PAH and modified PAH based polycations, PECs and APECs and to elucidate the 
influence of different physicochemical properties on their uptake and transport across 
CaCo2 cells. The underlying mechanism of their uptake was determined by performing 
TEER measurements, assessment of paracellular permeability of FITC-dextran and 
quantification of insulin transport across CaCo2 cells. Further investigations were done to 
confirm their uptake by direct visualisation of particles using fluorescent microscopy and 
quantification of uptake by using flow cytometry.  
CaCo2 cell line was selected for this study because it offers substantial similarities to 
the human intestinal epithelium. CaCo2 cell monolayers are characterized by formation of 
TJs at the apical membrane upon growth on the membrane filters [434, 467, 468]. They 
express a distinct and high TEER value and therefore are generally accepted to be an 
appropriate cell line for the transport studies [467]. TEER is a measure of TJ integrity 
which reduces when the junctions are opened or damaged and hence provides an essential 
way to determine the tightness of the cell membrane [469]. Since the mean size of the TJs 
is in the order of ˂10 A° therefore, the transport of large macromolecules is restricted 
unless the TJ are opened [67, 470]. TJs can open and close to a certain degree under the 
influence of various polymers such as chitosan, polyallylamine and their derivatives which 
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is determined by monitoring reduction in TEER [67, 427]. However, the reduction in 
TEER does not confirm the paracellular permeation, as it does not distinguish between 
membrane and paracellular conductance [428]. Therefore, TEER study was coupled with 
FITC-Dextran (10KDa) study to assess its paracellular permeability across the TJs at 
various time points. Since, the transport of hydrophilic macromolecules is restricted by 
the presence of TJs, they form an effective means to study the paracellular permeability 
of macromolecules across the TJs [178]  
The paracellular flux of tracers can provide information about whether the opening of 
the TJs is accompanied by a paracellular flux or not [471]. It has been reported that 
chitosan solution  and nanoparticles produced a sharp and reversible decrease in TEER 
and increased the permeability of two FITC-dextrans, MW 4kDa and 10kDa across cells 
[184]. Sandri and group has shown that nanoparticles based on TMC with different 
quaternization degree, decreased the TEER and increased the paracellular flux of Lucifer 
Yellow, a paracellular pathway marker, across CaCo2 cells [58]. 
It is well known that insulin is absorbed into the cells through the insulin receptors 
present in the cellular membrane of CaCo2 cells [472]. It is also known that insulin has no 
effect on the TJs and therefore no drop in TEER was expected in the presence of free 
insulin [444]. No reduction in TEER in the presence of free insulin confirmed that the 
permeation of free insulin does not occur via the paracellular route. The decrease in the 
percentage TEER and increase in the permeability of FITC-Dextran under the influence 
of all the formulations tested indicates that all formulations were able to promote 
paracellular transport. 
Generally, the cells incubated with polycations and PECs produced a greater reduction 
in TEER and higher transport of FITC-Dextran (except QPa2.5 based APECs) and insulin 
as compared to their respective APECs, presumably due to a higher positive surface 
charge. The presence of polyanion in APECs is thought to have caused repulsive 
interactions between the APECs and the negatively charged membrane proteoglycans 
[364] leading to a reduced interaction with the cell membrane. The findings are in line 
with the study done by Sadeghi et al. on the effect of chitosan solution and nanoparticle 
formulations on TEER of CaCo2 monolayers [431]. They showed that, chitosan 
nanoparticles had a much lower effect on decreasing the TEER compared to the free-
soluble chitosan. It was considered to be due to the reduced available amount of positive 
charge on the surface of nanoparticles, compared to the soluble form of chitosan [431]. 
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Discrepancy in the capacity to induce TJ opening between chitosan solution and 
nanoparticles has also been explained by a restriction in the movement of the chitosan 
chains in the nanoparticulate form, which hinder the contact of these chains with the 
plasma membranes and TJs  [473].  
The NIL PAH and QPa2.5 polymers displayed greater tendency to reduce TEER than 
their IL counterparts. The results are in agreement with a study conducted by Sadeghi and 
group who showed that nanoparticles consisting of chitosan and its quaternary ammonium 
derivatives loaded with insulin were less effective in facilitating paracellular transport 
across CaCo2 cell monolayers than the corresponding free polymers [431]. It has also been 
shown by Ma and Lim group that soluble chitosan was more effective in opening the 
intercellular TJ’s than chitosan nanoparticles [188]. This was explained by the possibility 
of a less effective interaction of chitosan nanoparticles with the cellular proteins because 
of their TPP-cross-linked chains [188].  
 The NIL QPa2.5 complexes produced a more significant reduction in original TEER 
(20-60%, p<0.001) than their IL counterparts (70-80%, p<0.05). The presence of insulin 
in IL QPa2.5 complexes significantly dropped their positive ZP (QPa2.5 PECs 52-20mV; 
QPa2.5-DS 19-16 and QPa2.5-PAA 17-7mV) which could have altered their interaction 
with the junctional proteins, subsequently preventing the TJ opening (Table 3.2).  
The reduction in original TEER was more marked in the cells incubated with NIL 
QPa2.5 APECs than NIL QPa2.5. This may be because the methyl groups in the bulky 
quaternary ammonium moiety in QPa2.5 produced significant steric effects which might 
have affected their interaction with the junctional proteins. It has previously been shown 
that pyridyl-methyl group of methylated N-(-4pyridinylmethyl) chitosan (TM-Py-CS) 
shielded the positive charges of the quaternary ammonium moieties of chitosan and 
hindered their binding to the negatively charged surface on the TJs [474]. The presence of 
polyanion in QPa2.5 APECs might have reduced the steric hindrance and subsequently 
promoted their interaction with the junctional proteins, leading to a more significant 
decline in the original TEER. The exact mechanism of how polyanion prevented the steric 
hindrance and promoted binding to the TJs remains to be further studied. The findings 
correspond to the recent findings which have shown that polyanion containing N-trimethyl 
chitosan/ poly(γ-glutamic acid) nanoparticles (TMC40/γ-PGA NPs) significantly 
decreased the original TEER and increased the amount of insulin transported across 
CaCo2 cell monolayers along the paracellular pathway [186].  
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Kotze et al. has shown that the opening of the TJs is strongly dependent on the positive 
charge density of the polycation [475]. The positive charge (29±2mV) of NIL PAH-PAA 
as compared to IL PAH-PAA (0.06±3mV) (Table 3.2) facilitated their interaction with the 
TJ proteins leading to a more significant reduction in original TEER. However, the 
presence of insulin in IL PAH-PAA complexes reduced the surface charge which altered 
their interaction with the TJs leading to a less significant reduction in original TEER (up 
to only 15%, p<0.05) than NIL PAH-PAA. Similar effect was observed for NIL PAH-DS 
(39±2mV) which showed higher TEER reduction than IL PAH-DS (25±3mV) due to their 
high positive surface charge.  
On the other hand, IL Pa2.5 based complexes showed greater reduction in original 
TEER than their NIL counterparts. A comparable TEER reduction (max 60%) by NIL 
Pa2.5 PAA and Pa2.5-DS APECs is attributed to the identical ZP (29mV). A more 
significant reduction in original TEER by IL Pa2.5 PECs (max 75%- p<0.05) than their 
corresponding APECs is ascribed to their more positive ZP (29mV) than the 
corresponding APECs (25mV) which might have promoted their interaction with the 
junctional proteins.  
There is evidence that higher positive charge density plays an important role in binding 
and internalisation of nanocarriers [476]. Positive charge has been shown to be responsible 
for interaction of nanocarriers with the TJ proteins and to promote their re-organization, 
subsequently opening the TJ [60, 431]. The alteration in the staining pattern of TJ proteins 
such as claudin [177] zonnula occludens (ZO-1) [186], CLDN4 [178] and JAM-1 [477] 
have been associated with transient opening of TJs. The ability of transient opening of TJs 
has also been associated with interaction of polycation such as chitosan with Protein 
Kinase C pathway [478].  
  The role of positive charge in opening the TJ and paracellular permeation of 
hydrophilic molecular tracers has previously been established by a number of research 
groups [471, 474]. The high charge density has been shown as a necessary factor to 
substantially improve the paracellular permeability of TMC across intestinal epithelia [58, 
475]. Florea et al. has ascribed the difference in permeation enhancement between 
quaternised chitosan derivatives i.e., TMC20 and TMC60, to the stronger cationic charge 
density of TMC60 which makes it apparently more effective in modulating the tight-
junctional barrier [476]. Hamman et al. reported that the effect TMC on the TEER 
reduction and transport of hydrophilic macromolecular compounds was associated with 
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the number of available positive charges on the TMC [479]. The higher FITC-Dextran and 
insulin transport in the cells incubated with PEC than their respective APECs are therefore 
attributed to their high positive surface charge. Among APECs, all DS based APECs 
showed higher TEER reduction and FITC-Dextran and insulin permeation across CaCo2 
monolayer than PAA based APECs. These effects are attributed to the flexible architecture 
and high MW of DS. However, altogether the flux of FITC-Dextran across CaCo2 
monolayer was ≤0.01% of original concentration of FITC-Dextran introduced in the apical 
chamber indicating very low paracellular transport. It has been reported by Woitiski et al. 
that detection of FITC-Dextran <0.01% of original concentration in the donor chamber 
indicates either no sufficient permeation of FITC-Dextran or intact integrity of intestinal 
mucosa [444].  The opening of the TJs by absorption enhancers is considered to be only 
20-50 nm in width [186]. It could be that the paracellular pathway was not adequately 
widened to allow the passage of large sized complexes across the cell monolayer [188]. 
Therefore, altogether the findings infer that all the formulations were able to open the TJs, 
but there was very low paracellular permeation across the TJs. This effect has previously 
been reported by Mao et al. who demonstrated that PEG(5K) 40g-TMC(100 copolymer 
complexes were not internalised through paracellular route despite the TJ opening, 
demonstrating that the paracellular transport was not the main route of their uptake [67]. 
Similarly, Woitiski et al. reported the uptake of multi-layered chitosan nanoparticles 
predominantly by transcellular route despite the significant opening of the TJ [444]. 
Flow cytometry study showed a higher uptake of NIL Pa2.5 complexes than IL Pa2.5 
complexes; and of IL QPa2.5 complexes than NIL QPa2.5 complexes. This shows that the 
presence of insulin interfered in the uptake of Pa2.5 complexes whereas promoted the 
uptake of QPa2.5 complexes (Table 5.2). This behaviour is once again considered to be 
due to the reduction in ZP upon introduction of insulin in Pa2.5 complexes which 
subsequently reduced their uptake by impairing their interaction with the membrane 
proteins. Conversely, the presence of insulin in IL QPa2.5 complexes prevented the steric 
hindrance and subsequently facilitated their interaction with the membrane proteins.  
The considerably low uptake of NIL QPa2.5 based complexes (Table 5.2) indicate that 
they were not efficiently internalised via the transcellular route due to their large size (228-
468nm) (Table 3.2). In particular, the NIL QPa2.5-PAA (228±1nm) and IL QPa2.5-PAA 
(388± 29nm) are assumed to have not been significantly internalised due to their large size 
(Table 3.2). The higher uptake of IL QPa2.5 and QPa2.5-DS and insulin transport across 
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CaCo2 cells substantiates the ground for uptake predominantly by a transcellular route 
Figure 5.12. The small size of IL QPa2.5 (117±2.4nm) and IL QPa2.5-DS (72±0.9nm) is 
assumed to have allowed efficient internalisation by transcellular route.  
 
 
 
 
 
 
 
 
 
Figure 5.12 Mechanism of uptake of Pa2.5 and QPa2.5 based PECs and APECs 
 
Thompson et al. reported that the internalisation of QPa2.5 PECs is not inhibited by 
blocking/down regulation of insulin receptor suggesting that their uptake is receptor 
independent [427]. It was also reported that QPa2.5 PECs demonstrated uptake despite 
blockage of endocytosis by nocodazole and cytochalasin D and in the absence of calcium 
in the media. These findings ruled out the possibility of uptake by endocytosis. This led 
them to consider the mechanism of uptake by an active process like organic cationic 
transporters [427]. Human organic cationic transporters represent a family of transporters 
likely to be involved in the disposition of small hydrophilic organic cations e.g., ranitidine 
and famotidine, however, their role in the transport of high molecular weight cations is yet 
to be elucidated [480]. The findings may well reflect the possibility of QPa2.5 PECs to be 
absorbed transcellularly via the interaction with the cationic transporters [481].  
The higher uptake of IL QPa2.5-DS than IL QPa2.5-PAA points towards polyanion 
dependent uptake. In addition, the small size and high positive ZP of IL QPa2.5-DS (size 
72±0.1; ZP 16±3) as compared to low positive ZP and larger size of IL QPa2.5-PAA (size 
388± 29; ZP 7mV) might have facilitated their uptake (Figure 5.11). These findings 
support the role of surface charge and size-selective uptake of the QPa2.5-DS complexes. 
Transcellular uptake of Pa2.5 and 
QPa2.5 
TJs opened under the influence of all 
formulation but without appreciable 
paracellular flux due to the large size of PECs 
and APECs  
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Since the ZP of QPa2.5-DS is less than the QPa2.5 PECs (Figure 5.11), there appears to 
be a reduced possibility of their uptake by cationic transporters. There is evidence that 
complexes formed of polyanions such as DS and hyaluronic acid are internalised via 
receptor mediated endocytosis [445, 482]. The uptake of DS by glomerular endothelial 
cells has been reported to occur via receptors associated with the cell-surface heparin 
sulphate [483]. More recently, it has been shown that coating a DNA/PEI polyplex with a 
low molecular weight anionic hyaluronan (<10 kDa) facilitates the receptor-mediated 
uptake of polyplexes [445]. Another similar study has shown that coating a 
DNA/polycation polyplex with poly(c-glutamic acid) (c-PGA), a polyanion, increased the  
cellular uptake by a c-PGA-specific receptor-mediated energy-dependent process [484].  
Yin Win et al. has shown size dependent uptake of polystyrene nanoparticles. They 
showed that 100 nm particles produced 2.3-fold greater uptake compared to that of 50nm 
particles, 1.3-fold to that of 500 nm particles, about 1.8 fold to 1000 nm particles [308]. 
Thus, nanoparticles of 100–200 nm size have shown to acquire the best properties for 
cellular uptake [308, 442]. Such small particles have been shown to be taken up by clathrin 
mediated endocytosis, as clathrin baskets due to their geometry can accommodate only a 
maximum size of 100 nm [485]. Based on all these reports, it may be considered herein 
that the QPa2.5-DS APECs initially bound to the receptors followed by events leading to 
receptor mediated endocytosis. However, further studies are needed to address these 
hypotheses. The size of nanoparticles may not be the only dominant factor influencing the 
uptake [486] 
The surface chemistry of nanocarriers also plays an important role in the uptake and 
transport. There have been contrasting findings related to the effect of hydrophilicity or 
hydrophobicity of nanocarriers on their uptake [201, 442, 487, 488]. Clare et al. has shown 
that PAH modified with 5% hydrophobic cholesteryl pendants enhanced the oral 
absorption of a model drug, griseofulvin, when administered intra-gastrically in rats [416]. 
The enhancement of hydrophilicity of nanoparticles has been linked to a declined cellular 
interaction and transcellular transport of the nanocarriers [442, 487]. Nam and colleagues 
investigated the cellular uptake mechanism and the intracellular fate of the 
hydrophobically modified glycol chitosan (HGC) [201]. These nanoparticles showed 
higher internalisation efficiency, compared to the parent hydrophilic GC polymers. These 
findings are in line with the NIL hydrophobically modified PAH based complexes (NIL 
Pa2.5 based complexes) which showed higher internalisation than their hydrophilic 
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counter-part (QPa2.5 based complexes) (Table 5.2). However, introduction of insulin in 
Pa2.5 complexes might have reduced their hydrophobicity leading to reduced uptake. 
Sahoo et al. showed that lower intracellular uptake of nanoparticles with higher amount 
of residual Polyvinyl alcohol was due to higher hydrophilicity of the nanoparticle surface 
[488]. It is thought that the positively charged NIL Pa2.5 complexes electrostatically 
interacted with negatively charged proteoglycans of the cell membrane, followed by non-
specific adsorptive endocytosis [67], whereas Pa2.5-DS internalised via receptor mediated 
endocytosis. However, further work should be performed to confirm these assumptions.   
It may be considered herein that the hydrophobic long alkyl chain of the palmitoyl group 
reduced the uptake of IL Pa2.5 complexes by CaCo2 cells. The long alkyl chain 
strengthened the interaction of complexes with the cell membrane such that the complexes 
were either not internalised efficiently or remained essentially close to the cell membrane. 
This effect was observed on the microscopic observations where IL Pa2.5 PECs were 
found in close proximity to the cell membrane. However, this assumption may not be valid 
as the NIL Pa2.5 complexes were taken up much more efficiently despite being equally 
hydrophobic. Since the uptake of Pa2.5 based APECs was significantly less than the 
corresponding PECs. This leads to a possibility of the role of positive surface charge in 
more efficient uptake.  These findings are not in agreement with Wang and group who 
recently showed that the cellular entry of four DNA ternary polyplexes was more efficient 
than the DNA binary polyplexes [131]. Several other research groups have reported 
findings contrary to our results. It has been shown that addition of polyanions (such as 
PGA, hyaluronic acid and anionic polyampholyte PEG derivatives) to a polycation 
system, forming polyanion/DNA/polycation ternary polyplexes, significantly improved 
the gene delivery efficiency in comparison to their original pDNA/polycation binary 
polyplexes [445, 446, 484].  
 IL Pa2.5 complexes exhibited lower positive ZP values and hence lower uptake than 
their corresponding NIL counterparts (Figure 5.11). Likewise, IL and NIL Pa2.5 PECs 
presented higher positive ZP and hence higher uptake than their corresponding APECs. 
These findings clearly indicate that high positive charges are associated with a higher 
uptake. However, since the difference in uptake profile between the IL and NIL Pa2.5 
based complexes and between PECs and APECs is not proportional to the decrease in the 
positive ZP. These findings raise the possibility of uptake of these complexes followed by 
their efflux by efflux pump e.g., P-gp efflux pump [489]. P-gp, is a transmembrane protein 
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of approximately 170kDa molecular mass which forms an energy-dependent drug efflux 
pump [354]. They present as one of the key elements in limiting drug absorption via the 
oral route [354]. A major limitation of tumor cell lines such as CaCo2 cells is the 
possibility of overexpression of P-gp pumps which may lead to a higher efflux and 
subsequently lower permeability in the absorptive direction [489]. P-gp pumps have 
shown to secrete a variety of lipophilic and cationic compounds out of cells including 
some anticancer agents such as anthracyclines, taxanes, vinca alkaloids, and 
epipodophyllotoxins consequently reducing their intracellular concentration [354]. The 
finding point to a P-gp mediated efflux of IL Pa2.5 PECs and IL Pa2.5-PAA. Future 
studies should be performed to explore the type of endocytic pathways involved in uptake 
of nanocarriers. 
5.7 CONCLUSION 
The amphiphilic PECs and APECs have ability to facilitate the transport of insulin 
across CaCo2 cell monolayers. PECs demonstrated greater TEER reduction, FITC- 
Dextran and insulin transport and transcellular uptake by CaCo2 cells than their 
corresponding APECs. The differences in the cellular uptake profile, localisation within 
the cells and mechanism of uptake of Pa2.5 and QPa2.5 based PECs and APECs are 
ascribed to the differences in size, surface charge and the surface chemistry of complexes. 
NIL QPa2.5 based complexes demonstrated minor uptake due to their large sizes. IL 
QPa2.5 and QPa2.5-DS demonstrated higher uptake by a transcellular route than their 
NIL counterparts due to their small size. DS based APECs (i.e., QPa2.5-DS and Pa2.5-
DS) demonstrated higher uptake by CaCo2 cells than their respective PAA based APECs. 
Further investigations should be done to elucidate the mechanism of transcellular uptake 
by using endocytosis specific inhibitors or by subjecting cells to low temperature to 
distinguish between energy dependent endocytosis and energy independent mechanism. 
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6 CONCLUSION AND FUTURE WORK 
6.1 CONCLUSION 
Oral delivery of proteins has always been preferred because of its convenience and 
long term compliance. However, it is limited due to the enzymatic susceptibility and 
physical and chemical instability of protein in the GIT [3, 68]. The high molecular 
weight, hydrophilic nature and proteolytic degradation prevents protein absorption 
through the intestinal mucosa [439, 490]. 
A growing number of strategies have been designed to deliver insulin to the site of 
absorption and facilitate its permeation through the intestinal membrane to achieve 
pharmacological effects [57, 67, 96, 444, 491]. These strategies include mucoadhesive 
polymers [13, 492], permeation enhancers [2, 34, 493] and enzyme inhibitors [28]. 
However, mucoadhesives such as chitosan based systems are associated with reduced 
stability at physiological conditions and non-specific mucoadhesion [62], while, 
permeation enhancers and enzyme inhibitors are associated with toxicity related issues 
[26, 27, 36]. Such limitations have severely restricted their use. 
In recent years, the polyelectrolyte complexes have been explored for their ability to 
complex protein drugs and protect them against chemical and enzymatic degradation. 
Polyelectrolyte complexes are formed by association of the oppositely charged 
polymers/proteins through intermolecular interactions [3, 68, 97]. The process of 
fabrication is devoid of potentially harmful organic solvents and heat. For this reason, 
polyelectrolyte complexes emerge as a very useful means for the delivery of protein 
drugs. The conventional binary polyelectrolyte systems (PECs) have mainly been 
formed by using polycations. It is well known that polycations are associated with 
charge related toxicity and non-specific interactions. Therefore, the development of 
polycation based binary systems present a substantial challenge in this field.  
Recently, a simple, novel approach has been developed to fabricate ternary 
polyelectrolyte complexes (APECs), which involve addition of a biocompatible 
polyanion to the binary complexes, to improve the stability and reduce the toxicity and 
non-specific bio-interactions associated with the former systems. This thesis aims to 
fabricate novel ternary complexes based on amphiphilic polyallylamine, for oral 
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delivery of proteins to overcome the aforementioned problems of toxicity and non-
specific bio-interactions. 
Eight NIL APECs were fabricated in a nano-size range (78-435nm) between a 
polycation (PAH, Pa2.5, QPa2.5 and Da10) and a polyanion (DS and PAA) at a mass 
ratio of (2:1) in the presence of a cross-linker ZnSO4 (4µM). The IL counterparts were 
fabricated by adding a model protein i.e., insulin in a polycation prior to adding the 
polyanion in the presence ZnSO4 (4µM). It is thought that the cross-linker linked the 
polymeric chain by forming ionic bridges and thus provided stability to the complexes. 
In addition, the COO- of insulin interacted electrostatically with the NH3
+of the 
polycation and the NH3
+ on the polycation and insulin interacted with COO- of PAA 
and SO4
-2 of DS leading to the formation of nano-sized APECs.  
The APECs formed by the hydrophobically modified PAH i.e., Pa2.5 and Da10 
exhibited smaller hydrodynamic sizes (100-200 nm) and higher ZP (22-35mV) 
compared to the complexes formed by the QPa2.5 (size-72-388nm, ZP- 7-20mV). The 
hydrophobic portions of the hydrophobically modified PAH chains is thought to 
provide hydrophobic association which strengthened the interaction between polymeric 
chains leading to smaller self-assemblies [119]. However, due to the presence of 
permanently charged bulky quaternary ammonium moieties, a solvation layer is formed 
around the complexes, which resulted in increased hydrodynamic sizes of QPa2.5 based 
complexes [119].  
As expected, the introduction of insulin and polyanion in complexes reduced the ZP 
of complexes confirming their association in the complexes. Insulin association 
efficiency was affected by the type of polycation and polyanion. The insulin association 
efficiency was found to be higher in PECs and APECs formed by the hydrophobically 
modified PAH based complexes (Pa2.5 and Da10, >75%) than the complexes formed 
by PAH and QPa2.5 based complexes (≤60%). Among hydrophobically grafted 
complexes, Da10 based APECs showed lower insulin complexation efficiency than 
Pa2.5 based complexes due to higher hydrophobic load which prevented their 
association with insulin. The bulky and rigid naphthalene rings in the dansyl moieties 
are also thought to have hindered insulin complexation by generating steric hindrance 
effects. On the other hand, the presence of polyanion in QPa2.5 APECs created a 
competitive interaction between two negative charges to complex with the polycation. 
The polyanion superseded in complexing with the QPa2.5 and thus impeded the 
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interaction of insulin with the QPa2.5. The competitive interaction took place 
particularly in QPa2.5 APECs because of the added steric hindrance mediated by the 
bulky quaternary ammonium moieties in the complexes. 
DS based APECs displayed a higher insulin association efficiency than the PAA 
based APECs, which is ascribed to the higher molecular weight (60-10KDa) of DS than 
PAA. The dense and branched architecture of DS, with more charged units (SO4
-2) than 
the less charged (COO-) PAA, is thought to have interacted more strongly with the NH3
+ 
of the insulin, and hence DS were able to trap more insulin molecules leading to higher 
association efficiency.  
The PECs and APECs formed by the hydrophobically modified PAH (i.e., Da10 and 
Pa2.5) were found to be more stable at varying temperature (37ºC and 45ºC), ionic 
strength (68mM, 102mM and 145mM) and pH (7.4, 6.6 and 1.2) (except Da10-PAA) 
than the unmodified and QPa2.5 based complexes. The hydrophobic modification of 
PAH with C16 long alkyl chain grafted on Pa2.5 or naphthalene group grafted on Da10) 
reduced the chain flexibility and allowed the chains to remain linked even at high ionic 
strength, temperature and pH conditions. The hydrophobic grafts appeared to generate 
hydrophobic interactions with the insulin chain thus providing stability to the 
complexes [118]. The hydrophobic interactions are essentially absent in the case of 
PAH based complexes which caused destabilisation of these complexes. 
The increase in temperature up to 45˚C facilitated the formation of PECs and APECs. 
It is known that the hydrophobic interactions increase in strength with the increase in 
the temperature [287]. These increasing hydrophobic associations are considered to 
have maintained the complex integrity. However, the QPa2.5 based PECs and APECs 
increased in size upon increase in the temperature due to the loss of hydrogen bonding 
between the hydrophilic QPa2.5 chains and water molecules upon increase in the 
thermal energy which subsequently led to the destabilisation of the complexes. 
The size and ZP of QPa2.5 based PECs increased progressively upon increasing ionic 
strength. This is possibly due to the shielding of surface charge of the polymeric chains 
by counterions which diminished the attractive interactions between the polymer chains 
and insulin leading to large sizes. The low positive surface charge (≤20mV) of QPa2.5 
PECs, as compared to the hydrophobically modified PECs and APECs (≥22mV), was 
observed to be neutralised more effectively by the counterions which caused the 
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destabilisation of QPa2.5 PECs.  Alternatively, the QPa2.5 APECs reduced in size and 
showed restoration of ZP at higher ionic strengths conditions (102mM and 145mM) 
indicating the role of higher concentration of salt in providing stability to these 
complexes by preventing charge neutralisation. The small monovalent ions (Na+ and 
Cl-) are assumed to have generated ion pairing effect with the free negative charges on 
the polymeric chains in the complexes subsequently providing stability to the 
complexes.  
On the other hand, the addition of salt in the hydrophobically modified PECs and 
APECs did not cause destabilisation of complexes. The counter ions are thought to have 
bound to the surface, which is clear from a reduction in the ZP. However, the 
concentration of counter ions was not enough to neutralise the surface charge of the 
complexes which could cause destabilisation of the complexes. In addition, the 
hydrophobic association is also thought to have prevented the complex destabilisation. 
The PECs and APECs formed by the modified polymers (Pa2.5, Da10 and QPa2.5) 
were more stable at varying pH (except Da10 and Da10-PAA) than complexes formed 
by unmodified PAH owing to the presence of hydrophobic associations. The 
protonation of carboxylic groups of PAA in Da10-PAA and PAH-PAA at low pH due 
to a higher pKa (2.5) than pKa of DS (1.2) suppressed the electrostatic interaction 
between the polymeric chains and insulin leading to destabilisation of these complexes. 
This data showed that presence of PAA in APECs altered the stability of complexes at 
low pH. PAH-PAA lost stability as no contributory hydrophobic associations were 
present to prevent destabilisation of complexes. On the other hand, similar to low 
insulin complexation efficiency shown by Da10, destabilisation of Da10 PECs and 
Da10-PAA at low pH is also attributed to the bulky and rigid naphthalene ring in Da10 
which conferred steric hindrance and prevented stronger interaction with insulin 
leading to destabilisation of complexes. However, unlike Da10 based complexes, Pa2.5 
based PECs and APECs showed stability irrespective of polyanion used. This effect 
might mean that long hydrocarbon chain (C16) in Pa2.5 promoted stronger hydrophobic 
interactions than the bulky and rigid naphthalene ring in Da10.  
The cytotoxicity of polycations and APECs was determined by MTT assay on the 
CaCo2 cells and J774 cells. The cytotoxicity of modified polycations was significantly 
less than the unmodified counterparts (PAH>Da10=Pa2.5>QPa2.5). The hydrophobic 
and hydrophilic grafting reduced the number of primary amines on the polymer 
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backbone and hence the cationic charge thereby reducing the PAH associated 
cytotoxicity. The hydrophilic quaternary moieties on polymer backbone contributed to 
most significant reduction in toxicity.  
Macrophages (J774 cells) were seen to be more sensitive to the effect of various 
polycations and APECs than the CaCo2 cells; however, the main pattern of the 
cytotoxicity remained the same on both the cell lines. The varying IC50 on the two cell 
lines is attributed to the difference in the morphological and physiological properties of 
the two cell lines. The enterocytes preferentially internalise nanocarriers in the range of 
100- 200 nm by endocytosis [411] whereas, macrophages internalise particles ≤500nm 
in diameter by phagocytosis [307, 411].  
The presence of polyanion in the APECs reduced the polycation associated toxicity 
on both the cell lines by reducing the positive charge density. PAA based complexes 
exhibited less cytotoxic profile probably due to low MW of PAA than high MW DS 
based APECs. The administration of PAH-PAA brought more significant improvement 
in IC50 due to its low positive ZP (29mV) compared to the high positive ZP (39mV) of 
PAH-DS. QPa2.5 APECs produced a comparable reduction in cytotoxicity irrespective 
of polyanions probably due to the similar ZP value (17-19 mV) of both APECs. Pa2.5-
PAA and Da10-PAA were clearly less cytotoxic than their DS based counterparts and 
brought most significant improvement in the IC50 of Pa2.5 and Da10 i.e., 14 fold and 
16 fold respectively on CaCo2 cells and 9.3 fold and 3.73 fold respectively on J774 
cells. However, this improvement in cytotoxicity was not due to the low ZP of PAA 
based APECs, as there was no considerable difference in the ZP between PAA and DS 
based APECs. These findings show that not only surface charge but parameters such as 
MW and structure of polyanions may influence the cytotoxicity profile of complexes. 
Thus the higher cytotoxicity of DS based APECs is ascribed to the high molecular 
weight and the dense branched architecture of DS.  
The in vitro haemolytic profile showed minor haemolytic activity (≤12%) by all 
polycations and APECs (0.075-5mgmL-1) (except Da10). Da10 produced a maximum 
haemolytic activity of approximately 37% at 10mgmL-1. The hydrophobicity of the 
polymers has previously been linked with the membrane-disruptive activity by Liu et 
al [417]. It is thought that the hydrocarbon chains formed mixed micelles with the 
phospholipid bilayers [416]. However, since Pa2.5 did not produce any haemolytic 
effect, the haemolytic activity of Da10 is ascribed to the higher hydrophobic load i.e., 
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10% hydrophobic grafting than Pa2.5 (2.5%). The Da10-DS and Da10-PAA APECs 
(8mgmL-1) clearly reduced the haemolytic activity associated with Da10. The 
improvement in the haemolytic activity is assumed to be due to the combined effects 
of reduction in the positive charge density as well as the structure and MW of polyanion 
which subsequently reduced the disruption of the erythrocyte membrane.  
The reactive oxygen specie assay showed that the polycations and APECs stimulated 
production of low levels of ROS (≤26%) in the CaCo2 cells at the experimental 
conditions employed. The degree of ROS generation (PAH≥Pa2.5=Da10≥QPa2.5) 
followed the same trend as the cytotoxicity profile indicating a direct association of 
ROS production with the cytotoxicity. The APECs demonstrated significant reduction 
in the polycations induced ROS production which is again due to the reduction in 
cationic charge. However, reduction in the ROS generation was not sufficiently 
sensitive enough to differentiate between PAA and DS based APECs.  
The cytokine generation assay (IL-6, IL-2 and TNF α) showed conflicting results 
between the in vitro and in vivo situations. The level of in vivo serum cytokine 
production was significantly less (≤ 27%) than the in vitro situation (90%). This 
disparity in the data can be explained by the difference in the in vitro and in vivo 
situations such as short half-life and localised in vivo production of cytokines leading 
to reduced systemic availability. In addition, there might have been in vivo stimulation 
of anti-inflammatory cytokines (IL-10) which caused down regulation of the pro-
inflammatory cytokines leading to low in vivo level of cytokines [361].  
Among APECs the reduction in in vitro and in vivo cytokine generation (˂25%) was 
most significant on exposure to Pa2.5-PAA. Conversely, Da10 based APECs showed 
less ability to reduce cytokine generation. Da10-PAA marginally reduced the TNF-α 
generation whereas Da10-DS increased the in vitro secretion of IL-6 and TNF-α. These 
findings indicate the role of DS in raising immune response which correlates with their 
higher cytotoxicity, haemocompatibility and ROS generation than PAA based APECs. 
The biocompatibility of PAA based APECs is ascribed to the low MW PAA (1.8kDa) 
than DS (6-10kDa). For this reason, only PAA based APECs were selected for the in 
vivo cytokine generation study. 
The induction of cytokines was greatest upon exposure to QPa2.5 and its APECs, in 
both the in vitro and in vivo situations. These findings do not correlate with cytotoxicity 
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and ROS assay where QPa2.5 based complexes were found to be the least cytotoxic 
and did not induce ROS. This reverse trend with cytotoxicity supports an inverse 
relationship of the cytokine generation with the cytotoxicity. The generation of cytokine 
on exposure to QPa2.5 is attributed to its hydrophilicity and large particle sizes (250-
468nm). Literature shows that the small sized particles are more immunogenic than the 
larger particles, however, immunogenicity of larger particles has been shown to depend 
on their chemical composition [494]. Macrophages have been shown to adhere better 
to the hydrophillic surfaces which activate them to produce higher levels of cytokine 
[362]. 
The transport study showed a transient decline in the percentage TEER of CaCo2 
cells on exposure to most of the formulations indicating reversible opening of the 
CaCo2 cell TJs. The reduction in the percentage TEER was more pronounced on 
exposure to the NIL QPa2.5 (58-78%) and NIL PAH complexes than their IL 
counterparts (20-30%). The application of polymeric nanocarriers to the CaCo2 cell 
monolayers has been reported to influence the junctional proteins, including actin, 
occludin, and claudin-1, leading to reversible opening of TJs [436]. The reduction in 
the positive ZP of NIL QPa2.5 PECs and APECs from (ZP- NIL 52-20mV) to (ZP IL-
20-17mV) upon complexation with insulin is thought to have altered their interaction 
with the junctional proteins and prevented the TJ opening by IL QPa2.5 and IL PAH 
based complexes. The higher positive charge of PECs than APECs allowed better 
interaction with cell membrane proteins resulting in higher transport of FITC-Dextran 
and insulin across CaCo2 cells (except QPa2.5-DS). Among APECs, the FITC Dextran 
and insulin flux was higher in the cells incubated with DS based APECs than PAA 
based APECs. 
The uptake study revealed internalisation of APECs by a transcellular route. Slight 
differences in particle size and surface charge have been shown to have significant 
implications in the cellular uptake of nanocarriers and mechanisms of uptake process 
[317]. The small sizes and high positive ZP of IL QPa2.5 PECs (size 117±2.4; ZP 20±3) 
and IL QPa2.5-DS (size 72±0.1; ZP 16±3) as compared to large sizes and low positive 
ZP of IL QPa2.5-PAA (size 388± 29; ZP 7mV) are thought to have promoted higher 
uptake of complexes i.e., 73% and 67% respectively. The low ZP of QPa2.5-PAA is 
assumed to have reduced the electrostatic interaction with the membrane proteins and 
prevented the uptake of the complexes. The large size particles require a stronger 
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driving force and additional energy for internalization thus prevent effective uptake of 
complexes [495]. 
Since DS based formulations have previously been shown to be taken up by receptor 
mediated uptake [482, 483], therefore it is thought that QPa2.5-DS are internalised via 
receptor mediated endocytosis, whereas QPa2.5-PAA appears to be taken up by non-
specific adsorptive endocytosis. 
By contrast, the IL Pa2.5 PECs and IL Pa2.5-PAA showed significantly lower uptake 
than the NIL counterparts. Among APECs, the uptake of IL Pa2.5-DS was significantly 
higher than IL Pa2.5-PAA. The uptake of Pa2.5 complexes was not observed to be 
affected by size or ZP but hydrophobic-hydrophilic balance. The presence of insulin in 
complexes altered the hydrophobic-hydrophilic balance resulting in reduced uptake of 
insulin loaded Pa2.5 complexes. There is a possibility that the uptake of these 
complexes was followed by their efflux by efflux pump e.g., P glycoprotein efflux 
pump [489]. P glycoprotein efflux pump have previously been shown to secrete a 
variety of lipophilic and cationic compounds out of cells [354]. However, further work 
should be performed to confirm these assumptions. It is thought that both IL and NIL 
Pa2.5 PECs and Pa2.5-PAA electrostatically interacted with the negatively charged 
proteoglycans of the cell membrane, followed by non-specific adsorptive endocytosis 
[67], whereas Pa2.5-DS internalised via receptor mediated endocytosis.  
Altogether the data on the APECs indicate that DS based APECs showed a higher 
insulin association efficiency and stability; however were found to be more cytotoxic 
and immunogenic than their PAA based counterparts. The DS based complexes (IL 
PAH-DS, QPa2.5-DS, and Da10-DS) produced a more significant reduction in the 
percentage TEER, more efficient uptake, higher insulin permeation and FITC-Dextran 
flux than their PAA based counterparts, indicating the influence of polyanion on 
cellular uptake. The findings show that the biocompatibility, internalization and 
transport of the complexes are governed by the physicochemical properties such as 
surface chemistry, size, surface charge and the type of the polyanion complexed. The 
presence of polyanion may be able to reduce the toxicity of the delivery system by 
reducing the overall positive. However, the reduced positive charge and hence 
interaction with the cell membrane may have implication in cellular uptake and 
transport of complexes. 
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6.2 FUTURE WORKS 
Development of drug delivery systems by polyelectrolyte complexation offer 
opportunities to tailor the properties of complexes to achieve desired systems. The 
novel ternary complexes (APECs) fabricated in this project were effective in improving 
the biocompatibility of the complexes, however, reduced the insulin complexation 
efficiency and eventual uptake and transport of the complexes. In regards to this 
limitation, optimisation of formulation to prepare more sophisticated delivery system 
which can improve the uptake and transport is crucial. Modification of the delivery 
system by using polyethylene glycol grafted PAH may increase the protein 
complexation efficiency as well as biocompatibility of complexes. 
In order to fully functionalise the potential of the ternary complexes, the precise 
behaviour and stability of ternary complexes should be studied in biological mediums 
(i.e., simulated gastric and intestinal fluids) and the release profile should also be 
elucidated. It is desirable to carry out a long term stability testing of the formulations 
to determine their potential as pharmaceutical excipients. 
Monitoring particle internalization by confocal microscopy can provide a more 
complete understanding of intracellular localization of complexes [440]. Besides, it will 
be useful to conduct study at different time points to determine the time taken by the 
formulation to be taken up.  It will also help to study the transport and release of 
bioactive protein from the nanocarriers and determine where the polymer and protein 
reside inside the cell.  
In addition to the microscopic study, cellular internalisation should also be studied to 
determine the mechanism of cellular uptake. Endocytosis specific biochemical 
inhibitors such as cytochlasin D (endocytosis inhibitor), chlorpromazine (inhibitor of 
clathrin-mediated endocytosis), dynasore (inhibitor of dynamin-dependent 
endocytosis), genistein (inhibitor of caveolin-mediated endocytosis), [440, 441, 496] 
should be used to elucidate specific endocytosis mechanisms. Once detailed in vitro 
study has been conducted, the oral in vivo studies should be done to elucidate the 
various APEC formulations as effective pharmaceutical therapies.  
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376. Kamiński, K., et al., Cationic derivatives of dextran and hydroxypropylcellulose as novel 
potential heparin antagonists. Journal of medicinal chemistry, 2011. 54(19): p. 6586-6596. 
377. Moreau, E., et al., Biocompatibility of polycations: in vitro agglutination and lysis of red blood 
cells and in vivo toxicity. Journal of drug targeting, 2002. 10(2): p. 161-173. 
378. Moreau, É., et al., Interactions between red blood cells and a lethal, partly quaternized tertiary 
polyamine. Journal of controlled release, 2000. 64(1): p. 115-128. 
379. Riquelme, B.D., et al., Hemocompatibility and biofunctionality of two poly (2‐(dimethylamino) 
ethyl methacrylate‐co‐poly (ethyleneglycol) copolymers. Journal of Biomedical Materials 
Research Part A, 2011. 99(3): p. 445-454. 
380. Gorochovceva, N. and R. Makuška, Synthesis and study of water-soluble chitosan-O-poly 
(ethylene glycol) graft copolymers. European Polymer Journal, 2004. 40(4): p. 685-691. 
381. Cui, L., C. Tang, and C. Yin, Effects of quaternization and PEGylation on the biocompatibility, 
enzymatic degradability and antioxidant activity of chitosan derivatives. Carbohydrate 
Polymers, 2012. 87(4): p. 2505-2511. 
382. Swarnakar, N.K., et al., Oral bioavailability, therapeutic efficacy and reactive oxygen species 
scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. Biomaterials, 2011. 
32(28): p. 6860-6874. 
383. Grotto, D., et al., Importance of the lipid peroxidation biomarkers and methodological aspects 
for malondialdehyde quantification. Quimica Nova, 2009. 32(1): p. 169-174. 
384. Leeuwenburgh, C. and J. Heinecke, Oxidative stress and antioxidants in exercise. Current 
medicinal chemistry, 2001. 8(7): p. 829-838. 
385. Shafirovich, V., et al., Role of free radical reactions in the formation of DNA damage. The 
Chemical Biology of DNA Damage, 2010: p. 81-104. 
386. Lee, J., N. Koo, and D. Min, Reactive oxygen species, aging, and antioxidative nutraceuticals. 
Comprehensive reviews in food science and food safety, 2004. 3(1): p. 21-33. 
387. Sayes, C.M., et al., Nano-C60 cytotoxicity is due to lipid peroxidation. Biomaterials, 2005. 
26(36): p. 7587-7595. 
xix 
 
388. Menon, D., et al., A novel chitosan/polyoxometalate nano-complex for anti-cancer 
applications. Carbohydrate polymers, 2011. 84(3): p. 887-893. 
389. Shinohara, N., et al., Is lipid peroxidation induced by the aqueous suspension of fullerene C60 
nanoparticles in the brains of Cyprinus carpio? Environmental Science & Technology, 2008. 
43(3): p. 948-953. 
390. Yang, Y.-W. and P.Y.-J. Hsu, The effect of poly (d, l-lactide- co-glycolide) microparticles with 
polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous 
antigens. Biomaterials, 2008. 29(16): p. 2516-2526. 
391. Nabeshi, H., et al., Amorphous nanosilica induce endocytosis-dependent ROS generation and 
DNA damage in human keratinocytes. Particle and fibre toxicology, 2011. 8(1): p. 1. 
392. Singh, M., et al., Nanotechnology in medicine and antibacterial effect of silver nanoparticles. 
Digest J. Nanomater. Biostructures, 2008. 3(3): p. 115-122. 
393. Yang, Y.W. and P.Y.J. Hsu, The effect of poly (d, l-lactide- co-glycolide) microparticles with 
polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous 
antigens. Biomaterials, 2008. 29(16): p. 2516-2526. 
394. Stevenson, R., et al., Nanoparticles and inflammation. The Scientific World JOURNAL, 2011. 
11: p. 1300-1312. 
395. Mogi, M., et al., Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are 
elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. 
Neuroscience letters, 1996. 211(1): p. 13-16. 
396. Akira, S., et al., Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). 
The FASEB journal, 1990. 4(11): p. 2860-2867. 
397. Schöler, N., et al., Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability 
and cytokine production of macrophages. International journal of pharmaceutics, 2002. 
231(2): p. 167-176. 
398. Xing, Z., et al., IL-6 is an antiinflammatory cytokine required for controlling local or systemic 
acute inflammatory responses. Journal of Clinical Investigation, 1998. 101(2): p. 311. 
399. Leon, L.R., Invited review: cytokine regulation of fever: studies using gene knockout mice. 
Journal of Applied Physiology, 2002. 92(6): p. 2648-2655. 
400. Malek, T.R. and I. Castro, Interleukin-2 receptor signaling: at the interface between tolerance 
and immunity. Immunity, 2010. 33(2): p. 153-165. 
401. Malek, T.R. and A.L. Bayer, Tolerance, not immunity, crucially depends on IL-2. Nature Reviews 
Immunology, 2004. 4(9): p. 665-674. 
402. Tryoen‐Tóth, P., et al., Viability, adhesion, and bone phenotype of osteoblast‐like cells on 
polyelectrolyte multilayer films. Journal of biomedical materials research, 2002. 60(4): p. 657-
667. 
403. Semete, B., et al., In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as 
drug delivery systems. Nanomedicine: Nanotechnology, Biology and Medicine, 2010. 6(5): p. 
662-671. 
404. Olbrich, C., et al., Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles (SLN) on RAW 
264.7 macrophages—impact of phagocytosis on viability and cytokine production. Journal of 
pharmacy and pharmacology, 2004. 56(7): p. 883-891. 
405. Schöler, N., et al., Surfactant, but not the size of solid lipid nanoparticles (SLN) influences 
viability and cytokine production of macrophages. International journal of pharmaceutics, 
2001. 221(1-2): p. 57-67. 
406. Carson, R.T. and D.A.A. Vignali, Simultaneous quantitation of 15 cytokines using a multiplexed 
flow cytometric assay. Journal of immunological methods, 1999. 227(1): p. 41-52. 
407. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. Journal of immunological methods, 1983. 65(1-2): p. 55-
63. 
xx 
 
408. Malik, N., et al., Dendrimers:: Relationship between structure and biocompatibility in vitro, and 
preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. 
Journal of Controlled Release, 2000. 65(1): p. 133-148. 
409. Vllasaliu, D., et al., Absorption-promoting effects of chitosan in airway and intestinal cell lines: 
a comparative study. International journal of pharmaceutics, 2012. 430(1): p. 151-160. 
410. Derfus, A.M., W.C. Chan, and S.N. Bhatia, Probing the cytotoxicity of semiconductor quantum 
dots. Nano letters, 2004. 4(1): p. 11-18. 
411. Paur, H.-R., et al., In-vitro cell exposure studies for the assessment of nanoparticle toxicity in 
the lung—a dialog between aerosol science and biology. Journal of Aerosol Science, 2011. 
42(10): p. 668-692. 
412. Fadeel, B., Clear and present danger? Engineered nanoparticles and the immune system. Swiss 
Med. Wkly, 2012. 142: p. w13609. 
413. Van Bambeke, F., et al., Cellular pharmacokinetics and pharmacodynamics of the glycopeptide 
antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrobial 
agents and chemotherapy, 2004. 48(8): p. 2853-2860. 
414. Colak, S., et al., Hydrophilic modifications of an amphiphilic polynorbornene and the effects on 
its hemolytic and antibacterial activity. Biomacromolecules, 2009. 10(2): p. 353-359. 
415. Thompson, C., et al., The complexation between novel comb shaped amphiphilic 
polyallylamine and insulin--Towards oral insulin delivery. International journal of 
pharmaceutics, 2009. 376(1-2): p. 46-55. 
416. Clare, H., et al., The use of nano polymeric self-assemblies based on novel amphiphilic polymers 
for oral hydrophobic drug delivery. Pharmaceutical research, 2012. 29(3): p. 782-794. 
417. Liu, Z., et al., Interactions between solubilized polymer molecules and blood components. 
Journal of Controlled Release, 2012. 160(1): p. 14-24. 
418. Oberdörster, G., et al., Principles for characterizing the potential human health effects from 
exposure to nanomaterials: elements of a screening strategy. Particle and fibre toxicology, 
2005. 2(1): p. 8. 
419. Xia, T., et al., Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and 
mitochondrial injury pathways. ACS nano, 2007. 2(1): p. 85-96. 
420. Naha, P.C., et al., Reactive oxygen species (ROS) induced cytokine production and cytotoxicity 
of PAMAM dendrimers in J774A. 1 cells. Toxicology and applied pharmacology, 2010. 246(1): 
p. 91-99. 
421. Donaldson, K., et al., Combustion-derived nanoparticles: a review of their toxicology following 
inhalation exposure. Particle and Fibre Toxicology, 2005. 2(1): p. 10. 
422. Nel, A., et al., Toxic potential of materials at the nanolevel. Science, 2006. 311(5761): p. 622-
627. 
423. Finkelman, F.D. and S.C. Morris, Development of an assay to measure in vivo cytokine 
production in the mouse. International immunology, 1999. 11(11): p. 1811-1818. 
424. Sullivan, K.E., et al., Measurement of cytokine secretion, intracellular protein expression, and 
mRNA in resting and stimulated peripheral blood mononuclear cells. Clinical and diagnostic 
laboratory immunology, 2000. 7(6): p. 920-924. 
425. Thatte, S., K. Datar, and R.M. Ottenbrite, Perspectives on: Polymeric drugs and drug delivery 
systems. Journal of bioactive and compatible polymers, 2005. 20(6): p. 585-601. 
426. Ward, P.D., T.K. Tippin, and D.R. Thakker, Enhancing paracellular permeability by modulating 
epithelial tight junctions. Pharmaceutical Science & Technology Today, 2000. 3(10): p. 346-
358. 
427. Thompson, C., et al., Uptake and Transport of Novel Amphiphilic Polyelectrolyte-Insulin 
Nanocomplexes by Caco-2 Cells—Towards Oral Insulin. Pharmaceutical research, 2011. 28(4): 
p. 886-896. 
xxi 
 
428. Kowapradit, J., et al., Methylated N-(4-N, N-dimethylaminobenzyl) chitosan, a novel chitosan 
derivative, enhances paracellular permeability across intestinal epithelial cells (Caco-2). AAPS 
PharmSciTech, 2008. 9(4): p. 1143-1152. 
429. Kowapradit, J., et al., Methylated N-(4-N, N-dimethylaminocinnamyl) chitosan enhances 
paracellular permeability across Caco-2 cells. Drug delivery, 2010. 17(5): p. 301-312. 
430. Thanou, M., et al., Effect of degree of quaternization of N-trimethyl chitosan chloride for 
enhanced transport of hydrophilic compounds across intestinal Caco-2 cell monolayers.  
Journal of Controlled Release, 2000. 64(1): p. 15-25. 
431. Sadeghi, A., et al., Permeation enhancer effect of chitosan and chitosan derivatives: 
comparison of formulations as soluble polymers and nanoparticulate systems on insulin 
absorption in Caco-2 cells. European Journal of Pharmaceutics and Biopharmaceutics, 2008. 
70(1): p. 270-278. 
432. Thanou, M., et al., A novel polymeric absorption enhancer for the oral delivery of 
macromolecules. Journal of controlled release, 2007. 117(2): p. 171-178. 
433. Kitchens, K.M., M.E. El-Sayed, and H. Ghandehari, Transepithelial and endothelial transport of 
poly (amidoamine) dendrimers. Advanced drug delivery reviews, 2005. 57(15): p. 2163-2176. 
434. El-Sayed, M., et al., Transport mechanism (s) of poly (amidoamine) dendrimers across Caco-2 
cell monolayers. International journal of pharmaceutics, 2003. 265(1): p. 151-157. 
435. Kitchens, K.M., et al., Transport of poly (amidoamine) dendrimers across Caco-2 cell 
monolayers: influence of size, charge and fluorescent labeling. Pharmaceutical research, 2006. 
23(12): p. 2818-2826. 
436. Dorkoosh, F.A., et al., Transport of octreotide and evaluation of mechanism of opening the 
paracellular tight junctions using superporous hydrogel polymers in Caco‐2 cell monolayers. 
Journal of pharmaceutical sciences, 2004. 93(3): p. 743-752. 
437. Borchard, G., et al., The potential of mucoadhesive polymers in enhancing intestinal peptide 
drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions 
in vitro. Journal of Controlled Release, 1996. 39(2): p. 131-138. 
438. Anderson, J. and C. Van Itallie, Tight junctions and the molecular basis for regulation of 
paracellular permeability. American Journal of Physiology-Gastrointestinal and Liver 
Physiology, 1995. 269(4): p. G467-G475. 
439. Morishita, M. and N.A. Peppas, Is the oral route possible for peptide and protein drug delivery? 
Drug discovery today, 2006. 11(19): p. 905-910. 
440. Gratton, S.E., et al., The effect of particle design on cellular internalization pathways. 
Proceedings of the National Academy of Sciences, 2008. 105(33): p. 11613-11618. 
441. Harush-Frenkel, O., et al., Surface charge of nanoparticles determines their endocytic and 
transcytotic pathway in polarized MDCK cells. Biomacromolecules, 2008. 9(2): p. 435-443. 
442. Gaumet, M., R. Gurny, and F. Delie, Interaction of biodegradable nanoparticles with intestinal 
cells: the effect of surface hydrophilicity. International journal of pharmaceutics, 2010. 390(1): 
p. 45-52. 
443. Desai, M.P., et al., The mechanism of uptake of biodegradable microparticles in Caco-2 cells is 
size dependent. Pharmaceutical research, 1997. 14(11): p. 1568-1573. 
444. Woitiski, C.B., et al., Facilitated nanoscale delivery of insulin across intestinal membrane 
models. International journal of pharmaceutics, 2011. 412(1): p. 123-131. 
445. Hornof, M., et al., Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates 
CD44 receptor mediated uptake in human corneal epithelial cells. The journal of gene 
medicine, 2008. 10(1): p. 70-80. 
446. Xu, P., G.K. Quick, and Y. Yeo, Gene delivery through the use of a hyaluronate-associated 
intracellularly degradable crosslinked polyethyleneimine. Biomaterials, 2009. 30(29): p. 5834-
5843. 
447. Jevprasesphant, R., et al., Transport of dendrimer nanocarriers through epithelial cells via the 
transcellular route. Journal of controlled release, 2004. 97(2): p. 259-267. 
xxii 
 
448. Dombu, C.Y., et al., Characterization of endocytosis and exocytosis of cationic nanoparticles in 
airway epithelium cells. Nanotechnology, 2010. 21(35): p. 355102. 
449. Jin, Y., et al., Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of 
mucus on insulin transport. Biomaterials, 2012. 33(5): p. 1573-1582. 
450. Qaddoumi, M.G., et al., Clathrin and caveolin-1 expression in primary pigmented rabbit 
conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol Vis, 2003. 9: p. 559-
568. 
451. Rajapaksa, T.E., et al., Claudin 4-targeted protein incorporated into PLGA nanoparticles can 
mediate M cell targeted delivery. Journal of Controlled Release, 2010. 142(2): p. 196-205. 
452. Beloqui, A., et al., Mechanism of transport of saquinavir-loaded nanostructured lipid carriers 
across the intestinal barrier. Journal of Controlled Release, 2012. 166(2): p. 115-123. 
453. Yee, S., In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) 
absorption in man—fact or myth. Pharmaceutical research, 1997. 14(6): p. 763-766. 
454. Kotzé, A.F., et al., Enhancement of paracellular drug transport with highly quaternized N‐
trimethyl chitosan chloride in neutral environments: In vitro evaluation in intestinal epithelial 
cells (Caco‐2). Journal of pharmaceutical sciences, 1999. 88(2): p. 253-257. 
455. Ingels, F., et al., Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. 
International journal of pharmaceutics, 2002. 232(1): p. 183-192. 
456. Jackson, C., R.F. Murphy, and J. Kovacevic, Intelligent acquisition and learning of fluorescence 
microscope data models. Image Processing, IEEE Transactions on, 2009. 18(9): p. 2071-2084. 
457. Brown, C.M., Fluorescence microscopy-avoiding the pitfalls. Journal of cell science, 2007. 
120(10): p. 1703-1705. 
458. Swedlow, J.R. and M. Platani, Live cell imaging using wide-field microscopy and deconvolution. 
Cell structure and function, 2002. 27(5): p. 335-341. 
459. Rieseberg, M., et al., Flow cytometry in biotechnology. Applied microbiology and 
biotechnology, 2001. 56(3): p. 350-360. 
460. Kuckuck, F.W., B.S. Edwards, and L.A. Sklar, High throughput flow cytometry. Cytometry, 2001. 
44(1): p. 83-90. 
461. Jaroszeski, M.J. and G. Radcliff, Fundamentals of flow cytometry. Molecular biotechnology, 
1999. 11(1): p. 37-53. 
462. Haynes, J.L., Principles of flow cytometry. Cytometry, 2005. 9(S3): p. 7-17. 
463. Carter, N. and M.G. Ormerod, Introduction to the principles of flow cytometry. Flow 
Cytometry: A Practical Approach, ed, 2000. 2: p. 1-25. 
464. Krysko, D.V., et al., Methods for distinguishing apoptotic from necrotic cells and measuring 
their clearance. Methods in enzymology, 2008. 442: p. 307-341. 
465. Lan, K., et al., Intra‐herb pharmacokinetics interaction between quercetin and isorhamentin1. 
Acta Pharmacologica Sinica, 2008. 29(11): p. 1376-1382. 
466. Song, Q., et al., Cellular internalization pathway and transcellular transport of pegylated 
polyester nanoparticles in Caco-2 cells. International journal of pharmaceutics, 2013. 445(1): 
p. 58-68. 
467. Neuhaus, W., et al., A novel tool to characterize paracellular transport: the APTS–dextran 
ladder. Pharmaceutical research, 2006. 23(7): p. 1491-1501. 
468. Tavelin, S., et al., Prediction of the oral absorption of low-permeability drugs using small 
intestine-like 2/4/A1 cell monolayers. Pharmaceutical research, 2003. 20(3): p. 397-405. 
469. Hsu, L.-W., et al., Elucidating the signaling mechanism of an epithelial tight-junction opening 
induced by chitosan. Biomaterials, 2012. 33(26): p. 6254-6263. 
470. Wen, H., et al., Selective decrease in paracellular conductance of tight junctions: role of the 
first extracellular domain of claudin-5. Molecular and cellular biology, 2004. 24(19): p. 8408-
8417. 
xxiii 
 
471. Kowapradit, J., et al., Structure–activity relationships of methylated N-aryl chitosan derivatives 
for enhancing paracellular permeability across Caco-2 cells. Carbohydrate Polymers, 2011. 
83(2): p. 430-437. 
472. Ichikawa, H. and N.A. Peppas, Novel complexation hydrogels for oral peptide delivery: In vitro 
evaluation of their cytocompatibility and insulin‐transport enhancing effects using Caco‐2 cell 
monolayers. Journal of Biomedical Materials Research Part A, 2003. 67(2): p. 609-617. 
473. Prego, C., et al., Transmucosal macromolecular drug delivery. Journal of controlled release, 
2005. 101(1): p. 151-162. 
474. Suksamran, T., et al., Oral Methylated N-Aryl Chitosan Derivatives for Inducing Immune 
Responses to Ovalbumin. Tropical Journal of Pharmaceutical Research, 2013. 11(6): p. 899-
908. 
475. Kotzé, A.F., et al., Effect of the degree of quaternization of N-trimethyl chitosan chloride on the 
permeability of intestinal epithelial cells (Caco-2). European Journal of Pharmaceutics and 
Biopharmaceutics, 1999. 47(3): p. 269-274. 
476. Florea, B.I., et al., Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl 
chitosan shows linear in vitro/in vivo correlation. Journal of controlled release, 2006. 110(2): 
p. 353-361. 
477. Sonaje, K., et al., Opening of Epithelial Tight Junctions and Enhancement of Paracellular 
Permeation by Chitosan: Microscopic, Ultrastructural, and Computed-Tomographic 
Observations. Molecular pharmaceutics, 2012. 9(5): p. 1271-1279. 
478. Smith, J.M., M. Dornish, and E.J. Wood, Involvement of protein kinase C in chitosan glutamate-
mediated tight junction disruption. Biomaterials, 2005. 26(16): p. 3269-3276. 
479. Hamman, J., C. Schultz, and A. Kotzé, N-trimethyl chitosan chloride: optimum degree of 
quaternization for drug absorption enhancement across epithelial cells. Drug development 
and industrial pharmacy, 2003. 29(2): p. 161-172. 
480. Bourdet, D.L., J.B. Pritchard, and D.R. Thakker, Differential substrate and inhibitory activities 
of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), 
hOCT2 (SLC22A2), and hOCT3 (SLC22A3). Journal of Pharmacology and Experimental 
Therapeutics, 2005. 315(3): p. 1288-1297. 
481. Kim, M.K. and C.-K. Shim, The transport of organic cations in the small intestine: current 
knowledge and emerging concepts. Archives of pharmacal research, 2006. 29(7): p. 605-616. 
482. Chalasani, K.B., et al., Effective oral delivery of insulin in animal models using vitamin B12-
coated dextran nanoparticles. Journal of Controlled Release, 2007. 122(2): p. 141-150. 
483. Russo, L., et al., The normal kidney filters nephrotic levels of albumin retrieved by proximal 
tubule cells: retrieval is disrupted in nephrotic states. Kidney international, 2007. 71(6): p. 504-
513. 
484. Ito, T., et al., DNA/polyethyleneimine/hyaluronic acid small complex particles and tumor 
suppression in mice. Biomaterials, 2010. 31(10): p. 2912-2918. 
485. Lerch, S., et al., Polymeric nanoparticles of different sizes overcome the cell membrane barrier. 
European journal of pharmaceutics and biopharmaceutics, 2013.  84(2): p. 265-274. 
486. Kim, Y.H., et al., Structural characteristics of size-controlled self-aggregates of deoxycholic 
acid-modified chitosan and their application as a DNA delivery carrier. Bioconjugate 
Chemistry, 2001. 12(6): p. 932-938. 
487. Wang, M. and M. Thanou, Targeting nanoparticles to cancer. Pharmacological Research, 2010. 
62(2): p. 90-99. 
488. Sahoo, S.K., et al., Residual polyvinyl alcohol associated with poly (D, L-lactide-co-glycolide) 
nanoparticles affects their physical properties and cellular uptake. Journal of controlled 
release, 2002. 82(1): p. 105-114. 
489. Antunes, F., et al., Establishment of a triple co-culture  in vitro cell models to study intestinal 
absorption of peptide drugs. European journal of pharmaceutics and biopharmaceutics, 2012. 
83(3): p. 427-435.  
xxiv 
 
490. Hamman, J.H., G.M. Enslin, and A.F. Kotzé, Oral delivery of peptide drugs: barriers and 
developments. BioDrugs, 2005. 19(3): p. 165-177. 
491. Sarmento, B.F.C.C., Improvement of Peptidic Drugs Oral Availability Througt Their 
Encapsulation In Polyelectrolytes Complexes-Made Nano Particles. 2011. 
492. Goycoolea, F.M., et al., Chitosan-alginate blended nanoparticles as carriers for the 
transmucosal delivery of macromolecules. Biomacromolecules, 2009. 10(7): p. 1736-1743. 
493. Bernkop-Schnürch, A., C. Kast, and D. Guggi, Permeation enhancing polymers in oral delivery 
of hydrophilic macromolecules: thiomer/GSH systems. Journal of Controlled Release, 2003. 
93(2): p. 95-103. 
494. Ovrevik, J. and P.E. Schwarze, Chemical composition and not only total surface area is 
important for the effects of ultrafine particles. Mutation Research/Fundamental and 
Molecular Mechanisms of Mutagenesis, 2006. 594(1): p. 201-202. 
495. Gao, H., W. Shi, and L.B. Freund, Mechanics of receptor-mediated endocytosis. Proceedings of 
the National Academy of Sciences of the United States of America, 2005. 102(27): p. 9469-
9474. 
496. Jiang, X., et al., Specific effects of surface amines on polystyrene nanoparticles in their 
interactions with mesenchymal stem cells. Biomacromolecules, 2010. 11(3): p. 748-753. 
 
 
         
